

Appendix 3. New studies/comparisons (11 November 2021)

Methods

The search strategy is shown in Appendix A, capturing patients with HIV and comparisons of interventions. The key comparisons of interest are:

- 1 3rd agent comparisons
 - DOL vs EFV + any 2NRTI
 - DOL vs BIC + any 2NRTI
 - DOL vs b/PI + any 2NRTI
 - DOR vs b/PI + any 2NRTI
 - DOR vs EFV + any 2NRTI
 - DOL/LAM vs TDF/FTC/DOL
 - DOL vs RALT + any 2NRTI
- 2 NRTI backbone comparison
 - TDF/FTC vs TAF/FTC with any 3rd agent
 - ABC/3TC vs TAF/FTC with any 3rd agent

The critical outcomes are:

- Virological suppression at 48 weeks
- Virological suppression at 96 weeks
- Virological failure at 48 weeks
- Virological failure at 96 weeks
- Failing with resistance at 48 weeks
- Failing with resistance at 96 weeks
- Adverse event (AE)-driven discontinuation
- Serious adverse events (SAE)
- Drug-related SAE
- Grade 3/4 AE
- Drug-related Grade 3/4 AE

One reviewer (JP) excluded obviously irrelevant records and a second reviewer (IR) selected the papers for inclusion for each comparison.

One reviewer (JP) extracted data and undertook a risk of bias assessment for each study using the Cochrane ROB 2.0 tool (Shown in Appendix B), and generated Forest plots and GRADE tables.



Results

3rd agent comparisons

1 DOL vs EFV + any 2 NRTI

Three trials examined this comparison. ADVANCE data were published for week 48 (Venter 2019) and week 96 results (Venter 2020). NAMSAL provided week 48 data in the NAMSAL ANRS 12313 (2019) paper. The SINGLE study data were reported for week 48 (Walmsley 2013) and week 96 and 144 (Walmsley 2015).

Table 1. Key features of the included studies

Study	Citation	Inclusion	Exclu	Population (n;	Intervention	Comparator	Outcomes
name/		criteria	sions	demographics)			
NCT							
number							
NCT0312	Venter WDF, Moorhouse M, Sokhela S,	Age ≥12	>30	1053 participants with HIV	Tenofovir	Tenofovir	The primary end point
2262;	Fairlie L, Mashabane N, Masenya M,	years,	days	infection in South Africa.	alafenamide	disoproxil	was the percentage of
ADVANC	Serenata C, Akpomiemie G, Qavi A,	weight	of	The mean age was 32 years	fumarate	fumarate	patients with an HIV-1
E	Chandiwana N, Norris S, Chersich M,	≥40kg, viral	treat	(range, 13 to 62); 14 patients	(TAF) plus	(TDF) plus	RNA level <50
	Clayden P, Abrams E, Arulappan N, Vos A,	load of ≥500	ment	were younger than 19 years	emtricitabin	emtricitabine	copies/mL at week 48.
	McCann K, Simmons B, Hill A. Dolutegravir	copies/mL,	with	of age. A total of 59% of the	e (FTC) and	(FTC) and	Secondary objectives
	plus Two Different Prodrugs of Tenofovir to	creatinine	any	patients were female, more	dolutegravir	efavirenz	were to evaluate
	Treat HIV. N Engl J Med. 2019 Aug	clearance	form	than 99% were black, and	(DTG) =	(EFV) = TDF-	additional viral-load
	29;381(9):803-815. doi:	>60 mL/min	of	62% were from South Africa.	TAF-FTC-	FTC-EFV	thresholds, CD4 count
	10.1056/NEJMoa1902824. Epub 2019 Jul	(Cockcroft–	ART,	The mean CD4 count was	DTG (TAF-	(standard-	changes, and side-effect
	24. PMID: 31339677.	Gault	any	337 cells per cubic millimeter	based	care group)	profile and safety,
		formula) in	ART	(range, 1 to 1721), and 78%	group)		including findings on
		patients 19	within	of the patients had a	OR		physical examination,
		years of age	the	baseline HIV-1 RNA level of	Tenofovir		laboratory analyses, and
		or older or >	past 6	less than 100,000 copies per	disoproxil		dual-energy x-ray
		80 mL/min	month	milliliter.	fumarate		absorptiometry (DXA)
		(modified	s,		(TDF) plus		scans.
		Cockcroft-	pregn		emtricitabin		
		Gault	ancy,		e (FTC) and		
		formula) in	or		dolutegravir		
		those <19	curre		(DTG) =		
		years of age	nt		TDF-FTC-		



			treat ment		DTG (TDF- based		
			for tuberc		group)		
	Venter, WDF; Sokhela, S; Simmons, B; Moorhouse, M; Fairlie, L; Mashabane, N; Serenata, C; Akpomiemie, G; Masenya, M; Qavi, A; Chandiwana, N; McCann, K; Norris, S; Chersich, M; Maartens, G; Lalla-Edward, S; Vos, A; Clayden, P; Abrams, E; Arulappan, N; Hill, A. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet. HIV 2020; 7(10): e666-676. DOI: 10.1016/S2352-3018(20)30241-1. https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02192063/full	As above	As above	As above	As above	As above	As above
NCT0277 7229; New Antiretrovi ral and Monitorin g Strategies in HIV- Infected Adults in Low- Income Countries (NAMSAL) ANRS 12313	NAMSAL ANRS 12313 Study Group, Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, Peeters M, Calmy A, Delaporte E. Dolutegravir-Based or Low-Dose Efavirenz- Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019 Aug 29;381(9):816- 826. doi: 10.1056/NEJMoa1904340. Epub 2019 Jul 24. PMID: 31339676.	≥18 years, had not received ART, and had HIV-1 group M infection with a viral load of at least 1000 copies /mL. Women of childbearing potential had to agree to use effective	Pregn ancy, breast - feedin g, sever e hepati c impair ment, renal failure , sever e psych iatric	613 participants. The median age was 37 years; 65.9% of the participants were women. The median baseline viral load was 5.3 log10 copies/mL and 66.4% of the participants had a baseline viral load of at least 100,000 copies/mL. The median CD4+ T-cell count was 281 per cubic millimeter. Of note in the NAMSAL trial, the participants were mainly women of childbearing potential, had high baseline viral loads (66.4% had a viral	Dolutegravir combined with tenofovir and lamivudine.	Low-dose efavirenz (a 400-mg dose, known as EFV400), combined with tenofovir and lamivudine.	The primary end point was the proportion of participants with a viral load of less than 50 copies per milliliter at week 48. Secondary end points included the viral load with other thresholds (a viral load of 1000 copies/mL after reinforcement of adherence) at weeks 24 and 48, as well as drug resistance; the change from baseline in the CD4+ T-cell count at weeks 24 and 48, morbidity (WHO stage), survival, adherence to



		contraceptiv e methods	illness , and unsta ble tuberc ulosis coinfe ction	load of ≥100,000 copies/mL, and 30.7% had a viral load of ≥500,000 copies/mL), and often had coexisting conditions, whereas the participants included in the SINGLE trial were predominantly men, and one third had a baseline viral load of at least 100,000 copies/mL.			treatment, safety, and patient-reported outcomes (depression, anxiety, and stress; HIV treatment symptoms, including efavirenz-related symptoms; and quality of life)
NCT0126 3015; SINGLE	Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G; SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013 Nov 7;369(19):1807-18. doi: 10.1056/NEJMoa1215541. PMID: 24195548.	≥18 years, had HIV-1 infection, had not previously received ART, had a plasma HIV-1 RNA level of at least 1000 copies/mL without genotypic evidence of viral resistance at screening, and were negative for the HLA-B*5701 allele.	Wom en who were pregn ant or breast - feedin g, perso ns with mode rate or sever e hepati c impair ment, and perso ns with an estim ated creati nine	844 participants. The median age was 35 years; 16% of the participants were women, 24% were black, and 4% were in class C of the Centers for Disease Control and Prevention HIV classification system (defined as the presence of specific opportunistic infections). The median HIV-1 RNA level at baseline was 4.68 log10 copies/mL, and the median CD4+ T-cell count was 338 per cubic millimeter.	Dolutegravir plus abacavir— lamivudine	Efavirenz– tenofovir disoproxil fumarate (DF)- emtricitabine	The primary end point was the proportion of participants with an HIV-1 RNA level of less than 50 copies/mL at week 48. Secondary end points included the time to viral suppression, the change from baseline in CD4+ T-cell count, safety, and viral resistance.



		cleara nce <50 mL/mi n				
Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, Kilby JM, Lutz T, Podzamczer D, Portilla J, Roth N, Wong D, Granier C, Wynne B, Pappa K. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):515-9. doi: 10.1097/QAI.0000000000000790. Erratum in: J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):e33. PMID: 26262777; PMCID: PMC4645960.	As above	As above	As above	As above	As above	As above

Table 2. Comparisons included in this section

Study name/ NCT number	Intervention (Two NRTI + DOL)	Comparator (2 NRTI + EFV)
NCT03122262; ADVANCE	Tenofovir alafenamide fumarate (TAF) plus	Tenofovir disoproxil fumarate (TDF) plus emtricitabine
	emtricitabine (FTC) and dolutegravir (DTG) = TAF–FTC–	(FTC) and efavirenz (EFV) = TDF–FTC–EFV (standard-
	DTG (TAF-based group)	care group)
	OR	
	Tenofovir disoproxil fumarate (TDF) plus	
	emtricitabine (FTC) and dolutegravir (DTG) = TDF–FTC–	
	DTG (TDF-based group)	
	The two groups were combined in the analyses.	
NCT02777229; New Antiretroviral and	Dolutegravir, tenofovir and lamivudine.	Low-dose efavirenz (a 400-mg dose, known as EFV400),
Monitoring Strategies in HIV-Infected Adults in	Dolutegravii, teriolovii ana iamivadine.	tenofovir and lamivudine.
		teriolovii aliu iaitiivuulile.
Low-Income Countries (NAMSAL) ANRS 12313		
NCT01263015; SINGLE	Dolutegravir, abacavir and lamivudine	Efavirenz, tenofovir disoproxil fumarate and emtricitabine



Virological success, failure and missing data


Forest plot of comparison: 1 DOL vs EFV + any 2 NRTI, outcome: 1.1 Virological success.

	DOL+2	NRTI	EFV + 2	FV + 2 NRTI		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
1.1.1 48 weeks							
ADVANCE; Venter 2019	592	702	276	351	37.9%	1.46 [1.06, 2.03]	
NAMSAL 2019	231	310	209	303	35.4%	1.32 [0.92, 1.87]	 •
SINGLE; Walmsley 2013 Subtotal (95% CI)	364	414 142 6	338	419 1073	26.7% 100.0%	1.74 [1.19, 2.56] 1.49 [1.21, 1.82]	•
Total events	1187		823				
Heterogeneity: Chi ^z = 1.15,	df= 2 (P=	0.56);	P= 0%				
Test for overall effect: Z = 3	.83 (P = 0.	0001)					
1.1.2 96 weeks							
ADVANCE; Venter 2020	551	702	258	351	55.1%	1.32 [0.98, 1.77]	
SINGLE; Walmsley 2015 Subtotal (95% CI)	331	414 1116	302	419 770	44.9% 100.0%	1.55 [1.12, 2.13] 1.42 [1.14, 1.76]	
Total events	882		560				
Heterogeneity: Chi² = 0.52,	df=1 (P=	0.47);	P= 0%				
Test for overall effect: Z = 3							
						-	0.5 0.7 1 1.5 2
							Favours EFV Favours DOL

Test for subgroup differences: $Chi^2 = 0.09$, df = 1 (P = 0.76), $I^2 = 0\%$

Forest plot of comparison: 1 DOL vs EFV + any 2 NRTI, outcome: 1.2 Virological failure.





Test for subgroup differences: $Chi^2 = 0.17$, df = 1 (P = 0.68), $I^2 = 0\%$

Of note, in the ADVANCE study, by week 48, the number of patients who had discontinued treatment or who had missing data was 41 (12%) in the TAF-based group, 39 (11%) in the TDF-based group, and 55 (16%) in the EFV group. Differences in efficacy between the groups were driven by a higher number of discontinuations in the standard-care group than in the other two groups. In the per-protocol analysis, the percentage of patients with an HIV-1 RNA level of less than 50 copies/mL was similar across the groups at week 48 (96% in the TAF-based group, 95% in the TDF-based group, and 96% in the standard-care group). At week 96, 11 (3%) of 351 participants in the TAF-based group, 14 (4%) of 351 participants in the TDF-based group, and 15 (4%) of 351 participants in the EFV group had plasma HIV-1 RNA concentrations of 50 copies per mL or higher at week 96 or discontinued due to poor efficacy. All other patients discontinued before week 96.

Similarly in the SINGLE trial, the superior responses in the DOL group at week 48 were driven primarily by a lower rate of discontinuation due to adverse events in the DTG-ABC-3TC group than in the EFV-TDF-FTC group (10 of 414 participants [2%] in the DTG-ABC-3TC group and 42 of 419 [10%] in the EFV-



TDF—FTC group). Also, at week 96, differences in the virological response rate were driven by a lower rate of discontinuations due to AEs or deaths in the dolutegravir + abacavir/ lamivudine arm than in the efavirenz/tenofovir DF/emtricitabine arm: 13/414 (3%) vs. 48/419 (11%).

Figure: 1. Success, failure and missing data at 48 weeks





Figure: 2. Success, failure and missing data at 96 weeks






Failing with resistance

Forest plot of comparison: 1 DOL vs EFV + any 2 NRTI, outcome: 1.3 Failure with resistance.






Test for subgroup differences: $Chi^2 = 0.46$, df = 1 (P = 0.50), $I^2 = 0\%$

Adverse event (AE)-driven discontinuation

Forest plot of comparison: 1 DOL vs EFV + any 2 NRTI, outcome: 1.4 AE-driven discontinuation.






Test for subgroup differences: Chi² = 0.29, df = 1 (P = 0.59), I² = 0%

Serious adverse events

Forest plot of comparison: 1 DOL vs EFV + any 2 NRTI, outcome: 1.5 Serious AE.





Test for subgroup differences: $Chi^2 = 0.50$, df = 1 (P = 0.48), $I^2 = 0\%$

Drug-related SAE

Forest plot of comparison: 1 DOL vs EFV + any 2 NRTI, outcome: 1.6 Drug-related serious AE.

BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022


DOL+ 2 NRTI EFV		EFV + 2	NRTI		Odds Ratio		Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
1.6.1 48 weeks									
SINGLE; Walmsley 2013 Subtotal (95% CI)	1	414 414	8	419 419	100.0% 100.0 %				
Total events Heterogeneity: Not applica Test for overall effect: Z = 1		05)	8						
							0.001	0.1 1 10 Favours DOL Favours EFV	1000

Test for subgroup differences: Not applicable

Grade 3/4 AE

Forest plot of comparison: 1 DOL vs EFV + any 2 NRTI, outcome: 1.7 Grade 3/4 AE.






Test for subgroup differences: $Chi^2 = 0.01$, df = 1 (P = 0.93), $I^2 = 0\%$

Drug-related Grade 3/4 AE

Forest plot of comparison: 1 DOL vs EFV + any 2 NRTI, outcome: 1.8 Drug-related grade 3/4 AE.





Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.96), I² = 0%

GRADE table for critical outcomes

	Anticipated absolu	Anticipated absolute effects* (95% CI)			Certainty of the		
Outcomes	Risk with EFV + any 2 NRTI	Risk with DOL	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments	
Virological success - 48 weeks	767 per 1,000	831 per 1,000 (799 to 857)	OR 1.49 (1.21 to 1.82)	2499 (3 RCTs)	Very low ^{a,b}		
Virological success - 96 weeks	727 per 1,000	791 per 1,000 (752 to 824)	OR 1.42 (1.14 to 1.76)	1886 (2 RCTs)	⊕⊖⊖⊖ Very low ^{a,b}		
Virological failure - 48 weeks	94 per 1,000	91 per 1,000 (70 to 118)	OR 0.96 (0.72 to 1.29)	2499 (3 RCTs)	⊕⊖⊖⊖ Very low ^{b,c,d}		



	Anticipated absolu	te effects* (95% CI)			Certainty of the	
Outcomes	Risk with EFV + any 2 NRTI	Risk with DOL	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological failure - 96 weeks	43 per 1,000	36 per 1,000 (19 to 66)	OR 0.83 (0.43 to 1.59)	1053 (1 RCT)	⊕⊕⊜ Lowc,d	
Failure with resistance - 48 weeks	485 per 1,000	94 per 1,000 (18 to 365)	OR 0.11 (0.02 to 0.61)	56 (3 RCTs)	⊕⊕⊖⊖ Low ^{b,c}	
Failure with resistance - 96 weeks	619 per 1,000	75 per 1,000 (16 to 297)	OR 0.05 (0.01 to 0.26)	49 (1 RCT)	⊕⊕⊕○ Moderate ^c	
AE-driven discontinuation - 48 weeks	48 per 1,000	9 per 1,000 (5 to 18)	OR 0.18 (0.09 to 0.35)	2499 (3 RCTs)	⊕⊕⊖⊖ Low ^{b,c}	
AE-driven discontinuation - 96 weeks	75 per 1,000	18 per 1,000 (10 to 32)	OR 0.23 (0.13 to 0.40)	1886 (2 RCTs)	⊕⊕⊖⊖ Low ^{b,c}	
Serious AE - 48 weeks	77 per 1,000	70 per 1,000 (50 to 97)	OR 0.91 (0.64 to 1.30)	1886 (2 RCTs)	⊕⊖⊖⊖ Very low ^{b,c,d}	
Serious AE - 96 weeks	106 per 1,000	84 per 1,000 (62 to 112)	OR 0.77 (0.55 to 1.06)	1886 (2 RCTs)	⊕○○○ Very low ^{b,c,d}	
Drug-related serious AE - 48 weeks	19 per 1,000	2 per 1,000 (0 to 19)	OR 0.12 (0.02 to 1.00)	833 (1 RCT)	⊕⊕⊖⊖ Low ^{b,d}	
Grade 3/4 AE - 48 weeks	199 per 1,000	114 per 1,000 (92 to 144)	OR 0.52 (0.41 to 0.68)	1886 (2 RCTs)	⊕⊕⊖⊖ Low ^{b,c}	
Grade 3/4 AE - 96 weeks	274 per 1,000	161 per 1,000 (125 to 209)	OR 0.51 (0.38 to 0.70)	1053 (1 RCT)	⊕⊕⊕○ Moderate ^c	



BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022

	Anticipated absolu	ute effects* (95% CI)			Certainty of the	
Outcomes	Risk with EFV + any 2 NRTI	Risk with DOL	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Drug-related grade 3/4 AE - 48 weeks	123 per 1,000	64 per 1,000 (43 to 96)	OR 0.49 (0.32 to 0.76)	1053 (1 RCT)	⊕⊕⊕○ Moderate ^c	
Drug-related grade 3/4 AE - 96 weeks	128 per 1,000	68 per 1,000 (46 to 102)	OR 0.50 (0.33 to 0.77)	1053 (1 RCT)	⊕⊕⊕○ Moderate∘	

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Explanations

- a. Difference between groups in numbers with missing data for virological outcomes
- b. In SINGLE, only 16% of the participants were women, and the proportion of participants with a CD4+ T-cell count of less than 200 per cubic millimeter was relatively low.
- c. Some concerns (open label study)
- d. 95% Confidence interval spans 1



2 DOL vs BIC + any 2 NRTI

Two studies were included (NCT02607930; NCT02607956). NCT02607930 data were published for week 48 results (Gallant 2017) and week 96 results (Wohl 2019). Similarly, NCT02607956 data were published for week 48 (Sax 2017) and week 96 results (Stellbrink 2019). This section therefore includes four fully published papers (Gallant 2017, Wohl 2019, Sax 2017 and Stellbrink 2019).

The following Table shows the key features of these studies in terms of their inclusion and exclusion criteria, the characteristics of the population studied, the intervention, comparator and the outcomes reported.

Table 3. Key features of the included studies

Study name/	Citation	Inclusion	Exclusions	Population (n;	Interventio	Comparat	Outcomes
NCT number		criteria		demographics)	n	or	
NCT026079	Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D,	HIV-1-	An	629 participants in 122	Dolutegrav	Bictegravir	The primary
30; GS-US-	Tebas P, et al. Bictegravir, emtricitabine, and tenofovir	infected	opportunistic	outpatient centres in	ir, abacavir	,	outcome
380-1489;	alafenamide versus dolutegravir, abacavir, and	adults (aged	illness	nine countries in	and	emtricitabi	was the
2015-	lamivudine for initial treatment of HIV-1 infection (GS-	≥18 years)	indicative of	Europe, Latin America,	lamivudine	ne and	proportion
004024-54	US-380-1489): a double-blind, multicentre, phase 3,	who were	stage 3 HIV	and North America.		tenofovir	of
(EudraCT	randomised controlled non-inferiority trial. Lancet	previously	diagnosed	B/F/TAF group (n=314);		alafenami	participants
Number)	(london, england). 2017;390(10107):2063-72.	untreated	within the 30	DTG/ABC/3TC group		de	with plasma
		and had	days prior to	(n=315)			HIV-1 RNA
		plasma HIV-	screening	Age (years) 31 (18–71);			< 50 copies
		1 RNA	(refer to study	32 (18–68)			per mL at
		concentratio	protocol)	Female 29 (9%); 33			week 48, as
		ns of 500	Decompensat	(10%)			defined by
		copies per	ed cirrhosis	Male 285 (91%); 282			the US
		mL or more,	(e.g., ascites,	(90%)			Food and
		no hepatitis	encephalopat	Race:			Drug
		B virus	hy, or variceal	White 180 (57%); 179			Administrati
		infection,	bleeding)	(57%)			on (FDA)
		were HLA-	Current	Black 114 (36%); 112			snapshot
		B*5701-	alcohol or	(36%)			algorithm.
		negative,	substance	Asian 6 (2%); 10 (3%)			Additional
		had an	use judged by	American Indian or			prespecified
		eGFR of 50	the	Alaska Native 2 (1%); 4			efficacy
		mL/min or	Investigator	(1%)			endpoints
		more	to potentially	Native Hawaiian or			included the
		(Cockcroft–	interfere with	Pacific Islander 1			proportion
		Gault		(<1%); 2 (1%)			of



	equation),	subject study	Other 9 (3%); 8 (3%)		participants
	and had no	compliance	Not permitted 2 (1%); 0		with plasma
	documented	Females who	Hispanic or Latino 72		HIV-1 RNA
	resistance	are pregnant	(23%); 65 (21%)		<50 copies
	to	(as confirmed	HIV disease status:		per mL at
	emtricitabin	by positive	Asymptomatic 286		week 48
	e, tenofovir,	serum	(91%); 286 (91%)		after
	abacavir, or	pregnancy	Symptomatic 16 (5%);		imputation
	lamivudine.	test)	14 (4%)		of missing-
	iamivadine.	Females who	AIDS 12 (4%); 15 (5%)		as-failure
		are	HIV risk factor:		and
		breastfeeding	Heterosexual sex 61		missing-as-
		Chronic	(19%); 62 (20%)		excluded
		Hepatitis B	Homosexual sex 251		values.
		Virus (HBV)	(80%); 250 (79%)		values.
		infection	Intravenous drug use 5		
		iniection	(2%); 4 (1%)		
			HIV-1 RNA (log10		
			copies per mL) 4.42		
			(4·03–4·87); 4·51		
			(4·04–4·87)		
			HIV-1 RNA >100 000		
			copies per mL 53		
			(17%); 50 (16%)		
			CD4 count (cells per		
			μL): 443 (299–590); 450		
			(324–608)		
			<50: 7 (2%); 10 (3%)		
			≥50 to <200: 29 (9%);		
			22 (7%)		
			≥200 to <350: 69 (22%);		
			58 (18%)		
			≥350 to <500: 87 (28%);		
			91 (29%)		
			≥500: 122 (39%); 134		
			(43%)		
			Creatinine clearance		
			(mL/min)* 125.9		
			(107.7–146.3); 123.0		
			(107·0–144·3)		
			Body-mass index		
			(kg/m²) 25·1 (22·4–		



				28-7); 24-9 (22-5–29-1) Data are median (IQR [range for age]) or n (%). B/F/TAF=bictegravir, emtricitabine, and tenofovir alafenamide. DTG/ABC/3TC=dolutegr avir, abacavir, and lamivudine. *Estimated with the Cockcroft— Gault equation.			
	Wohl, DA; Yazdanpanah, Y; Baumgarten, A; Clarke, A; Thompson, MA; Brinson, C; Hagins, D; Ramgopal, MN; Antinori, A; Wei, X; Acosta, R; Collins, SE; Brainard, D; Martin, H. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The lancet. HIV 2019; 6(6): e355-363. DOI: 10.1016/S2352-3018(19)30077-3. https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01963192/full	As above	As above	As above	As above	As above	As above
NCT026079 56; GS-US- 380-1490; 2015- 003988-10 (EudraCT Number)	Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet (london, england). 2017;390(10107):2073-82.	Adults (aged ≥18 years) with HIV-1 infection who were previously untreated, with plasma HIV-1 RNA levels of at least 500 copies per mL, with estimated glomerular filtration rate (eGFR) of	An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening Decompensat ed cirrhosis (eg, ascites, encephalopat hy, or variceal bleeding) Current alcohol or substance	645 participants at 126 outpatient centres in 10 countries (Australia, Belgium, France, Germany, Italy, Spain, the UK, Dominican Republic, the USA, and Canada). Bictegravir regimen (n=320); Dolutegravir regimen (n=325) Median age, years 33 (27.46); 34 (27.46) Women 40 (13%); 37 (11%) Men 280 (88%); 288 (89%) Race:	Dolutegrav ir with coformulat ed emtricitabi ne and tenofovir alafenamid e	Bictegravir, emtricitabi ne and tenofovir alafenami de	The primary outcome was the proportion of participants who had plasma HIV-1 RNA <50 copies per mL at week 48 as defined by the US FDA snapshot algorithm. Additional prespecified



at least 30	use judged by	White 183 (57%); 195		efficacy
mL per min	the	(60%)		endpoints
(calculated	Investigator	Black 97 (30%); 100		included the
by the	to potentially	(31%)		proportion
Cockcroft-	interfere with	Asian 7 (2%); 10 (3%)		of
Gault	subject study	Ethnic origin:		participants
equation),	compliance	Hispanic or Latino 83		with plasma
and with	Females who	(26%); 81 (25%)		HIV-1 RNA
virological	are pregnant	Region:		<50 copies
resistance	(as confirmed	USA 193 (60%); 193		per mL at
testing	by positive	(59%)		week 48
showing	serum	Outside the USA 127		when
sensitivity to	pregnancy	(40%); 132 (41%)		imputing
emtricitabin	test)	HIV disease status:		missing
e and	Females who	Asymptomatic 286		data as
tenofovir	are	(89%); 288 (89%)		failure (M =
	breastfeeding	Symptomatic 10 (3%);		F) and
		11 (3%)		missing as
		AIDS 24 (8%); 26 (8%)		excluded
		HIV risk factor:*		(M = E) and
		Heterosexual sex 81		changes in
		(25%); 77 (24%)		log10 HIV-1
		Homosexual sex 237		RNA and
		(74%); 250 (77%)		CD4 count
		Intravenous drug use 3		from
		(1%); 6 (2%)		baseline at
		Median HIV-1 RNA		week 48.
		log10 copies per mL		Safety
		4.43 (3.95-4.90); 4.45		outcomes
		(4.03-4.84)		were
		HIV-1 RNÁ		assessed
		concentration:		by changes
		>100 000 to ≤400 000		from
		copies per mL: 54		baseline in
		(17%); 41 (13%)		fasting
		>400 000 copies per mL		glucose,
		12 (4%); 13 (4%)		lipid panels,
		Median CD4 count		serum
		(cells per µL) 440 (289-		creatinine,
		591); 441 (297-597)		and eGFR
		CD4 count (cells per		at week 48.
		μL):		



	tellbrink, HJ; Arribas, JR; Stephens, JL; Albrecht, H;	As above	As above	<50: 15 (5%); 13 (4%) ≥50 to <200: 29 (9%); 21 (6%) ≥200 to <350: 67 (21%); 77 (24%) ≥350 to <500: 91 (28%); 94 (29%) ≥500: 118 (37%); 120 (37%) Median creatinine clearance (mL/min) 120.4 (100.8-141.8); 120.6 (102.8-145.1) Patients with HIV/HBV co-infection 8 (3%); 6 (2%) Patients with HIV/HCV co-infection 5 (2%); 5 (2%) Median body-mass index (kg/m2) 25.0 (22.2-28.3); 24.6 (22.2-28.0) Data are median (IQR) or n (%), except for age, which is median (range). *A participant may fit more than one HIV risk factor category; therefore, percentages may add to more than 100%. HBV=hepatitis B virus. HCV=hepatitis C virus. As above	As above	As above	As above
X; Co ala	ax, PE; Maggiolo, F; Creticos, C; Martorell, CT; Wei, ; Acosta, R; Collins, SE; Brainard, D; Martin, H. o-formulated bictegravir, emtricitabine, and tenofovir lafenamide versus dolutegravir with emtricitabine and enofovir alafenamide for initial treatment of HIV-1						



infection: week 96 results from a randomised, double-			
blind, multicentre, phase 3, non-inferiority trial.			
The lancet. HIV 2019; 6(6): e364-372.			
DOI: 10.1016/S2352-3018(19)30080-3.			
https://www.cochranelibrary.com/central/doi/10.1002/c			
entral/CN-01963191/full			


Table 4. Comparisons included in this section

Study name/ NCT number	Intervention (Two NRTI + DOL)	Comparator (2 NRTI + BIC)
NCT02607930; GS-US-380-1489; 2015-004024-54 (EudraCT	Dolutegravir, abacavir and lamivudine	Bictegravir, emtricitabine and tenofovir
Number)		alafenamide
NCT02607956; GS-US-380-1490; 2015-003988-10 (EudraCT	Dolutegravir, emtricitabine and tenofovir	Bictegravir, emtricitabine and tenofovir
Number)	alafenamide	alafenamide

Virological success, failure and missing data

Forest plot of comparison: 2 DOL vs BIC + any 2 NRTI, outcome: 2.1 Virological success.





Test for subgroup differences: $Chi^2 = 0.12$, df = 1 (P = 0.73), $I^2 = 0\%$

Forest plot of comparison: 2 DOL vs BIC + any 2 NRTI, outcome: 2.2 Virological failure.






Figure: 3. Success, failure and missing data at 48 weeks







Figure: 4. Success, failure and missing data at 96 weeks






Failing with resistance

Forest plot of comparison: 2 DOL vs BIC + any 2 NRTI, outcome: 2.3 Failure with resistance.






Test for subgroup differences: Not applicable

Adverse event (AE)-driven discontinuation

Forest plot of comparison: 2 DOL vs BIC + any 2 NRTI, outcome: 2.4 AE-driven discontinuation.






Test for subgroup differences: $Chi^2 = 0.38$, df = 1 (P = 0.54), $I^2 = 0\%$

Serious adverse events

Forest plot of comparison: 2 DOL vs BIC + any 2 NRTI, outcome: 2.5 Serious AE.






Test for subgroup differences: $Chi^2 = 2.54$, df = 1 (P = 0.11), $I^2 = 60.7\%$

Drug-related SAE

Forest plot of comparison: 2 DOL vs BIC + any 2 NRTI, outcome: 2.6 Drug-related serious AE.






Test for subgroup differences: $Chi^2 = 0.20$, df = 1 (P = 0.66), $I^2 = 0\%$

Grade 3/4 AE

Forest plot of comparison: 2 DOL vs BIC + any 2 NRTI, outcome: 2.7 Grade 3/4 AE.






Test for subgroup differences: $Chi^2 = 0.32$, df = 1 (P = 0.57), $I^2 = 0\%$

Drug-related Grade 3/4 AE

Forest plot of comparison: 2 DOL vs BIC + any 2 NRTI, outcome: 2.8 Drug-related grade 3/4 AE.





Test for subgroup differences: Not applicable

GRADE table for critical outcomes

	Anticipated absolute effects* (95% CI)				Certainty of the	
Outcomes	Risk with BIC + any 2 NRTI	Risk with DOL	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological success - 48 weeks	909 per 1,000	930 per 1,000 (898 to 952)	OR 1.33 (0.89 to 2.00)	1274 (2 RCTs)	⊕⊕⊖⊖ Low ^{a,b}	
Virological success - 96 weeks	860 per 1,000	881 per 1,000 (842 to 912)	OR 1.21 (0.87 to 1.69)	1274 (2 RCTs)	⊕⊖⊖⊖ Very low ^{a,b,c}	
Virological failure - 48 weeks	27 per 1,000	19 per 1,000 (9 to 39)	OR 0.69 (0.33 to 1.46)	1274 (2 RCTs)	⊕⊖⊖⊖ Very low ^{a,b,d}	



	Anticipated absolute effects* (95% CI)				Certainty of the	
Outcomes	Risk with BIC + any 2 NRTI	Risk with DOL	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological failure - 96 weeks	25 per 1,000	25 per 1,000 (13 to 49)	OR 0.99 (0.49 to 1.99)	1274 (2 RCTs)	⊕⊖⊖⊖ Very low ^{a,b,d}	
Failure with resistance - 48 weeks	not pooled	not pooled	not pooled	17 (2 RCTs)	-	No events in either group
Failure with resistance - 96 weeks	not pooled	not pooled	not pooled	17 (2 RCTs)	-	No events in either group
AE-driven discontinuation - 48 weeks	8 per 1,000	8 per 1,000 (2 to 25)	OR 0.99 (0.30 to 3.23)	1274 (2 RCTs)	⊕⊖⊖⊖ Very low ^{a,b,d}	
AE-driven discontinuation - 96 weeks	9 per 1,000	15 per 1,000 (6 to 39)	OR 1.61 (0.60 to 4.30)	1274 (2 RCTs)	⊕⊖⊖⊖ Very low ^{a,b,d}	
Serious AE - 48 weeks	61 per 1,000	79 per 1,000 (44 to 138)	OR 1.34 (0.72 to 2.48)	629 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Serious AE - 96 weeks	144 per 1,000	113 per 1,000 (83 to 150)	OR 0.76 (0.54 to 1.05)	1274 (2 RCTs)	⊕⊖⊖⊖ Very low ^{a,b,d}	
Drug-related serious AE - 48 weeks	3 per 1,000	3 per 1,000 (0 to 49)	OR 1.00 (0.06 to 16.01)	629 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Drug-related serious AE - 96 weeks	9 per 1,000	5 per 1,000 (1 to 19)	OR 0.49 (0.12 to 1.98)	1274 (2 RCTs)	⊕⊕⊖⊖ Low ^{a,b}	
Grade 3/4 AE - 48 weeks	73 per 1,000	76 per 1,000 (44 to 130)	OR 1.04 (0.58 to 1.89)	629 (1 RCT)	⊕⊕⊜ Low ^{a,b}	

BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022

	Anticipated absolute effects* (95% CI)				Certainty of the		
Outcomes	Risk with BIC + any 2 NRTI	Risk with DOL	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments	
Grade 3/4 AE - 96 weeks	134 per 1,000	118 per 1,000 (88 to 156)	OR 0.86 (0.62 to 1.19)	1274 (2 RCTs)	⊕⊕⊖⊖ Low ^{a,b}		
Drug-related grade 3/4 AE - 48 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome	
Drug-related grade 3/4 AE - 96 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome	

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Explanations

- a. Small proportion of study participants were women or had advanced HIV disease
- b. 95% Confidence interval includes 1
- c. >10% missing data
- d. I² >60%



3 DOL vs b/PI + any 2 NRTI

Two studies were included. The results of the ARIA study were reported at 48 weeks (Orrell 2017). The results of the FLAMNIGO study were reported at 48 weeks (Clotet 2014) and at 96 weeks (Molina 2015).

Table 5. Key features of the included studies

Study name/ NCT number	Citation	Inclusion criteria	Exclusions	Population (n; demographics)	Intervention	Comparator	Outcomes
NCT01910402; ARIA	Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, et al. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. The lancet HIV. 2017;4(12):e536-e46.	Women aged ≥18 years who had HIV-1 RNA viral loads of ≥500 copies per mL, received ≤10 days of previous ART, tested negative for the HLA- B*5701 allele; had to test negative for pregnancy and agree to protocol-defined approved contraception method.	Participants were excluded if they had any evidence of active US Centers for Disease Control and Prevention (CDC) Category C HIV disease, hepatic impairment, creatinine clearance of less than 50 mL/min, or primary viral resistance based on the presence of any major resistance-associated mutation according to the 2013 International AIDS Society guidelines. Participants who became pregnant during the study were required to withdraw.	499 participants in 86 hospital and university infectious disease clinics, local health clinics, and private infectious disease clinics in 12 countries and one US territory, in North America, South America, Europe, Africa, and Asia. Dolutegravir group (n=248); Atazanavir group (n=248); Atazanavir group (n=247) Mean age, years (SD) 38·1 (11.15); 37·8 (10.14) Ethnic origin: Black 102 (41%); 108 (44%) White 115 (46%); 107 (43%) Asian 22 (9%); 23 (9%) Other 9 (4%); 9 (4%) Country or territory of origin: USA* 62 (25%); 69 (28%) Puerto Rico 0; 2 (<1%)	Dolutegravir plus abacavir and lamivudine	Ritonavir- boosted atazanavir plus coformulated tenofovir disoproxil fumarate and emtricitabine	The primary endpoint was the proportion of participants with plasma HIV-1 RNA <50 copies per mL at week 48 assessed with the US FDA snapshot algorithm for the intention-to-treat exposed (ITT-E) population, defined as all participants who received at least one dose of study medication. Secondary efficacy endpoints included the proportion of participants with plasma HIV-1 RNA <50 copies per mL and <400 copies per mL and <400 copies per mL over time, absolute values and change from baseline in plasma HIV-1 RNA over time, CD4 lymphocyte cell counts and changes

BH	IVA 🎘
	HV Association

South Africa 33	from baseline, and
(13%); 33 (13%)	incidence of disease
Spain 23 (9%); 31	progression (HIV-
(13%)	associated
Russia 28 (11%); 22	conditions, AIDS,
(9%)	and death). Safety
Argentina 24 (10%);	endpoints were
20 (8%)	identified by the
Thailand 19 (8%); 21	following: serious
(9%)	adverse events;
Italy 17 (7%); 11	haematology, blood
(4%)	
UK 14 (6%); 11 (4%)	chemistry, and
	fasting lipid
Canada 11 (4%); 9	assessments;
(4%)	physical
France* 7 (3%); 8	assessments;
(3%)	urinalysis results;
Mexico 6 (2%); 5	assessment and
(2%)	documentation of all
Portugal 4 (2%); 5	concomitant
(2%)	medications and
Hepatitis C infection	blood products
16 (6%); 21 (9%)	received; and
CDC category of	monitoring of
HIV-1 infection:	suicidal intent with
Asymptomatic 210	the Columbia
(85%); 208 (84%)	Suicide-Severity
Symptomatic, not	Rating Scale. Other
AIDS 27 (11%); 30	endpoints included
(12%)	the incidence of
AIDS 11 (4%); 9	treatment-emergent
(4%)	genotypic and
HIV-1 RNA	phenotypic
concentration:	resistance in
≤100 000 copies per	patients who met
mL 179 (72%); 181	confirmed virological
(73%)	withdrawal criteria,
>100 000 copies per	and health outcome
mL 69 (28%); 66	measures of quality
(27%)	of life and treatment
Median, log copies	satisfaction.
per mL 4-410 (3-91-	

BH	IVA 🔅
British H	IIV Association

5.09); 4.430 (3.92–
5.05)
CD4 count:
<50 cells per μL 9
(4%); 15 (6%)
50 to <200 cells per
μL 55 (22%); 34
(14%)
200 to <350 cells per
μL 66 (27%); 74
(30%)
350 to <500 cells per
μL 56 (23%); 65
(26%)
≥500 cells per µL 62
(25%); 59 (24%)
Median cells per μL
340.0 (197.0–497.5);
350.0 (241.0-487.0)
Known HIV risk
factors†:
Heterosexual contact
233 (94%); 233
(94%)
Homosexual contact
1 (<1%); 2 (1%)
Injectable drug use
12 (5%); 8 (3%)
Transfusion 5 (2%);
2 (1%)
Other 5 (2%); 5 (2%)
Data are n (%)
unless otherwise
indicated. CDC=US
Centers for Disease
Control and
Prevention. *Four
participants did not
receive treatment:
USA n=3, France
n=1. †Some patients



				had more than one risk factor.			
NCT01449929; FLAMINGO	Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S; ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviralnaive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014 Jun 28;383(9936):2222-31. doi: 10.1016/S0140-6736(14)60084-2. Epub 2014 Apr 1. Erratum in: Lancet. 2015 Jun 27;385(9987):2576. PMID: 24698485.	≥18 years; had a concentration of plasma HIV-1 RNA ≥1000 copies/mL, no previous treatment with antiretroviral therapy, and no primary resistance to NRTIs or protease inhibitors	Patients with active disease of category C from the Centers for Disease Control and Prevention, and defined laboratory values or medical characteristics such as pregnancy, moderate or severe hepatic impairment, an anticipated need for hepatitis C treatment during the study, estimated creatinine clearance of <50 mL/min (due to use of fixed-dose NRTI combinations), recent (within the past 5 years) or ongoing malignancy, or treatment with an HIV-1 vaccine within 90 days of screening or with any immunomodulator within 28 days. Patients could receive abacavir—lamivudine only after screening negative for the HLA-B57*01 allele.	488 participants. Dolutegravir (n=242); Darunavir/ritonavir (n=242) Median age (range), years: 34 (18–67); 34 (19–67) Male sex 211 (87%); 201 (83%) Race: White 173 (71%); 176 (73%) African American or African heritage 60 (25%); 53 (22%) Other 8 (3%); 13 (5%) Baseline HIV-1 RNA Median (IQR), log10 copies per mL: 4.49 (4.02–5.02); 4.48 (4.01–5.01) >100 000 copies per mL: 61 (25%); 61 (25%) Baseline CD4 cell count Median (IQR), cells per μL: 390 (290–500); 400 (300–530)	Dolutegravir with investigator-selected combination tenofovir and emtricitabine or combination abacavir and lamivudine	Darunavir plus ritonavir with investigator-selected combination tenofovir and emtricitabine or combination abacavir and lamivudine	Primary endpoint: the proportion of patients with a concentration of HIV-1 RNA lower than 50 copies per mL at week 48, using the US Food and Drug Administration (FDA) snapshot (missing, switch, or discontinuation equals failure; MSDF) algorithm. Secondary: changes from baseline in CD4 cell counts, incidence and severity of adverse events, changes in laboratory variables (such as fasting low- density lipoprotein [LDL] cholesterol), time to virological suppression, and treatment-emergent genotypic or phenotypic or phenotypic evidence of resistance; disease progression, proportion of patients who discontinued treatment because of adverse events, and health outcomes



						measures, including the EuroQol five dimension (EQ-5D), HIV Treatment Satisfaction Questionnaire, and Symptom Distress Module.
Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, Kulagin V, Givens N, de Oliveira CF, Brennan C; FLAMINGO study team. Once-daily dolutegravir versus darunavir plus ritonavir for treatmentnaive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015 Apr;2(4):e127-36. doi: 10.1016/S2352-3018(15)00027-2. Epub 2015 Mar 10. Erratum in: Lancet HIV. 2015 Apr;2(4):e126. PMID: 26424673.	As above					


Table 6. Comparisons included in this section

Study name/ NCT	Intervention (Two NRTI + DOL)	Comparator (2 NRTI + b/PI)
number		
NCT01910402; ARIA	Dolutegravir, abacavir and lamivudine	Ritonavir-boosted atazanavir, tenofovir disoproxil fumarate and
		emtricitabine
NCT01449929;	Dolutegravir with investigator-selected combination tenofovir (DF)	Darunavir plus ritonavir with investigator-selected combination tenofovir
FLAMINGO	and emtricitabine or combination abacavir and lamivudine	(DF) and emtricitabine or combination abacavir and lamivudine



Virological success, failure and missing data

Forest plot of comparison: 3 DOL vs b/PI + any 2 NRTI, outcome: 3.1 Virological success.



Test for subgroup differences: $Chi^2 = 0.04$, df = 1 (P = 0.84), $I^2 = 0\%$


Of note, the ARIA study reported superiority primarily driven by the lower rates of adverse-event-related discontinuations and virological non-response in the dolutegravir group.

Similarly, the FLAMINGO study reported that discontinuation due to adverse events or stopping criteria at 48 weeks was less frequent for dolutegravir (four [2%] patients) than for darunavir plus ritonavir (ten [4%] patients) and contributed to the difference in response rates. This study also reported that part of



the difference in the virological response rates at 96 weeks was driven by a higher percentage of discontinuations for other reasons (e.g., lost to follow-up) in the darunavir plus ritonavir group than in the dolutegravir group.

Forest plot of comparison: 3 DOL vs b/PI + any 2 NRTI, outcome: 3.2 Virological failure.



165(10) Subdicup differences: Offi = 0.17, di = 1 (1 = 0.00), 1 = 0.

Figure 5. Success, failure and missing data at 48 weeks







Figure 6. Success, failure and missing data at 96 weeks





Failing with resistance

Forest plot of comparison: 3 DOL vs b/PI + any 2 NRTI, outcome: 3.3 Failure with resistance.




	DOL + 2	NRTI	b/PI + 2	NRTI		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI	
3.3.1 48 weeks									
ARIA; Orrell 2017	0	6	0	4		Not estimable			
FLAMINGO; Clotet 2014 Subtotal (95% CI)	0	2 8	0	2 6		Not estimable Not estimable			
Total events Heterogeneity: Not applica Test for overall effect: Not :			0						
3.3.2 96 weeks									
FLAMINGO; Molina 2014 Subtotal (95% CI)	0	2 2	0	4 4		Not estimable Not estimable			
Total events Heterogeneity: Not applica Test for overall effect: Not :			0						
							0.001	0.1 1 10 avours DOL Favours b/PI	100

Test for subgroup differences: Not applicable

Adverse event (AE)-driven discontinuation

Forest plot of comparison: 3 DOL vs b/PI + any 2 NRTI, outcome: 3.4 AE-driven discontinuation.






Test for subgroup differences: $Chi^2 = 0.02$, df = 1 (P = 0.90), $I^2 = 0\%$

Serious adverse events

Forest plot of comparison: 3 DOL vs b/PI + any 2 NRTI, outcome: 3.5 Serious AE.






Test for subgroup differences: $Chi^2 = 1.46$, df = 1 (P = 0.23), $I^2 = 31.3\%$

Drug-related SAE

Forest plot of comparison: 3 DOL vs b/PI + any 2 NRTI, outcome: 3.6 Drug-related serious AE.






Test for subgroup differences: $Chi^2 = 2.32$, df = 1 (P = 0.13), $I^2 = 56.8\%$

Grade 3/4 AE

Forest plot of comparison: 3 DOL vs b/PI + any 2 NRTI, outcome: 3.7 Grade 3/4 AE.






Test for subgroup differences: Not applicable

Drug-related Grade 3/4 AE

Forest plot of comparison: 3 DOL vs b/PI + any 2 NRTI, outcome: 3.8 Drug-related grade 3/4 AE.





Test for subgroup differences: Not applicable

GRADE table for critical outcomes

	Anticipated absolute effects* (95% Cl)				Certainty of the	
Outcomes	Risk with b/PI + any 2 NRTI	Risk with DOL	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological success - 48 weeks	769 per 1,000	858 per 1,000 (813 to 894)	OR 1.82 (1.31 to 2.54)	979 (2 RCTs)	⊕⊖⊖⊖ Very low ^{a,b,c}	
Virological success - 96 weeks	678 per 1,000	801 per 1,000 (728 to 860)	OR 1.92 (1.27 to 2.91)	484 (1 RCT)	⊕⊖⊖⊖ Very low ^{a,b}	
Virological failure - 48 weeks	108 per 1,000	64 per 1,000 (41 to 97)	OR 0.56 (0.35 to 0.88)	979 (2 RCTs)	⊕⊕⊖⊖ Low ^{b,c,d}	



	Anticipated absolu	te effects* (95% CI)			Certainty of the	
Outcomes	Risk with b/PI + any 2 NRTI	Risk with DOL	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological failure - 96 weeks	116 per 1,000	78 per 1,000 (44 to 136)	OR 0.65 (0.35 to 1.20)	484 (1 RCT)	⊕⊖⊖⊖ Very low ^{b,d,e}	c
Failure with resistance - 48 weeks	not pooled	not pooled	not pooled	14 (2 RCTs)	-	No events in either group
Failure with resistance - 96 weeks	0 per 1,000	0 per 1,000 (0 to 0)	not estimable	6 (1 RCT)		No events in either group
AE-driven discontinuation - 48 weeks	53 per 1,000	26 per 1,000 (13 to 51)	OR 0.48 (0.24 to 0.95)	979 (2 RCTs)	⊕⊕⊖⊖ Low ^{b,c,d}	
AE-driven discontinuation - 96 weeks	54 per 1,000	25 per 1,000 (10 to 64)	OR 0.45 (0.17 to 1.20)	484 (1 RCT)	⊕⊖⊖⊖ Very low ^{b,d,e}	
Serious AE - 48 weeks	67 per 1,000	77 per 1,000 (50 to 120)	OR 1.16 (0.72 to 1.88)	979 (2 RCTs)	⊕⊖⊖⊖ Very low ^{b,c,d,e,f}	
Serious AE - 96 weeks	87 per 1,000	149 per 1,000 (90 to 236)	OR 1.84 (1.04 to 3.25)	484 (1 RCT)	⊕⊕⊖⊖ Low ^{b,d}	
Drug-related serious AE - 48 weeks	6 per 1,000	3 per 1,000 (1 to 17)	OR 0.50 (0.09 to 2.72)	979 (2 RCTs)	⊕⊖⊖⊖ Very low ^{b,c,d,e}	
Drug-related serious AE - 96 weeks	0 per 1,000	0 per 1,000 (0 to 0)	OR 7.09 (0.36 to 137.95)	484 (1 RCT)	⊕⊖⊖⊖ Very low ^{b,d,e}	
Grade 3/4 AE - 48 weeks	186 per 1,000	84 per 1,000 (50 to 138)	OR 0.40 (0.23 to 0.70)	495 (1 RCT)	⊕⊕⊖⊖ Low ^{c,d}	



BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022

	Anticipated absolute effects* (95% CI)				Certainty of the	
Outcomes	Risk with b/PI + any 2 NRTI	Risk with DOL	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Grade 3/4 AE - 96 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome
Drug-related grade 3/4 AE - 48 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome
Drug-related grade 3/4 AE - 96 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Explanations

- a. Difference between groups in numbers with missing data for virological outcomes
- b. FLAMINGO: Low number of non-white, female, co-infected (HIV and hepatitis B or HIV and hepatitis C) patients or patients with advanced disease were enrolled
- c. ARIA: women only.
- d. Some concerns (open label study)
- e. 95% Confidence interval spans 1
- f. I² >60%





4 DOR vs b/PI + any 2 NRTI

NCT02275780 (DRIVE-FORWARD) data were published for week 48 results (Molina 2018) and week 96 results (Molina 2020).

Table 7. Key features of the included studies

Study name/ NCT number	Citation	Inclusion criteria	Exclusions	Population (n; demographic s)	Interventio n	Comparato r	Outcomes
NCT0227578 0; DRIVE- FORWARD; MK-1439- 018	Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. The lancet HIV. 2018;5(5):e211-e20.	Adults (aged ≥18 years) with HIV-1 infection who were naive to antiretroviral therapy, with plasma HIV-1 RNA at screening ≥1000 copies per mL, alkaline phosphatase concentrations ≤three times the upper limit of normal, aminotransfera se concentrations ≤five times the upper limit of normal, a creatinine clearance rate of ≥50 mL/min at the time of screening, and no documented or	Uses or has had a recent history of using recreational or illicit drugs. Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1. Has documented or known resistance to study drugs including doravirine, darunavir, ritonavir, emtricitabine, tenofovir, abacavir and/or lamivudine. Has participated in a study with an investigational compound/device within the prior month, or	769 participants at 125 clinical centres in 15 countries (Argentina, Australia, Austria, Canada, Chile, Denmark, France, Germany, Italy, Romania, Russia, South Africa, Spain, UK, USA). The median age of the treated population was 33 years (IQR 27–42) and 760 (99%) participants were aged younger than	Doravirine with two investigato r-selected NRTIs (tenofovir and emtricitabi ne or abacavir and lamivudine)	Darunavir plus ritonavir with two investigato r-selected NRTIs (tenofovir and emtricitabi ne or abacavir and lamivudine)	The primary efficacy endpoint was the proportion of participants who had plasma HIV-1 RNA <50 copies per mL at week 48 as defined by the US FDA snapshot algorithm. Secondary endpoints were HIV-1 RNA <40 copies per mL and change from baseline in CD4 T-cell count. Exploratory endpoints were HIV-1 RNA <200 copies per mL and change from baseline in CD4 T-cell count.



Molina, JM; Squires, K; Sax, PE; Cahn, P; Lombaard, J;	known resistance to any of the study regimen components (defined broadly according to the presence of exclusionary mutations)	anticipates doing so during this study. Has used systemic immunosuppressi ve therapy or immune modulators within the prior 30 days, or anticipates doing so during this study. Has significant hypersensitivity or other contraindication to any of the components of the study drugs. Has a current (active) diagnosis of acute hepatitis due to any cause. Is pregnant, breastfeeding or expecting to conceive at any time during the study. Female who expects to donate eggs, or male who expects to donate sperm at any time during the study. As above	65 years. The treated population included 645 (84%) men and 121 (16%) women, of whom 560 (73%) were white, 73 (10%) had previously been diagnosed with AIDS (as reported by the investigator), and 538 (70%) had subtype B HIV-1 infection	As above	As above	mL, time to loss of virological response, protocoldefined virological failure (PDVF), and the development of viral resistance to the study medications. Safety outcomes were change from baseline in LDL-cholesterol and non-HDL-cholesterol, incidence of adverse events, time to discontinuati on because of adverse events, and predefined limits of change in laboratory parameters.
DeJesus, E; Lai, MT; Rodgers, A; Lupinacci, L; Kumar, S; Sklar, P; Hanna, GJ; Hwang, C; Martin, EA.	3.50.50		3 5.00 5 7 5			



Doravirine versus ritonavir-boosted darunavir in			
antiretroviral-naive adults with HIV-1 (DRIVE-			
FORWARD): 96-week results of a randomised, double-			
blind, non-inferiority, phase 3 trial. The lancet. HIV 2020;			
7(1): e16-e26. DOI: 10.1016/S2352-3018(19)30336-4.			
https://www.cochranelibrary.com/central/doi/10.1002/cen			
tral/CN-02007909/full			


Table 8. Comparisons included in this section

Study name/ NCT number	Intervention (2 NRTI + DOR)	Comparator (2 NRTI + b/PI)
NCT02275780; DRIVE-FORWARD; MK-1439-	Doravirine with two investigator-selected NRTIs	Darunavir plus ritonavir with two investigator-selected NRTIs
018	(tenofovir [DF] and emtricitabine or abacavir and	(tenofovir [DF] and emtricitabine or abacavir and lamivudine)
	lamivudine)	

Virological success, failure and missing data

Forest plot of comparison: 4 DOR vs b/PI + any 2 NRTI, outcome: 4.1 Virological success.





Test for subgroup differences: Chi² = 0.09, df = 1 (P = 0.77), I² = 0%

Forest plot of comparison: 4 DOR vs b/PI + any 2 NRTI, outcome: 4.2 Virological failure.



	DOR + 2	NRTI	b/PI + 2	NRTI		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
4.2.1 48 weeks								
DRIVE-FORWARD; Molina 2018 Subtotal (95% CI)	43	383 383	50	383 383	100.0% 100.0%	0.84 [0.55, 1.30] 0.84 [0.55, 1.30]		-
Total events Heterogeneity: Not applicable Test for overall effect: Z = 0.77 (P =	43 = 0.44)		50					
4.2.2 96 weeks								
DRIVE-FORWARD; Molina 2020 Subtotal (95% CI)	65	379 379	76	376 376	100.0% 100.0%	0.82 [0.57, 1.18] 0.82 [0.57, 1.18]		-
Total events Heterogeneity: Not applicable Test for overall effect: Z = 1.08 (P =	65 = 0.28)		76					
T-16							0.05	0.2 1 5 20 Favours DOR Favours b/PI

Test for subgroup differences: $Chi^2 = 0.01$, df = 1 (P = 0.92), $I^2 = 0\%$

Figure 7. Success, failure and missing data at 48 weeks







Figure 8. Success, failure and missing data at 96 weeks






Failing with resistance

Forest plot of comparison: 4 DOR vs b/PI + any 2 NRTI, outcome: 4.3 Failure with resistance.






Test for subgroup differences: $Chi^2 = 2.57$, df = 1 (P = 0.11), $I^2 = 61.0\%$

Adverse event (AE)-driven discontinuation

Forest plot of comparison: 4 DOR vs b/PI + any 2 NRTI, outcome: 4.4 AE-driven discontinuation.






Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.91), I² = 0%

Serious adverse events

Forest plot of comparison: 4 DOR vs b/PI + any 2 NRTI, outcome: 4.5 Serious AE.






Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.97), I² = 0%

Drug-related SAE

Forest plot of comparison: 4 DOR vs b/PI + any 2 NRTI, outcome: 4.6 Drug-related serious AE.






Test for subgroup differences: $Chi^2 = 0.00$, df = 1 (P = 1.00), $I^2 = 0\%$

Grade 3/4 AE

Forest plot of comparison: 4 DOR vs b/PI + any 2 NRTI, outcome: 4.7 Grade 3/4 AE.






Test for subgroup differences: Not applicable

Drug-related Grade 3/4 AE

Forest plot of comparison: 4 DOR vs b/PI + any 2 NRTI, outcome: 4.8 Drug-related grade 3/4 AE.





Test for subgroup differences: Not applicable

GRADE table for critical outcomes

	Anticipated absolu	te effects* (95% CI)			Certainty of the	
Outcomes	Risk with b/PI + any 2 NRTI	Risk with DOR	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological success - 48 weeks	799 per 1,000	838 per 1,000 (781 to 882)	OR 1.30 (0.90 to 1.88)	766 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Virological success - 96 weeks	660 per 1,000	731 per 1,000 (666 to 787)	OR 1.40 (1.03 to 1.91)	755 (1 RCT)	⊕⊕⊜⊖ Low ^{a,c}	
Virological failure - 48 weeks	131 per 1,000	112 per 1,000 (76 to 163)	OR 0.84 (0.55 to 1.30)	766 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	



	Anticipated absolu	Anticipated absolute effects* (95% CI)			Certainty of the	
Outcomes	Risk with b/PI + any 2 NRTI	Risk with DOR	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological failure - 96 weeks	202 per 1,000	172 per 1,000 (126 to 230)	OR 0.82 (0.57 to 1.18)	755 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Failure with resistance - 48 weeks	375 per 1,000	57 per 1,000 (0 to 597)	OR 0.10 (0.00 to 2.47)	15 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Failure with resistance - 96 weeks	71 per 1,000	182 per 1,000 (17 to 739)	OR 2.89 (0.23 to 36.87)	25 (1 RCT)	⊕⊕⊜⊖ Low ^{a,b}	
AE-driven discontinuation - 48 weeks	31 per 1,000	16 per 1,000 (6 to 41)	OR 0.49 (0.18 to 1.32)	766 (1 RCT)	⊕⊕⊜⊖ Low ^{a,b}	
AE-driven discontinuation - 96 weeks	34 per 1,000	16 per 1,000 (6 to 40)	OR 0.45 (0.17 to 1.20)	766 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Serious AE - 48 weeks	60 per 1,000	50 per 1,000 (27 to 89)	OR 0.82 (0.44 to 1.53)	766 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Serious AE - 96 weeks	86 per 1,000	70 per 1,000 (42 to 114)	OR 0.80 (0.47 to 1.37)	766 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Drug-related serious AE - 48 weeks	3 per 1,000	3 per 1,000 (0 to 40)	OR 1.00 (0.06 to 16.05)	766 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Drug-related serious AE - 96 weeks	3 per 1,000	3 per 1,000 (0 to 40)	OR 1.00 (0.06 to 16.05)	766 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Grade 3/4 AE - 48 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome



BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022

	Anticipated absolu	ute effects* (95% CI)			Certainty of the			
Outcomes	Risk with b/PI + any 2 NRTI	Risk with DOR	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments		
Grade 3/4 AE - 96 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome		
Drug-related grade 3/4 AE - 48 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome		
Drug-related grade 3/4 AE - 96 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome		

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Explanations

- a. Molina 2018: low number of women (121 [16%]) and participants aged older than 65 years (1%) enrolled in the trial.
- b. 95% Confidence interval spans 1
- c. >10% missing data



5 DOR vs EFV + any 2 NRTI

NCT02403674 (DRIVE-AHEAD) data were published for week 48 results (Orkin 2019) and week 96 results (Orkin 2021).

Table 9. Key features of the included studies

Study name/	Citation	Inclusion criteria	Exclusions	Population (n;	Intervention	Comparator	Outcomes
NCT number				demographics)			
NCT02403674;	Orkin C, Squires KE, Molina J-M, Sax	Men and women	Documented or	728 participants	Doravirine/	Efavirenz/	The primary
DRIVE-	PE, Wong W-W, Sussmann O, et al.	≥18 years of age	known resistance	at 126 sites	lamivudine/	emtricitabine/	efficacy endpoint
AHEAD; MK-	Doravirine/Lamivudine/Tenofovir	with plasma HIV-	to any study drug.	worldwide.	tenofovir	tenofovir	was the proportion
1439A Protocol	Disoproxil Fumarate is non-inferior to	1 RNA of ≥1000	Treatment for a	Age (years),	disoproxil	disoproxil	of participants with
021	Efavirenz/Emtricitabine/Tenofovir	copies/mL	viral infection other	Median (range)	fumarate	fumarate	<50 HIV-1 RNA
	Disoproxil Fumarate in treatment-naive	(within 45 days	than HIV-1 (such	31.0 (18, 70)			copies/mL at week
	adults with Human Immunodeficiency	before study	as hepatitis B) with	Male, n (%) 616			48 (FDA snapshot
	Virus-1 Infection: Week 48 Results of	treatment) who	an agent that is	(85%)			approach; non-
	the DRIVE-AHEAD Trial. Clinical	were naive to	active against HIV-	Race, n (%):			inferiority margin
	infectious diseases: an official	antiretroviral	1, including, but not	White 347			10%). Secondary
	publication of the Infectious Diseases	therapy were	limited to, adefovir,	(48%)			and exploratory
	Society of America. 2019;68(4):535-	eligible for the	tenofovir, entecavir,	Black or African			efficacy endpoints
	44.	trial if they had	emtricitabine, or	American 135			included HIV-1
		no documented	lamivudine (unless	(19%)			RNA of <40
		or known	treatment occurred	Asian 124			copies/mL, HIV-1
		resistance to any	prior to the	(17%)			RNA of <200
		of the study	diagnosis of HIV).	Other (includes			copies/mL, change
		drugs and had	Significant	multiracial,			from baseline in
		calculated	hypersensitivity or	American			CD4+ T-cell
		creatinine	other	Indian, or			counts,
		clearance of ≥50	contraindication to	Alaska Native)			development of
		mL/min.	any of the	122 (17%)			viral drug
			components of the	Hispanic or			resistance and
			study drugs.	Latino Ethnicity			efficacy by
			Current (active)	246 (34%)			subgroup.
			diagnosis of acute	CD4+ T-Cell			
			hepatitis due to any	Count:			
			cause; evidence of	Median (range),			
			decompensated	cells/mm3: 397			
			liver disease; or	(19, 1452)			
			liver cirrhosis and a	≤200			
			Child-Pugh Class C	cells/mm3, n			



		score or Pugh- Turcotte (CPT) score >9. Pregnancy, breastfeeding, or expecting to conceive. Use of recreational or illicit drugs, or recent history of drug or alcohol abuse or dependence.	(%): 90 (12%) >200 cells/mm3, n (%): 638 (88%) Plasma HIV-1 RNA: Median (range), log10 copies/mL 4.4 (2.4, 6.4) ≤100 000 copies/mL, n (%) 573 (79%) >100 000 copies/mL, n (%) 155 (21%) History of AIDS, n (%) 99 (14%) Hepatitis B and/or C (evidence of hepatitis B surface antigen or hepatitis C virus RNA), n (%) 20 (3%) HIV-1 Subtype B, n (%) 485 (67%)			
Orkin C, Squires KE, Molina JM, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ, Hwang C, Martin E, Teppler H. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) versus Efavirenz/Emtricitabine/TDF in treatment-naive adults with Human Immunodeficiency Virus Type 1 infection: Week 96 results of the randomized, double-blind, Phase 3 DRIVE-AHEAD noninferiority trial. Clin Infect Dis. 2021 Jul 1;73(1):33-42. doi:	As above	As above	As above	As above	As above	As above



10.1093/cid/ciaa822. PMID:			
33336698; PMCID: PMC8246893.			

Table 10. Comparisons included in this section

Study name/ NCT number	Intervention (2 NRTI + DOR)	Comparator (2 NRTI + EFV)
NCT02403674; DRIVE-AHEAD; MK-1439A Protocol	Doravirine, lamivudine and tenofovir disoproxil	Efavirenz, emtricitabine and tenofovir disoproxil
021	fumarate	fumarate

Virological success, failure and missing data


Forest plot of comparison: 5 DOR vs EFV + any 2 NRTI, outcome: 5.1 Virological success.

	DOR + 2	NRTI	EFV + 2	NRTI		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
5.1.1 48 weeks							_
DRIVE-AHEAD; Orkin 2019 Subtotal (95% CI)	307	364 364	294	364 364	100.0% 100.0%	1.28 [0.87, 1.88] 1.28 [0.87, 1.88]	
Total events Heterogeneity: Not applicable	307 e		294				
Test for overall effect: $Z = 1.2$	7 (P = 0.20)					
5.1.2 96 weeks							
DRIVE-AHEAD; Orkin 2021 Subtotal (95% CI)	282	364 364	268	364 364	100.0% 100.0 %	1.23 [0.88, 1.73] 1.23 [0.88, 1.73]	
Total events Heterogeneity: Not applicable	282 e		268				
Test for overall effect: Z = 1.2	1 (P = 0.23)					
							0.5 0.7 1 1.5 2 Favours FEV Favours DOR

Test for subgroup differences: $Chi^2 = 0.02$, df = 1 (P = 0.88), $I^2 = 0\%$



Forest plot of comparison: 5 DOR vs EFV + any 2 NRTI, outcome: 5.2 Virological failure.



The proportion of participants with missing data differed between groups as the rates of discontinuations for AEs differed between groups.

Figure 9. Success, failure and missing data at 48 weeks







Figure 10. Success, failure and missing data at 96 weeks






Failing with resistance

Forest plot of comparison: 5 DOR vs EFV + any 2 NRTI, outcome: 5.3 Failure with resistance.






Test for subgroup differences: $Chi^2 = 0.22$, df = 1 (P = 0.64), $I^2 = 0\%$

Adverse event (AE)-driven discontinuation

Forest plot of comparison: 5 DOR vs EFV + any 2 NRTI, outcome: 5.4 AE-driven discontinuation.






Test for subgroup differences: $Chi^2 = 0.06$, df = 1 (P = 0.81), $I^2 = 0\%$

Serious adverse events

Forest plot of comparison: 5 DOR vs EFV + any 2 NRTI, outcome: 5.5 Serious AE.






Test for subgroup differences: $Chi^2 = 0.07$, df = 1 (P = 0.80), $I^2 = 0\%$

Drug-related SAE

Forest plot of comparison: 5 DOR vs EFV + any 2 NRTI, outcome: 5.6 Drug-related serious AE.






Test for subgroup differences: Chi² = 0.00, df = 1 (P = 1.00), I² = 0%

Grade 3/4 AE

Forest plot of comparison: 5 DOR vs EFV + any 2 NRTI, outcome: 5.7 Grade 3/4 AE.






Drug-related Grade 3/4 AE

Forest plot of comparison: 5 DOR vs EFV + any 2 NRTI, outcome: 5.8 Drug-related grade 3/4 AE.





GRADE table for critical outcomes

	Anticipated absolute effects* (95% CI)				Certainty of the	
Outcomes	Risk with EFV + any 2 NRTI	Risk with DOR	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological success - 48 weeks	808 per 1,000	843 per 1,000 (785 to 888)	OR 1.28 (0.87 to 1.88)	728 (1 RCT)	⊕⊖⊖⊖ Very low ^{a,b,c}	
Virological success - 96 weeks	736 per 1,000	774 per 1,000 (711 to 828)	OR 1.23 (0.88 to 1.73)	728 (1 RCT)	⊕⊖⊖⊖ Very low ^{a,b,c}	
Virological failure - 48 weeks	102 per 1,000	107 per 1,000 (69 to 162)	OR 1.06 (0.66 to 1.71)	728 (1 RCT)	⊕⊕⊖⊖ Low ^{b,c}	



	Anticipated absolu	te effects* (95% CI)			Certainty of the	
Outcomes	Risk with EFV + any 2 NRTI	Risk with DOR	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological failure - 96 weeks	121 per 1,000	151 per 1,000 (105 to 214)	OR 1.29 (0.85 to 1.98)	728 (1 RCT)	⊕⊕⊜⊖ Low ^{b,c}	
Failure with resistance - 48 weeks	900 per 1,000	539 per 1,000 (83 to 923)	OR 0.13 (0.01 to 1.34)	23 (1 RCT)	⊕⊕⊖⊖ Low ^{b,c}	
Failure with resistance - 96 weeks	667 per 1,000	333 per 1,000 (107 to 671)	OR 0.25 (0.06 to 1.02)	36 (1 RCT)	⊕⊕⊖⊖ Low ^{b,c}	
AE-driven discontinuation - 48 weeks	66 per 1,000	30 per 1,000 (15 to 61)	OR 0.44 (0.21 to 0.92)	728 (1 RCT)	⊕⊕⊕ Moderate ^b	
AE-driven discontinuation - 96 weeks	74 per 1,000	30 per 1,000 (15 to 60)	OR 0.39 (0.19 to 0.80)	728 (1 RCT)	⊕⊕⊕ Moderate ^b	
Serious AE - 48 weeks	58 per 1,000	35 per 1,000 (18 to 70)	OR 0.60 (0.30 to 1.23)	728 (1 RCT)	⊕⊕⊜⊖ Low ^{b,c}	
Serious AE - 96 weeks	82 per 1,000	58 per 1,000 (33 to 98)	OR 0.68 (0.38 to 1.21)	728 (1 RCT)	⊕⊕⊜⊖ Low ^{b,c}	
Drug-related serious AE - 48 weeks	11 per 1,000	3 per 1,000 (0 to 24)	OR 0.25 (0.03 to 2.23)	728 (1 RCT)	⊕⊕⊜⊖ Low ^{b,c}	
Drug-related serious AE - 96 weeks	11 per 1,000	3 per 1,000 (0 to 24)	OR 0.25 (0.03 to 2.23)	728 (1 RCT)	⊕⊕⊖⊖ Low ^{b,c}	
Grade 3/4 AE - 48 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome



BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022

	Anticipated absolute effects* (95% CI)				Certainty of the	
Outcomes	Risk with EFV + any 2 NRTI	Risk with DOR	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Grade 3/4 AE - 96 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome
Drug-related grade 3/4 AE - 48 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome
Drug-related grade 3/4 AE - 96 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Explanations

- a. Difference between groups in numbers with missing data for virological outcomes
- b. Orkin 2019: Low numbers of women (15.4%), Blacks/African Americans (18.5%), and those with high baseline viral loads (>100000 copies/mL, 21.3%), low CD4+ T-cell counts (≤200/mm3, 12.4%), or hepatitis B/C co-infections (2.7%).
- c. 95% Confidence interval spans 1



6 DOL/LAM vs TDF/FTC/DOL

GEMINI-1 and GEMINI-2 were identical in protocol (only undertaken in different study centres) and were published as pooled data; hereafter they are treated as a single trial (GEMINI-1/2) with all data pooled. GEMINI-1/2 data were published for week 48 (Cahn 2019) and week 96 (Cahn 2020).

Table 11. Key features of the included studies

Study name/ NCT number	Citation	Inclusion criteria	Exclusion s	Population (n; demographics	Intervention	Comparator	Outcomes
)			
NCT0283167	Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE,	≥18 years	Pre-	1441	Dolutegravi	Dolutegravir	The primary
3 (GEMINI-1)	et al. Dolutegravir plus lamivudine versus dolutegravir plus	with HIV-1	existing	participants at	r plus	plus	endpoint
and	tenofovir disoproxil fumarate and emtricitabine in antiretroviral-	infection and	major viral	192 centres in	lamivudine	tenofovir	was the
NCT0283176	naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2):	naive to ART	resistance	21 countries.		disoproxil	proportion
4 (GEMINI-2)	week 48 results from two multicentre, double-blind,	(≤10 days	mutations	Participants		fumarate	of
	randomised, non-inferiority, phase 3 trials. Lancet.	previous	to NRTIs	had a median		and	participants
	2019;393(10167):143-55.	therapy with	NNRTIs	age of 33		emtricitabin	with plasma
		any ART).	or PIs;	years (range		е	HIV-1 RNA
		Entry criteria	and active	18–72), with			<50 copies
		at study start	US CDC	most			per mL at
		specified	stage 3	participants			week 48
		screening	HIV	being younger			using the FDA
		viral loads of 1000-100	disease, except for	than 50 years (1288 [90%]			Snapshot
		000 copies	cutaneous	of 1433), men			algorithm.
		per mL but,	Kaposi's	(1222 [85%]),			Secondary
		as permitted	sarcoma	and white			endpoints
		per protocol,	and CD4+	(977 [68%]).			included
		the upper	cell	Baseline HIV-			proportion
		limit was	counts <	1 RNA of			of
		increased to	200 cells	more than 100			participants
		500 000	per µL.	000 copies			with HIV-1
		copies per		per mL			RNA <50
		mL during the		occurred in			copies per
		study after an		293 (20%)			mL at week
		independent		and CD4+ cell			24, time to
		review of		count of 200			achieve
		data from		cells per µL or			HIV-1 RNA
		independentl		less occurred			<50 copies
		y sponsored					per mL,



	studies evaluating the two-drug regimen of dolutegravir plus lamivudine. The study included women of reproductive potential if they were not pregnant or lactating and were using approved contraception .		in 118 (8%) participants.			absolute values and change from baseline to week 48 in CD4+ cell count, disease progression (i.e., HIV- associated conditions, AIDS, or death), and incidence of emergence of mutations conferring genotypic and phenotypic resistance to
Cahn, P; Madero, JS; Arribas, JR; Antinori, A; Ortiz, R; Clarke,	As above	As above	As above	As above	As above	dolutegravir plus lamivudine or tenofovir disoproxil fumarate and emtricitabin e in participants meeting criteria for confirmed virological withdrawal.
AE; Hung, CC; Rockstroh, JK; Girard, PM; Sievers, J; Man, CY; Urbaityte, R; Brandon, DJ; Underwood, M; Tenorio, AR;						

BH	IVA 🌣
British H	IIV Association

Pappa, KA; Wynne, B; Gartland, M; Aboud, M; van Wyk, J;			
Smith, KY. Durable Efficacy of Dolutegravir Plus Lamivudine in			
Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-			
Week Results From the GEMINI-1 and GEMINI-2 Randomized			
Clinical Trials. Journal of acquired immune deficiency			
syndromes (1999) 2020; 83(3): 310-318. DOI:			
10.1097/QAÌ.000000000002275.			
https://www.cochranelibrary.com/central/doi/10.1002/central/C			
N-02093396/full			


Table 12. Comparisons included in this section

Study name/ NCT number	Intervention (DOL/LAM)	Comparator (TDF/FTC/DOL)
NCT02831673 (GEMINI-1) and NCT02831764 (GEMINI-2)	Dolutegravir plus lamivudine	Dolutegravir plus tenofovir disoproxil fumarate and emtricitabine

Virological success, failure and missing data

Forest plot of comparison: 6 DOL/LAM vs TDF/FTC/DOL, outcome: 6.1 Virological success.






Test for subgroup differences: $Chi^2 = 0.07$, df = 1 (P = 0.79), $I^2 = 0\%$

Forest plot of comparison: 6 DOL/LAM vs TDF/FTC/DOL, outcome: 6.2 Virological failure.





restror subdroup differences. Crit = 0.00, dr = 1 (F = 0.90), r = 0 %

Figure 11. Success, failure and missing data at 48 weeks







Figure 12. Success, failure and missing data at 96 weeks






Failing with resistance

Forest plot of comparison: 6 DOL/LAM vs TDF/FTC/DOL, outcome: 6.3 Failure with resistance.






Adverse event (AE)-driven discontinuation

Forest plot of comparison: 6 DOL/LAM vs TDF/FTC/DOL, outcome: 6.4 AE-driven discontinuation.






Test for subgroup differences: $Chi^2 = 0.05$, df = 1 (P = 0.81), $I^2 = 0\%$

Serious adverse events

Forest plot of comparison: 6 DOL/LAM vs TDF/FTC/DOL, outcome: 6.5 Serious AE.






Test for subgroup differences: $Chi^2 = 0.04$, df = 1 (P = 0.85), $I^2 = 0\%$

Drug-related SAE

Forest plot of comparison: 6 DOL/LAM vs TDF/FTC/DOL, outcome: 6.6 Drug-related serious AE.






Grade 3/4 AE

Forest plot of comparison: 6 DOL/LAM vs TDF/FTC/DOL, outcome: 6.7 Grade 3/4 AE.






Drug-related Grade 3/4 AE

Forest plot of comparison: 6 DOL/LAM vs TDF/FTC/DOL, outcome: 6.8 Drug-related grade 3/4 AE.





GRADE table for critical outcomes

	Anticipated absolute effects* (95% CI)		Relative effect	Nº of participants	Certainty of the evidence		
Outcomes	Risk with TDF/FTC/DOL	Risk with DOL/LAM	(95% CI)	(studies)	(GRADE)	Comments	
Virological success - 48 weeks	933 per 1,000	915 per 1,000 (879 to 941)	OR 0.77 (0.52 to 1.14)	1433 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}		
Virological success - 96 weeks	895 per 1,000	860 per 1,000 (817 to 894)	OR 0.72 (0.52 to 0.99)	1433 (1 RCT)	⊕⊕⊕○ Moderateª		
Virological failure - 48 weeks	18 per 1,000	28 per 1,000 (14 to 55)	OR 1.56 (0.77 to 3.15)	1433 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}		



	Anticipated absolu	te effects* (95% CI)	Relative effect	No of months on to	Certainty of the	
Outcomes	Risk with TDF/FTC/DOL	Risk with DOL/LAM	(95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological failure - 96 weeks	20 per 1,000	31 per 1,000 (16 to 59)	OR 1.59 (0.81 to 3.14)	1433 (1 RCT)	⊕⊕⊜ Low ^{a,b}	
Failure with resistance - 48 weeks	0 per 1,000	0 per 1,000 (0 to 0)	not estimable	10 (1 RCT)	-	No events in either group
Failure with resistance - 96 weeks	0 per 1,000	0 per 1,000 (0 to 0)	not estimable	18 (1 RCT)	-	No events in either group
AE-driven discontinuation - 48 weeks	22 per 1,000	21 per 1,000 (10 to 42)	OR 0.94 (0.46 to 1.91)	1433 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
AE-driven discontinuation - 96 weeks	32 per 1,000	34 per 1,000 (19 to 58)	OR 1.05 (0.59 to 1.87)	1433 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Serious AE - 48 weeks	77 per 1,000	70 per 1,000 (48 to 101)	OR 0.90 (0.61 to 1.35)	1433 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Serious AE - 96 weeks	93 per 1,000	89 per 1,000 (64 to 123)	OR 0.95 (0.66 to 1.36)	1433 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Drug-related serious AE - 48 weeks	6 per 1,000	6 per 1,000 (1 to 22)	OR 1.00 (0.25 to 4.02)	1433 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Drug-related serious AE - 96 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome
Grade 3/4 AE - 48 weeks	78 per 1,000	67 per 1,000 (46 to 97)	OR 0.85 (0.57 to 1.27)	1433 (1 RCT)	⊕⊕⊜⊖ Low ^{a,b}	



BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022

	Anticipated absolute effects* (95% CI) Risk with TDF/FTC/DOL Risk with DOL/LAM		Relative effect	No of participants	Certainty of the		
Outcomes			(95% CI)	№ of participants (studies)	evidence (GRADE)	Comments	
Grade 3/4 AE - 96 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome	
Drug-related grade 3/4 AE - 48 weeks	11 per 1,000	10 per 1,000 (4 to 27)	OR 0.88 (0.32 to 2.43)	1433 (1 RCT)	⊕⊕⊜ Low ^{a,b}		
Drug-related grade 3/4 AE - 96 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome	

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Explanations

a. The study population was predominantly white (69%), male (85%) and aged <50 years at enrolment (90%); few participants were enrolled with baseline CD4+ cell count ≤200 cells/mm3, or with very high viral loads; those with hepatitis B virus infection or any major drug-resistance mutations were excluded.

b. 95% Confidence interval spans 1



7 DOL vs RALT + any 2 NRTIs

One study was included: SPRING-2; data were reported for 48 weeks (Raffi 2013a) and 96 weeks (Raffi 2013b).

Table 13. Key features of the included studies

Study name/	Citation	Inclusion	Exclusions	Population (n;	Intervention	Comparator	Outcomes
NCT number		criteria		demographics)			
NCT01227824;	Raffi F, Rachlis A,	≥18 years;	Patients with active	822	Dolutegravir. At the	Raltegravir. At the	The prespecified
SPRING-2	Stellbrink HJ, Hardy	naive for	US Centers for	participants.	investigators'	investigators'	primary endpoint was
	WD, Torti C, Orkin	antiretroviral	Disease Control and	Dolutegravir	discretion, patients	discretion, patients	the proportion of
	C, Bloch M,	therapy with	Prevention category	(n=411);	received an NRTI	received an NRTI	patients with HIV-1
	Podzamczer D,	HIV-1	C disease, except for	Raltegravir	backbone of	backbone of	RNA of less than 50
	Pokrovsky V, Pulido	infection and	Kaposi's sarcoma.	(n=411) Median	coformulated	coformulated	copies per mL at
	F, Almond S,	HIV-1 RNA	We also excluded	age (range;	tenofovir/	tenofovir/	week 48. Main
	Margolis D, Brennan	≥1000 copies	patients with defi ned	years) 37 (18–	emtricitabine or	emtricitabine or	secondary endpoints
	C, Min S; SPRING-2	per mL; no	laboratory values or	68); 35 (18–75)	abacavir/lamivudine	abacavir/lamivudine	were changes from
	Study Group. Once-	primary	medical	Men 348 (85%);			baseline in CD4 cell
	daily dolutegravir	resistance in	characteristics,	355 (86%) Race			counts, incidence and
	versus raltegravir in antiretroviral-naive	reverse	including pregnancy; moderate or severe	White 346			severity of adverse
	adults with HIV-1	transcriptase		(84%); 352			events, changes in laboratory
	infection: 48 week	or protease enzymes	hepatic impairment; an anticipated need	(86%)			parameters, and
	results from the	enzymes	for hepatitis C	Black 49 (12%);			genotypic or
	randomised, double-		treatment during the	39 (9%)			phenotypic evidence
	blind, non-inferiority		study; estimated	Other 16 (4%);			of resistance. Other
	SPRING-2 study.		creatinine clearance	20 (5%)			secondary endpoints
	Lancet. 2013 Mar		of less than 50	Baseline HIV-1			were dolutegravir
	2;381(9868):735-43.		mL/min; recent or	RNA Median			pharmacokinetics,
	doi: 10.1016/S0140-		ongoing malignancy;	concentration			pharmacokinetics,
	6736(12)61853-4.		or treatment with an	(log10 copies			pharma codynamic
	Epub 2013 Jan 8.		HIV-1 vaccine within	per mL) 4.52			relations, and health
	PMID: 23306000.		90 days of screening	(4.08–5.06);			outcomes. The
	1 111121 20000000		or with any	4.58 (4.12–			authors used EQ-5D
			immunomodulator	5.07)			(EuroQol, Rotterdam,
			within 28 days.	>100 000			Netherlands), a
			Patients could	copies per mL			generic, non-disease-
			receive abacavir only	114 (28%) ;116			specific, preference-
			after exclusion of the	(28%) Baseline			based utility measure
			HLA-B*5701 allele	CD4 cell count			that includes a



			Median (cells per μL) 359 (276–470); 362 (267–469)			descriptive system and a visual analogue scale, to measure health outcome
Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H, Belonosova E, Gatell JM, Baril JG, Domingo P, Brennan C, Almond S, Min S; extended SPRING-2 Study Group. Once- daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double- blind, non-inferiority trial. Lancet Infect Dis. 2013 Nov;13(11):927-35. doi: 10.1016/S1473- 3099(13)70257-3. Epub 2013 Sep 25. PMID: 24074642.	As above	As above	As above	As above	As above	As above


Table 14. Comparisons included in this section

Study name/ NCT	Intervention (DOL + 2 NRTIs)	Comparator (RALT + 2 NRTIs)
number		
NCT01227824; SPRING-2	Dolutegravir. At the investigators' discretion, patients received an NRTI backbone of coformulated tenofovir [DF]/ emtricitabine or abacavir/lamivudine	Raltegravir. At the investigators' discretion, patients received an NRTI backbone of coformulated tenofovir [DF]/ emtricitabine or abacavir/lamivudine



Virological success, failure and missing data


Forest plot of comparison: 7 DOL vs RALT + any 2 NRTI, outcome: 7.1 Virological success.



Test for subgroup differences: $Chi^2 = 0.04$, df = 1 (P = 0.85), $I^2 = 0\%$

Forest plot of comparison: 7 DOL vs RALT + any 2 NRTI, outcome: 7.2 Virological failure.





The difference between week 48 and week 96 responses was driven mainly by discontinuations for reasons other than adverse events; the proportion of virological non-response was unchanged for dolutegravir from week 48 to week 96, whereas it rose by 2% for raltegravir from week 48 to week 96.

Figure 13. Success, failure and missing data at 48 weeks







Figure 14. Success, failure and missing data at 96 weeks





Failing with resistance

Forest plot of comparison: 7 DOL vs RALT + any 2 NRTI, outcome: 7.3 Failure with resistance.



	DOL + 2	NRTI	RALT + 2	NRTI		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
7.3.1 48 weeks							
SPRING-2; Raffi 2013a	0	20	4	28	100.0%	0.13 [0.01, 2.61]	
Subtotal (95% CI)		20		28	100.0%	0.13 [0.01, 2.61]	
Total events	0		4				
Heterogeneity: Not applicat	ble						
Test for overall effect: Z = 1.	.33 (P = 0	0.18)					
7.3.2 96 weeks							
SPRING-2; Raffi 2013b	0	22	4	29	100.0%	0.13 [0.01, 2.47]	
Subtotal (95% CI)		22		29	100.0%	0.13 [0.01, 2.47]	
Total events	0		4				
Heterogeneity: Not applicat	ble						
Test for overall effect: $Z = 1$.	.36 (P = 0)	0.17)					
	-						
							0.004 04 4 40 4000
							0.001 0.1 1 10 1000
T16			-14 A 470	0.000 13	0.07		Favours DOL Favours RALT

Test for subgroup differences: $Chi^2 = 0.00$, df = 1 (P = 0.98), $I^2 = 0\%$



Raltegravir vs dolutegravir comparison by viral load (SPRING-2 study)

Forest plot of comparison: 15 DOL vs RALT + any 2 NRTI; subgroups by baseline viral load, outcome: 15.1 Virological success.

	DOL + 2	NRTI	RALT + 2	NRTI		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
15.1.1 48 weeks; baselir	ne load <1	00,000					<u>L</u>
SPRING-2; Raffi 2013a Subtotal (95% CI)	267	297 297	264		100.0% 100.0%	1.05 [0.62, 1.78] 1.05 [0.62, 1.78]	
Total events Heterogeneity: Not applic	267		264				
Test for overall effect: Z=		0.87)					
15.1.2 48 weeks; baselir	ne load >1	00,000					
SPRING-2; Raffi 2013a Subtotal (95% CI)	94	114 114	87		100.0% 100.0 %	1.57 [0.83, 2.97] 1.57 [0.83, 2.97]	
Total events Heterogeneity: Not applic	94 able		87				
Test for overall effect: Z=		0.17)					
15.1.3 96 weeks; baselin	ne load <1	00,000					<u></u>
SPRING-2; Raffi 2013b Subtotal (95% CI)	243	297 297	241		100.0% 100.0%	1.01 [0.66, 1.53] 1.01 [0.66, 1.53]	-
Total events Heterogeneity: Not applic	243 able		241				
Test for overall effect: Z=		0.97)					
15.1.4 96 weeks; baselin	ne load >1	00,000					_
SPRING-2; Raffi 2013b Subtotal (95% CI)	89	114 114	73		100.0% 100.0 %	2.10 [1.17, 3.75] 2.10 [1.17, 3.75]	
Total events	89		73				
Heterogeneity: Not applic Test for overall effect: Z=		0.01)					
						_	
Toot for outpayous differen							0.5 0.7 1 1.5 2 Favours RALT Favours DOL

Test for subgroup differences: $Chi^2 = 4.96$, df = 3 (P = 0.17), $I^2 = 39.5\%$



Forest plot of comparison: 15 DOL vs RALT + any 2 NRTI; subgroups by baseline viral load, outcome: 15.2 Virological success; week 48 only.

	DOL + 2	NRTI	RALT + 2	NRTI		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
15.2.1 48 weeks; baseling	ne load <10	00,000					
SPRING-2; Raffi 2013a Subtotal (95% CI)	267	297 297	264	295 295	100.0% 100.0%	1.05 [0.62, 1.78] 1.05 [0.62, 1.78]	
Total events Heterogeneity: Not applic Test for overall effect: Z=		1 97)	264				
15.2.2 48 weeks; baselir	•	ŕ					
SPRING-2; Raffi 2013a Subtotal (95% CI)	94	114 114	87	116 116	100.0% 100.0 %	1.57 [0.83, 2.97] 1.57 [0.83, 2.97]	
Total events Heterogeneity: Not applic Test for overall effect: Z =		0.17)	87				
Test for subgroup differe	nces: Chi²	= 0.91,	df=1 (P=	0.34), I²	·= 0%	-	0.5 0.7 1 1.5 2 Favours RALT Favours DOL

Forest plot of comparison: 15 DOL vs RALT + any 2 NRTI; subgroups by baseline viral load, outcome: 15.3 Virological success; week 96 only.



BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022

_

Test for subgroup differences: Chi² = 4.02, df = 1 (P = 0.05), I² = 75.1%



Virological failure: Raltegravir vs dolutegravir comparison by viral load (SPRING-2 study)

Forest plot of comparison: 15 DOL vs RALT + any 2 NRTI; subgroups by baseline viral load, outcome: 15.5 Virological failure; week 96 only.


	DOL + 2	NRTI	RALT + 2	NRTI		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
15.5.1 96 weeks; baselin	ie load <10	0,000						
SPRING-2; Raffi 2013b Subtotal (95% CI)	12	297 297	17	295 295	100.0% 100.0%	0.69 [0.32, 1.47] 0.69 [0.32, 1.47]		
Total events Heterogeneity: Not applic	12 able		17					
Test for overall effect: Z =	0.97 (P = 0	.33)						
15.5.2 96 weeks; baselin	ie load >10	0,000						_
SPRING-2; Raffi 2013b Subtotal (95% CI)	12	114 114	26	116 116	100.0% 100.0%	0.41 [0.19, 0.85] 0.41 [0.19, 0.85]		-
Total events Heterogeneity: Not applic Test for overall effect: Z=		1.02)	26					
							0.05	0.2 1 5 20 Favours DOL Favours RALT

Test for subgroup differences: $Chi^2 = 0.94$, df = 1 (P = 0.33), $I^2 = 0\%$

Adverse event (AE)-driven discontinuation

Forest plot of comparison: 7 DOL vs RALT + any 2 NRTI, outcome: 7.4 AE-driven discontinuation.






Test for subgroup differences: Chi² = 0.29, df = 1 (P = 0.59), I² = 0%

Serious adverse events

Forest plot of comparison: 7 DOL vs RALT + any 2 NRTI, outcome: 7.5 Serious AE.






Test for subgroup differences: $Chi^2 = 0.09$, df = 1 (P = 0.76), $I^2 = 0\%$

Drug-related SAE

Forest plot of comparison: 7 DOL vs RALT + any 2 NRTI, outcome: 7.6 Drug-related serious AE.






Test for subgroup differences: $Chi^2 = 0.00$, df = 1 (P = 1.00), $I^2 = 0\%$

Grade 3/4 AE

Forest plot of comparison: 7 DOL vs RALT + any 2 NRTI, outcome: 7.7 Grade 3/4 AE.






Test for subgroup differences: Not applicable

Drug-related Grade 3/4 AE

Forest plot of comparison: 7 DOL vs RALT + any 2 NRTI, outcome: 7.8 Drug-related grade 3/4 AE.





Test for subgroup differences: Not applicable

GRADE table for critical outcomes

	Anticipated absolu	te effects* (95% CI)			Certainty of the	
Outcomes	Risk with RALT + any 2 NRTI	Risk with DOL	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological success - 48 weeks	854 per 1,000	878 per 1,000 (827 to 915)	OR 1.23 (0.82 to 1.85)	822 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Virological success - 96 weeks	764 per 1,000	808 per 1,000 (751 to 854)	OR 1.30 (0.93 to 1.81)	822 (1 RCT)	⊕⊖⊖⊖ Very low ^{a,b,c}	
Virological failure - 48 weeks	75 per 1,000	49 per 1,000 (28 to 84)	OR 0.63 (0.35 to 1.12)	822 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Virological failure - 96 weeks	105 per 1,000	53 per 1,000 (32 to 87)	OR 0.48 (0.28 to 0.82)	822 (1 RCT)	⊕⊖⊖⊖ Very low ^{a,b,c}	



	Anticipated absolut	te effects* (95% CI)			Certainty of the	
Outcomes	Risk with RALT + any 2 NRTI	Risk with DOL	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Failure with resistance - 48 weeks	143 per 1,000	21 per 1,000 (2 to 303)	OR 0.13 (0.01 to 2.61)	48 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Failure with resistance - 96 weeks	138 per 1,000	20 per 1,000 (2 to 283)	OR 0.13 (0.01 to 2.47)	51 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
AE-driven discontinuation - 48 weeks	17 per 1,000	24 per 1,000 (9 to 62)	OR 1.44 (0.54 to 3.82)	822 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
AE-driven discontinuation - 96 weeks	24 per 1,000	24 per 1,000 (10 to 57)	OR 1.00 (0.41 to 2.43)	822 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Serious AE - 48 weeks	75 per 1,000	71 per 1,000 (43 to 114)	OR 0.93 (0.55 to 1.57)	822 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Serious AE - 96 weeks	117 per 1,000	100 per 1,000 (67 to 147)	OR 0.84 (0.54 to 1.30)	822 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Drug-related serious AE - 48 weeks	12 per 1,000	7 per 1,000 (2 to 30)	OR 0.60 (0.14 to 2.51)	822 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Drug-related serious AE - 96 weeks	12 per 1,000	7 per 1,000 (2 to 30)	OR 0.60 (0.14 to 2.51)	822 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Grade 3/4 AE - 48 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome
Grade 3/4 AE - 96 weeks	114 per 1,000	112 per 1,000 (75 to 162)	OR 0.98 (0.63 to 1.50)	822 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	



	Anticipated absolu	te effects* (95% CI)			Certainty of the	
Outcomes	Risk with RALT + any 2 NRTI	Risk with DOL	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Drug-related grade 3/4 AE - 48 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome
Drug-related grade 3/4 AE - 96 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Explanations

- a. A limitation of this study is the low number of non-white and female patients enrolled, which is not fully representative of the HIV global epidemic
- b. 95% Confidence interval includes 1
- c. The difference between week 48 and week 96 responses was driven mainly by discontinuations for reasons other than adverse events; the proportion of virological non-response was unchanged for dolutegravir from week 48 to week 96, whereas it rose by 2% for raltegravir from week 48 to week 96



NRTI backbone comparison

8 TDF/FTC vs TAF/FTC with any 3rd agent

ADVANCE data were published for week 48 (Venter 2019) and week 96 results (Venter 2020). One paper (Sax 2015) reported on a pre-specified pooled analysis of two RCTs (week 48 outcomes): NCT01780506 (also known as GS-US-292-0104) and NCT01797445 (also known as GS-US-292-0111). These were identical protocols done at 134 sites in North America, Europe, Australia, Japan, and Thailand (GS-US-292-0104), and 128 sites in North America, Europe, and Latin America (GS-US-292-0111). Data from the AMBER study were published for week 48 (Eron 2018). Week 48 data were reported in the NCT01565850 (GS-US-299-0102) study (Mills 2015).

Table 15. Key features of the included studies

Study name/	Citation	Inclusion	Exclusions	Population	Intervention	Comparator	Outcomes
NCT number		criteria		(n;			
				demographic			
				s)			
NCT0312226	Venter WDF, Moorhouse M, Sokhela S, Fairlie L,	Age ≥12	>30 days of	1053	Tenofovir	Tenofovir	The primary
2; ADVANCE	Mashabane N, Masenya M, Serenata C, Akpomiemie G,	years,	treatment	participants	disoproxil	alafenamide	end point
	Qavi A, Chandiwana N, Norris S, Chersich M, Clayden P,	weight	with any	with HIV	fumarate	fumarate	was the
	Abrams E, Arulappan N, Vos A, McCann K, Simmons B, Hill	≥40kg, viral	form of ART,	infection in	(TDF) plus	(TAF) plus	percentage of
	A. Dolutegravir plus Two Different Prodrugs of Tenofovir to	load of ≥500	any ART	South Africa.	emtricitabin	emtricitabin	patients with
	Treat HIV. N Engl J Med. 2019 Aug 29;381(9):803-815. doi:	copies/mL,	within the	The mean	e (FTC) and	e (FTC) and	an HIV-1
	10.1056/NEJMoa1902824. Epub 2019 Jul 24. PMID:	creatinine	past 6	age was 32	efavirenz	dolutegravir	RNA level
	31339677.	clearance	months,	years (range,	(EFV) =	(DTG) =	<50
		>60 mL/min	pregnancy,	13 to 62); 14	TDF-FTC-	TAF-FTC-	copies/mL at
		(Cockcroft-	or current	patients were	EFV	DTG (TAF-	week 48.
		Gault	treatment for	younger than	(standard-	based	Secondary
		formula) in	tuberculosis	19 years of	care group)	group)	objectives
		patients 19		age. A total	OR		were to
		years of age		of 59% of the	Tenofovir		evaluate
		or older or >		patients were	disoproxil		additional
		80 mL/min		female, more	fumarate		viral-load
		(modified		than 99%	(TDF) plus		thresholds,
		Cockcroft-		were black,	emtricitabin		CD4 count
		Gault		and 62%	e (FTC) and		changes, and
		formula) in		were from	dolutegravir		side-effect
		those <19		South Africa.	(DTG) =		profile and
		years of age		The mean	TDF_FTC_		safety,
		, ,		CD4 count	DTG (TDF-		including



				was 337 cells per cubic millimeter (range, 1 to 1721), and 78% of the patients had a baseline HIV-1 RNA level of less than 100,000 copies per milliliter.	based group)		findings on physical examination, laboratory analyses, and dual- energy x-ray absorptiometr y (DXA) scans.
	Venter, WDF; Sokhela, S; Simmons, B; Moorhouse, M; Fairlie, L; Mashabane, N; Serenata, C; Akpomiemie, G; Masenya, M; Qavi, A; Chandiwana, N; McCann, K; Norris, S; Chersich, M; Maartens, G; Lalla-Edward, S; Vos, A; Clayden, P; Abrams, E; Arulappan, N; Hill, A. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet. HIV 2020; 7(10): e666-676. DOI: 10.1016/S2352-3018(20)30241-1. https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02192063/full	As above	As above	As above	As above	As above	As above
NCT0178050 6 (also known as GS-US- 292-0104) and NCT0179744 5 (also known as GS-US- 292-0111)	Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, Pozniak A, Thompson M, Podzamczer D, Molina JM, Oka S, Koenig E, Trottier B, Andrade-Villanueva J, Crofoot G, Custodio JM, Plummer A, Zhong L, Cao H, Martin H, Callebaut C, Cheng AK, Fordyce MW, McCallister S; GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15. Erratum in: Lancet. 2016 Apr 30;387(10030):1816. PMID: 25890673.	≥18 years; had HIV-1 and no previous antiretroviral treatment, had HIV-1 RNA concentratio n ≥1000 copies/mL, and an estimated glomerular filtration (creatinine	Patients with positive hepatitis B surface antigen or hepatitis C antibody or a new AIDS-defining illness within 30 days of screening	Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide (n=866); Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate (n=867) Age (years) 33 (26–42); 35 (28–44)	Elvitegravir, cobicistat, emtricitabin e, and tenofovir disoproxil fumarate	Elvitegravir, cobicistat, emtricitabin e, tenofovir alafenamide	The main outcomes were the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL (non-inferiority margin of 12%) and pre-specified renal and bone



clearance,	Women 133	endpoints at
Cockcroft-	(15%); 127	48 weeks
Gault) rate	(15%)	(centrally
>50 mL/min;	Ethnic origin	assessed).
screening	White 485;	Secondary
HIV-1	(56%) 498	outcomes
genotype	(57%)	were
showing	Black or	percentage
sensitivity to	African	change from
elvitegravir,	heritage 223	baseline in
emtricitabin	(26%); 213	hip bone
e, and	(25%)	mineral
tenofovir	Hispanic or	density at
	Latino 167	week 48,
	(19%); 167	percentage
	(19%)	change from
	Asian 91	baseline in
	(11%); 89	spine bone
	(10%)	mineral
	HIV disease	density at
	status:	week 48,
	Asymptomati	change from
	c 780 (90%);	baseline in
	802 (93%)	serum
	Symptomatic:	creatinine at
	53 (6%); 35	week 48,
	(4%)	treatment-
	AIDS: 30	emergent
	(4%); 26	proteinuria
	(3%) HIV risk	through week
	factor:	48,
	Heterosexual	proportion of
	sex 210	participants
	(24%); 219	with HIV-1
	(25%)	RNA lower
	Homosexual	than 20 per
	sex 652	mL at week
	(75%); 645	48, change
	(74%)	from baseline
	Intravenous	in CD4 cell
	drug use 5	count at
	(1%); 6 (1%)	week 48,

	Median HIV-1	percentage
	RNA (log10	change from
	c/mL) 4.58	baseline in
	(4.04–4.95)	urine retinol
	4.58 (4.15–	binding
	4.96)	protein to
	HIV-1 RNA	creatinine
	concentration	ratio at week
	>100 000	48,
	copies per	percentage
	mL 196	change from
	(23%); 195	baseline in
	(22%)	urine β2-
	Median CD4	microglobulin
	count (cells	to creatinine
	per µL) 404	ratio at week
	(283–550);	48,
	406 (291–	
	542)	percentage
	Number with	change from baseline in
	CD4 cell	urine protein
	count (cells	to creatinine
	per µL)	ratio at week
	<50: 24 (3%);	48, and
	27 (3%)	percentage
	≥50 to <200:	change from
		baseline in
l l	88 (10%);	urine albumin
	90 (10%)	to creatinine
	≥200: 753	ratio. Safety
	(87%); 750	was
	(87%)	assessed by
	Median	physical
	estimated	examinations
	glomerular	, laboratory
	filtration rate	tests, 12-lead
	(Cockcroft-	electro-
	Gault;	cardiogram,
	mL/min) 117	and recording
	(100–136);	of adverse
	114 (99–134)	events
	Median BMI	GVGIIIG



NCT0243124 7; AMBER	Eron JJ, Orkin C, Gallant J, Molina JM, Negredo E, Antinori A, Mills A, Reynes J, Van Landuyt E, Lathouwers E, Hufkens V, Jezorwski J, Vanveggel S, Opsomer M; AMBER study group. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2018 Jul 17;32(11):1431-1442. doi: 10.1097/QAD.0000000000001817. PMID: 29683855; PMCID: PMC6039393.	≥18 years; treatment-naive, HIV-1-infected with a screening plasma viral load >1000 copies/mL, CD4+ cell count >50 cells/mL, genotypic sensitivity to darunavir, emtricitabin e, and tenofovir, and an estimated glomerular filtration rate based on serum creatinine (eGFRcr) ≥70 ml/min (Cockcroft–Gault formula)	Diagnosis of a new AIDS-defining condition within 30 days prior to screening, hepatitis B or C coinfection, clinically significant disease (e.g. malignancy, severe infections), and pregnancy or breast-feeding in women. Medications or herbal supplements known or suspected to have drug interactions with the investigation al medications were disallowed.	(kg/m²) 24.4 (22.0–28.0); 24.5 (21.7– 28.0) Data are median (IQR) or n (%). 725 participants. Median age was 34 years, 88% were men, 83% were white, and 18% had viral load at least 100 000 copies/mL. Median baseline CD4+ cell count was 453 cells/mL	Darunavir/ cobicistat plus emtricitabin e/ tenofovir disoproxyl fumarate (TDF)	Darunavir/ cobicistat/ emtricitabin e/ tenofovir alafenamide (D/C/F/TAF)	Primary: proportion of patients with viral load <50 copies/mL (response rate) by the Food and Drug Administratio n (FDA)- snapshot analysis. Secondary outcomes included proportion of patients with viral load <20 and <200 copies/mL (FDA- snapshot analysis) and viral load <50 copies/mL (time-to-loss- of-virologic- response algorithm) at week 48; changes from baseline in log10 viral
------------------------	---	---	--	--	--	--	--



NCT0156585 0 (GS-US-	Mills A, Crofoot G Jr, McDonald C, Shalit P, Flamm JA, Gathe J Jr, Scribner A, Shamblaw D, Saag M, Cao H,	≥18 years; HIV-	Pregnant, hepatitis B or	153 participants.	Darunavir, cobicistat,	Darunavir, cobicistat,	CD4+ cell count; antiretroviral resistance development in PDVFs; safety and tolerability through 48 weeks; changes from baseline in serum creatinine, eGFRcr, eGFRcyst, and ratios of total urine protein, urine albumin, urine RBP, and beta-2- microglobulin to creatinine. HIV-1 RNA <50
299-0102)	Martin H, Das M, Thomas A, Liu HC, Yan M, Callebaut C, Custodio J, Cheng A, McCallister S. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):439-45. doi: 10.1097/QAI.00000000000000618. PMID: 25867913.	positive, treatment- naive with plasma HIV- 1 RNA ≥5000 copies/mL and CD4+ cell count >50 cells per microliter. Genotype sensitivity to DRV, TDF, and FTC,	C coinfected, or had a new AIDS-defining condition within 30 days of screening	92.8% male; median age 33 years; 34.6% Black/African American and 20.9% were of Hispanic ethnicity. The median VL at baseline was 4.66 log10 copies/mL, and median CD4 count	emtricitabin e, tenofovir disoproxil fumarate (TDF)	emtricitabin e, tenofovir alafenamide (TAF)	copies/mL at week 24 (primary end point) and week 48 (secondary end point). NB This phase 2 study was not sufficiently powered for non-inferiority, but rather to provide



and	was 384 cells	clinical data
estimated	per microliter	that would
glomerular	with 80% of	guide
filtration rate	participants	planning
(eGFR) by	having an	phase 3
Cockcroft-	HIV-1 RNA	studies.
Gault	VL ≤100,000	
formula	copies/mL	
(eGFRCG)	and 14% of	
≥70 mL/min	participants	
were	having a CD4	
required	<200 cells	
·	per microliter.	
	The median	
	eGFRCG	
	values were	
	similar in the	
	2 treatment	
	groups: TAF	
	116.0 mL/min	
	and TDF	
	109.6	
	mL/min.	

Table 16. Comparisons included in this section

Study name/ NCT number	Intervention (TDF/FTC with any 3rd agent)	Comparator (TAF/FTC with any 3rd agent)
NCT03122262; ADVANCE	Tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) and efavirenz (EFV) = TDF–FTC–EFV (standard-care group) OR Tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) and dolutegravir (DTG) = TDF–FTC–DTG (TDF-based group)	Tenofovir alafenamide fumarate (TAF) plus emtricitabine (FTC) and dolutegravir (DTG) = TAF-FTC-DTG (TAF-based group)
	The two groups were combined in the analyses.	
NCT01780506 (also known as GS-US-292-0104) and	Elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil	Elvitegravir, cobicistat, emtricitabine,
NCT01797445 (also known as GS-US-292-0111)	fumarate	tenofovir alafenamide
NCT02431247; AMBER	Darunavir, cobicistat, emtricitabine, tenofovir disoproxyl fumarate	Darunavir, cobicistat, emtricitabine, tenofovir
	(TDF)	alafenamide (D/C/F/TAF)



NCT01565850 (GS-US-299-0102)	Darunavir, cobicistat, emtricitabine, tenofovir disoproxil fumarate	Darunavir, cobicistat, emtricitabine, tenofovir
	(TDF)	alafenamide (TAF)

Virological success, failure and missing data

Forest plot of comparison: 8 TDF/FTC vs TAF/FTC + any 3rd agent, outcome: 8.1 Virological success.

Fixed, 95% CI
-

•
•

Test for subgroup differences: $Chi^2 = 0.02$, df = 1 (P = 0.89), $I^2 = 0\%$

Forest plot of comparison: 8 TDF/FTC vs TAF/FTC + any 3rd agent, outcome: 8.2 Virological failure.




	TDF/FTC + any 3rd	agent	TAF/FTC + any 3rd	d agent		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
8.2.1 48 weeks							
ADVANCE; Venter 2019	33	702	16	351	25.9%	1.03 [0.56, 1.90]	-
AMBER; Eron 2018	12	363	16	362	19.7%	0.74 [0.34, 1.59]	
NCT01565850; Mills 2015	6	50	16	103	11.7%	0.74 [0.27, 2.03]	
NCT01780506/01797445; Sax 2015 Subtotal (95% CI)	35	867 1982	35	866 1682	42.7% 100.0%	1.00 [0.62, 1.61] 0.93 [0.67, 1.27]	*
Total events	86		83				
Heterogeneity: Chi ² = 0.74, df = 3 (P = 0 Test for overall effect: $Z = 0.47$ (P = 0.64 8.2.2 96 weeks							
ADVANCE; Venter 2020 Subtotal (95% CI)	29	702 702	11	351 351	100.0% 100.0%	1.33 [0.66, 2.70] 1.33 [0.66, 2.70]	-
Total events Heterogeneity: Not applicable Test for overall effect: Z = 0.80 (P = 0.43	29		11				
							0.05 0.2 1 5 2 Favours TDF/FTC Favours TAF/FTC

Test for subgroup differences: $Chi^2 = 0.84$, df = 1 (P = 0.36), $I^2 = 0\%$

Figure 15. Success, failure and missing data at 48 weeks






Of note, the authors of the Mills 2015 study reported that the difference in virologic response rates at week 48 was primarily driven by the higher rate of participants in the TAF group (6.8%) compared with the TDF group (2%) who discontinued study drug with last available VL <50 copies/mL (e.g. due to reasons other than virologic failure such as loss to follow-up or investigator's discretion).

Figure 16. Success, failure and missing data at 96 weeks






Failing with resistance

Forest plot of comparison: 8 TDF/FTC vs TAF/FTC + any 3rd agent, outcome: 8.3 Failure with resistance.






Test for subgroup differences: Chi² = 3.90, df = 1 (P = 0.05), I² = 74.3%

Adverse event (AE)-driven discontinuation

Forest plot of comparison: 8 TDF/FTC vs TAF/FTC + any 3rd agent, outcome: 8.4 AE-driven discontinuation.






Test for subgroup differences: Chi² = 0.08, df = 1 (P = 0.78), I² = 0%

Serious adverse events

Forest plot of comparison: 8 TDF/FTC vs TAF/FTC + any 3rd agent, outcome: 8.5 Serious AE.






Test for subgroup differences: $Chi^2 = 0.52$, df = 1 (P = 0.47), $I^2 = 0\%$

Drug-related SAE

Forest plot of comparison: 8 TDF/FTC vs TAF/FTC + any 3rd agent, outcome: 8.6 Drug-related serious AE.





Test for subgroup differences: Not applicable

Grade 3/4 AE

Forest plot of comparison: 8 TDF/FTC vs TAF/FTC + any 3rd agent, outcome: 8.7 Grade 3/4 AE.



	TDF/FTC + any 3rd	l agent	TAF/FTC + any 3r	d agent		Odds Ratio	Odds	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixe	d, 95% CI	
8.7.1 48 weeks									
ADVANCE; Venter 2019	136	702	42	351	34.7%	1.77 [1.22, 2.57]		-	
AMBER; Eron 2018	22	363	19	362	13.7%	1.16 [0.62, 2.19]	_	-	
NCT01565850; Mills 2015	4	50	7	103	3.2%	1.19 [0.33, 4.28]			
NCT01780506/01797445; Sax 2015 Subtotal (95% CI)	78	867 1982	69	866 1682	48.3% 100.0%	1.14 [0.81, 1.60] 1.36 [1.09, 1.71]	4	•	
Total events	240		137						
Heterogeneity: $Chi^z = 3.20$, $df = 3$ (P = 0.0 Test for overall effect: $Z = 2.68$ (P = 0.0 8.7.2 96 weeks									
ADVANCE; Venter 2020 Subtotal (95% CI)	156	702 702	54	351 351	100.0% 100.0%	1.57 [1.12, 2.21] 1.57 [1.12, 2.21]		◆	
Total events Heterogeneity: Not applicable Test for overall effect: Z = 2.60 (P = 0.0	156 09)		54						
							0.001 0.1 1 Favours TDF/FTC	10 Favours TAF/FTC	1000

Test for subgroup differences: $Chi^2 = 0.46$, df = 1 (P = 0.50), $I^2 = 0\%$

Of note, the originally published supplement for Sax 2015 reports data for Grade 3/4 AE as:

"Any Grade 3 or 4 AE: TAF: 8%; TDF: 0%"

However, the 0% in the TDF group must be an error as the drug-related Grade 3/4 AE is >0.

There is a further publication relating to this paper:

Department of Error (<u>Department of Error (thelancet.com</u>): Sax PE, Wohl D, Yin MT, et al, for the GS-US-292-0104/0111 Study Team. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015; 385: 2606–15—In this Article, in figure 2A, the 95% CI should have been –0·7 to 4·7. Additionally,



in table 3 in the appendix, the grade 3 or 4 AE row in the E/C/F/TDF group should have been 9%. This correction has been made to the online version and the appendix has been corrected as of April 28, 2016.

Drug-related Grade 3/4 AE

Forest plot of comparison: 8 TDF/FTC vs TAF/FTC + any 3rd agent, outcome: 8.8 Drug-related grade 3/4 AE.

	TDF/FTC + any 3r	d agent	TAF/FTC + any 3r	d agent		Odds Ratio	Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI	
8.8.1 48 weeks								
ADVANCE; Venter 2019	69	702	19	351	71.9%	1.90 [1.13, 3.22]		
NCT01780506/01797445; Sax 2015 Subtotal (95% CI)	9	867 1569	9	866 1217	28.1% 100.0%	1.00 [0.39, 2.53] 1.65 [1.05, 2.59]	•	
Total events Heterogeneity: $Chi^2 = 1.41$, $df = 1$ (P = 0 Test for overall effect: $Z = 2.18$ (P = 0.03)			28					
8.8.2 96 weeks								
ADVANCE; Venter 2020 Subtotal (95% CI)	72	702 702	21	351 351	100.0% 100.0 %	1.80 [1.08, 2.97] 1.80 [1.08, 2.97]		
Total events Heterogeneity: Not applicable Test for overall effect: Z = 2.28 (P = 0.0)	72 2)		21					
							0.1 0.2 0.5 1 2 Favours TDF/FTC Favours T/	5 10 AF/FTC

Test for subgroup differences: $Chi^2 = 0.06$, df = 1 (P = 0.81), $I^2 = 0\%$



GRADE table for critical outcomes

	Anticipated absolu	te effects* (95% CI)			Certainty of the	
Outcomes	Risk with TAF/FTC + any 3rd agent	Risk with TDF/FTC	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological success - 48 weeks	894 per 1,000	875 per 1,000 (852 to 897)	OR 0.83 (0.68 to 1.03)	3664 (4 RCTs)	⊕⊖⊖⊖ Very low ^{a,b,c}	
Virological success - 96 weeks	786 per 1,000	760 per 1,000 (699 to 812)	OR 0.86 (0.63 to 1.17)	1053 (1 RCT)	⊕⊕⊜⊖ Low ^{c,d}	
Virological failure - 48 weeks	49 per 1,000	46 per 1,000 (34 to 62)	OR 0.93 (0.67 to 1.27)	3664 (4 RCTs)	⊕⊖⊖⊖ Very low ^{b,c,d}	
Virological failure - 96 weeks	31 per 1,000	41 per 1,000 (21 to 80)	OR 1.33 (0.66 to 2.70)	1053 (1 RCT)	⊕⊕⊜⊖ Low ^{c,d}	
Failure with resistance - 48 weeks	200 per 1,000	156 per 1,000 (54 to 373)	OR 0.74 (0.23 to 2.38)	74 (4 RCTs)	⊕⊖⊖⊖ Very low ^{b,c,d}	
Failure with resistance - 96 weeks	0 per 1,000	0 per 1,000 (0 to 0)	OR 17.22 (0.95 to 312.93)	49 (1 RCT)	⊕⊕⊜⊖ Low ^{c,d}	
AE-driven discontinuation - 48 weeks	11 per 1,000	23 per 1,000 (13 to 40)	OR 2.21 (1.25 to 3.90)	3664 (4 RCTs)	⊕⊕⊜⊖ Low ^{b,d}	
AE-driven discontinuation - 96 weeks	6 per 1,000	16 per 1,000 (3 to 67)	OR 2.78 (0.61 to 12.60)	1053 (1 RCT)	⊕⊕⊜⊖ Low ^{c,d}	
Serious AE - 48 weeks	64 per 1,000	65 per 1,000 (51 to 84)	OR 1.03 (0.79 to 1.35)	3664 (4 RCTs)	⊕⊖⊖⊖ Very low ^{b,c,d}	

	Anticipated absolu	te effects* (95% CI)			Certainty of the	
Outcomes	Risk with TAF/FTC + any 3rd agent	Risk with TDF/FTC	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Serious AE - 96 weeks	51 per 1,000	66 per 1,000 (38 to 109)	OR 1.30 (0.74 to 2.27)	1053 (1 RCT)	⊕⊕⊜⊖ Low ^{c,d}	
Drug-related serious AE - 48 weeks	2 per 1,000	6 per 1,000 (2 to 20)	OR 2.43 (0.70 to 8.45)	2458 (2 RCTs)	⊕⊖⊖⊖ Very low ^{c,e,f}	
Drug-related serious AE - 96 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome
Grade 3/4 AE - 48 weeks	81 per 1,000	108 per 1,000 (88 to 132)	OR 1.36 (1.09 to 1.71)	3664 (4 RCTs)	⊕⊕⊖⊖ Low ^{b,d}	
Grade 3/4 AE - 96 weeks	154 per 1,000	222 per 1,000 (169 to 287)	OR 1.57 (1.12 to 2.21)	1053 (1 RCT)	⊕⊕⊕ Moderate ^d	
Drug-related grade 3/4 AE - 48 weeks	23 per 1,000	37 per 1,000 (24 to 57)	OR 1.65 (1.05 to 2.59)	2786 (2 RCTs)	⊕⊕⊖⊖ Low ^{d,g}	
Drug-related grade 3/4 AE - 96 weeks	60 per 1,000	103 per 1,000 (64 to 159)	OR 1.80 (1.08 to 2.97)	1053 (1 RCT)	⊕⊕⊕ Moderate ^d	

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.



Explanations

- a. Difference between groups in numbers with missing data for virological outcomes for ADVANCE and Mills 2015
- b. ADVANCE had good generalisability but AMBER included >80% white patients and a comparatively small proportion of female or older (>50 years) participants or who had high viral loads; Mills 2015 enrolled relatively few women and Sax 2015 enrolled a small proportion of women or participants with advanced HIV disease, and excluded patients with chronic hepatitis B virus infection.
- c. 95% Confidence interval spans 1
- d. Some concerns (ADVANCE was an open label study)
- e. I2 >60%
- f. AMBER included >80% white patients and a comparatively small proportion of female or older (>50 years) participants or who had high viral loads and Sax 2015 enrolled a small proportion of women or participants with advanced HIV disease, and excluded patients with chronic hepatitis B virus infection.
- g. ADVANCE had good generalisability but Sax 2015 enrolled a small proportion of women or participants with advanced HIV disease, and excluded patients with chronic hepatitis B virus infection.



TDF/FTC vs TAF/FTC with any 3rd agent excluding ADVANCE and including week 96 data

Virological success, failure and missing data

Forest plot of comparison: 14 TDF/FTC vs TAF/FTC + any 3rd agent excluding ADVANCE, outcome: 14.1 Virological success.

	TDF/FTC + any 3rd	d agent	TAF/FTC + any 3i	rd agent		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
14.1.1 48 weeks							
AMBER; Eron 2018	321	363	331	362	31.1%	0.72 [0.44, 1.17]	
NCT01565850; Mills 2015	42	50	79	103	6.7%	1.59 [0.66, 3.86]	- -
NCT01780506/01797445; Sax 2015 Subtotal (95% CI)	784	867 1280	800	866 1331	62.2% 100.0%	0.78 [0.56, 1.09] 0.81 [0.63, 1.06]	
Total events Heterogeneity: Chi ² = 2.56, df = 2 (P = 0 Test for overall effect: $Z = 1.53$ (P = 0.13	**		1210				
14.1.2 96 weeks							
AMBER; Orkin 2020	304	363	308	362	31.2%	0.90 [0.60, 1.35]	
NCT01780506/01797445; Wohl 2016 Subtotal (95% CI)	739	867 1230	750	866 1228	68.8% 100.0%	0.89 [0.68, 1.17] 0.90 [0.72, 1.12]	+
Total events Heterogeneity: $Chi^2 = 0.00$, $df = 1$ (P = 0 Test for overall effect: $Z = 0.96$ (P = 0.34	**		1058				
Test for subgroup differences: $Chi^2 = 0$.	30, df=1 (P=0.59)	, I² = 0%				-	0.2 0.5 2 5 Favours TAF/FTC Favours TDF/FTC

Forest plot of comparison: 14 TDF/FTC vs TAF/FTC + any 3rd agent excluding ADVANCE, outcome: 14.2 Virological failure.




	TDF/FTC + any 3r	d agent	TAF/FTC + any 3r	rd agent		Odds Ratio		Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI		
14.2.1 48 weeks										
AMBER; Eron 2018	12	363	16	362	26.6%	0.74 [0.34, 1.59]				
NCT01565850; Mills 2015	6	50	16	103	15.8%	0.74 [0.27, 2.03]				
NCT01780506/01797445; Sax 2015 Subtotal (95% CI)	35	867 1280	35	866 1331	57.6% 100.0%	1.00 [0.62, 1.61] 0.89 [0.61, 1.29]		.		
Total events	53		67							
Heterogeneity: $Chi^2 = 0.58$, $df = 2$ (P = 0 Test for overall effect: $Z = 0.61$ (P = 0.54										
14.2.2 96 weeks										
AMBER; Orkin 2020	16	363	20	362	100.0%	0.79 [0.40, 1.55]		_		
NCT01780506/01797445; Wohl 2016	0	0	0	0	400.00	Not estimable				
Subtotal (95% CI)		363		362	100.0%	0.79 [0.40, 1.55]				
Total events Heterogeneity: Not applicable Test for overall effect: Z = 0.69 (P = 0.49	16 n		20							
	,									
								.21	5	20
T 16 1 100 017 0							Favour	s TDF/FTC Favours 1	IAF/FTC	

Test for subgroup differences; $Chi^2 = 0.09$, df = 1 (P = 0.76), $I^2 = 0\%$

Failing with resistance

Forest plot of comparison: 14 TDF/FTC vs TAF/FTC + any 3rd agent excluding ADVANCE, outcome: 14.3 Failure with resistance.




Test for subgroup differences: $Chi^2 = 0.00$, df = 1 (P = 0.97), $I^2 = 0\%$



Adverse event (AE)-driven discontinuation

Forest plot of comparison: 14 TDF/FTC vs TAF/FTC + any 3rd agent excluding ADVANCE, outcome: 14.4 AE-driven discontinuation.



Serious adverse events

Forest plot of comparison: 14 TDF/FTC vs TAF/FTC + any 3rd agent excluding ADVANCE, outcome: 14.5 Serious AE.




	TDF/FTC + any 3r	d agent	TAF/FTC + any 3	rd agent		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
14.5.1 48 weeks							
AMBER; Eron 2018	21	363	17	362	19.2%	1.25 [0.65, 2.40]	
NCT01565850; Mills 2015	2	50	5	103	3.8%	0.82 [0.15, 4.36]	
NCT01780506/01797445; Sax 2015 Subtotal (95% CI)	61	867 1280	69	866 1331	77.0% 100.0 %	0.87 [0.61, 1.25] 0.94 [0.69, 1.28]	-
Total events	84		91				
Heterogeneity: Chi² = 0.89, df = 2 (P = 0 Test for overall effect: Z = 0.37 (P = 0.71							
14.5.2 96 weeks							
AMBER; Orkin 2020	36	363	39	362	28.7%	0.91 [0.57, 1.47]	
NCT01780506/01797445; Wohl 2016 Subtotal (95% CI)	87	867 1230	97	866 1228	71.3% 100.0%	0.88 [0.65, 1.20] 0.89 [0.69, 1.15]	•
Total events Heterogeneity: Chi² = 0.01, df = 1 (P = 0 Test for overall effect: Z = 0.87 (P = 0.39	**		136				
T 16 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1							0.1 0.2 0.5 1 2 5 10 Favours TDF/FTC Favours TAF/FTC

Test for subgroup differences: $Chi^2 = 0.07$, df = 1 (P = 0.78), $I^2 = 0\%$

Drug-related SAE

Forest plot of comparison: 14 TDF/FTC vs TAF/FTC + any 3rd agent excluding ADVANCE, outcome: 14.6 Drug-related serious AE.




Test for subgroup differences: $Chi^2 = 0.52$, df = 1 (P = 0.47), $I^2 = 0\%$



Grade 3/4 AE

Forest plot of comparison: 14 TDF/FTC vs TAF/FTC + any 3rd agent excluding ADVANCE, outcome: 14.7 Grade 3/4 AE.



Test for subgroup differences: $Chi^2 = 2.97$, df = 1 (P = 0.08), $I^2 = 66.3\%$

Drug-related Grade 3/4 AE

Forest plot of comparison: 14 TDF/FTC vs TAF/FTC + any 3rd agent excluding ADVANCE, outcome: 14.8 Drug-related grade 3/4 AE.



	TDF/FTC + any 3r	d agent	TAF/FTC + any 3r	d agent		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
14.8.1 48 weeks							
NCT01780506/01797445; Sax 2015 Subtotal (95% CI)	9	867 867	9	866 866	100.0% 100.0%	1.00 [0.39, 2.53] 1.00 [0.39, 2.53]	
Total events Heterogeneity: Not applicable Test for overall effect: Z = 0.00 (P = 1.00)	9		9				
14.8.2 96 weeks							
AMBER; Orkin 2020	6	363	11	362	100.0%	0.54 [0.20, 1.47]	
NCT01780506/01797445; Wohl 2016 Subtotal (95% CI)	0	0 363	0	0 362	100.0%	Not estimable 0.54 [0.20, 1.47]	
Total events Heterogeneity: Not applicable Test for overall effect: Z = 1.21 (P = 0.22)	6		11				
							0.1 0.2 0.5 1 2 5 10 Favours TDF/FTC Favours TAF/FTC

Test for subgroup differences: $Chi^2 = 0.79$, df = 1 (P = 0.37), $I^2 = 0\%$



GRADE

Summary of findings:

TDF/FTC compared to TAF/FTC + any 3rd agent excluding ADVANCE for HIV

Patient or population: HIV

Setting:

Intervention: TDF/FTC

Comparison: TAF/FTC + any 3rd agent excluding ADVANCE

	Anticipated absolu	te effects* (95% CI)				
Outcomes	Risk with TAF/FTC + any 3rd agent excluding ADVANCE	Risk with TDF/FTC	Relative effect (95% CI)	№ of participants (studies)	Certainty of the evidence (GRADE)	Comments
Virological success - 48 weeks	909 per 1,000	890 per 1,000 (863 to 914)	OR 0.81 (0.63 to 1.06)	2611 (3 RCTs)	⊕⊖⊖⊖ Very low ^{a,b,c}	
Virological success - 96 weeks	862 per 1,000	849 per 1,000 (818 to 875)	OR 0.90 (0.72 to 1.12)	2458 (2 RCTs)	⊕⊕⊜⊖ Low ^{c,d}	
Virological failure - 48 weeks	50 per 1,000	45 per 1,000 (31 to 64)	OR 0.89 (0.61 to 1.29)	2611 (3 RCTs)	⊕⊖⊖⊖ Very low ^{a,b,c}	
Virological failure - 96 weeks	55 per 1,000	44 per 1,000 (23 to 83)	OR 0.79 (0.40 to 1.55)	725 (2 RCTs)	⊕⊕⊜⊝ Low ^{c,e}	
Failure with resistance - 48 weeks	205 per 1,000	114 per 1,000 (32 to 328)	OR 0.50 (0.13 to 1.89)	66 (3 RCTs)	⊕⊕⊜⊖ Low ^{c,d}	



Summary of findings:

TDF/FTC compared to TAF/FTC + any 3rd agent excluding ADVANCE for HIV

Patient or population: HIV

Setting:

Intervention: TDF/FTC

Comparison: TAF/FTC + any 3rd agent excluding ADVANCE

	Anticipated absolu	te effects* (95% CI)				
Outcomes	Risk with TAF/FTC + any 3rd agent excluding ADVANCE	Risk with TDF/FTC	Relative effect (95% CI)	№ of participants (studies)	Certainty of the evidence (GRADE)	Comments
Failure with resistance - 96 weeks	393 per 1,000	237 per 1,000 (88 to 502)	OR 0.48 (0.15 to 1.56)	58 (2 RCTs)	⊕⊕⊜ Low ^{c,d}	
AE-driven discontinuation - 48 weeks	13 per 1,000	25 per 1,000 (14 to 44)	OR 1.97 (1.08 to 3.59)	2611 (3 RCTs)	⊕⊕⊕ Moderate ^b	
AE-driven discontinuation - 96 weeks	16 per 1,000	30 per 1,000 (18 to 51)	OR 1.88 (1.08 to 3.26)	2458 (2 RCTs)	⊕⊕⊕ Moderated	
Serious AE - 48 weeks	68 per 1,000	65 per 1,000 (48 to 86)	OR 0.94 (0.69 to 1.28)	2611 (3 RCTs)	⊕⊕⊜⊖ Low ^{b,c}	
Serious AE - 96 weeks	111 per 1,000	100 per 1,000 (79 to 125)	OR 0.89 (0.69 to 1.15)	2458 (2 RCTs)	⊕⊕⊜⊖ Low ^{c,d}	
Drug-related serious AE - 48 weeks	2 per 1,000	6 per 1,000 (2 to 20)	OR 2.43 (0.70 to 8.45)	2458 (2 RCTs)	⊕⊖⊖⊖ Very lowc,d,f	



Summary of findings:

TDF/FTC compared to TAF/FTC + any 3rd agent excluding ADVANCE for HIV

Patient or population: HIV

Setting:

Intervention: TDF/FTC

Comparison: TAF/FTC + any 3rd agent excluding ADVANCE

	Anticipated absolute effects* (95% CI)					
Outcomes	Risk with TAF/FTC + any 3rd agent excluding ADVANCE	Risk with TDF/FTC	Relative effect (95% CI)	№ of participants (studies)	Certainty of the evidence (GRADE)	Comments
Drug-related serious AE - 96 weeks	5 per 1,000	6 per 1,000 (2 to 19)	OR 1.33 (0.46 to 3.85)	2458 (2 RCTs)	⊕⊖⊖⊖ Very low ^{c,d,f}	
Grade 3/4 AE - 48 weeks	71 per 1,000	81 per 1,000 (62 to 106)	OR 1.15 (0.86 to 1.54)	2611 (3 RCTs)	⊕⊕⊜⊖ Low ^{b,c}	
Grade 3/4 AE - 96 weeks	124 per 1,000	90 per 1,000 (59 to 138)	OR 0.70 (0.44 to 1.13)	725 (2 RCTs)	⊕⊕⊜⊖ Low ^{c,e}	
Drug-related grade 3/4 AE - 48 weeks	10 per 1,000	10 per 1,000 (4 to 26)	OR 1.00 (0.39 to 2.53)	1733 (1 RCT)	⊕⊕⊜⊝ Low ^{c,g}	
Drug-related grade 3/4 AE - 96 weeks	30 per 1,000	17 per 1,000 (6 to 44)	OR 0.54 (0.20 to 1.47)	725 (2 RCTs)	⊕⊕⊜⊝ Low ^{c,e}	

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio



Summary of findings:

TDF/FTC compared to TAF/FTC + any 3rd agent excluding ADVANCE for HIV

Patient or population: HIV

Setting:

Intervention: TDF/FTC

Comparison: TAF/FTC + any 3rd agent excluding ADVANCE

	Anticipated absolut	te effects* (95% CI)				
Outcomes	Risk with TAF/FTC + any 3rd agent excluding ADVANCE	Risk with TDF/FTC	Relative effect (95% CI)	№ of participants (studies)	Certainty of the evidence (GRADE)	Comments

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Explanations

- a. Difference between groups numbers with missing data for virological outcomes in Mills 2015
- b. AMBER included >80% white patients and a comparatively small proportion of female or older (>50 years) participants or who had high viral loads; Mills 2015 enrolled relatively few women and Sax 2015 enrolled a small proportion of women or participants with advanced HIV disease and excluded patients with chronic hepatitis B infection
- c. 95% Confidence interval spans 1
- d. AMBER included >80% white patients and a comparatively small proportion of female or older (>50 years) participants or who had high viral loads and Sax 2015 enrolled a small proportion of women or participants with advanced HIV disease and excluded patients with chronic hepatitis B infection
- e. AMBER included >80% white patients and a comparatively small proportion of female or older (>50 years) participants or who had high viral loads
- f. I² >60%
- q. Sax 2015 enrolled a small proportion of women or participants with advanced HIV disease and excluded patients with chronic hepatitis B infection





9 ABC/3TC vs TAF/FTC with any 3rd agent

NCT02607930 data were published for week 48 results (Gallant 2017) and week 96 results (Wohl 2019).

Table 17. Key features of the included studies

NCT number NCT026079 G	2	criteria				Comparat	Outcomes
NCT026079 G				demographics)	n	or	
	Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D,	HIV-1-	An	629 participants in 122	Dolutegrav	Bictegravir	The primary
30; GS-US- Te	ebas P, et al. Bictegravir, emtricitabine, and tenofovir	infected	opportunistic	outpatient centres in	ir,	,	outcome
380-1489; al	lafenamide versus dolutegravir, abacavir, and	adults (aged	illness	nine countries in	abacavir	emtricitabi	was the
	amivudine for initial treatment of HIV-1 infection (GS-	≥18 years)	indicative of	Europe, Latin America,	and	ne and	proportion
004024-54 U	JS-380-1489): a double-blind, multicentre, phase 3,	who were	stage 3 HIV	and North America.	lamivudine	tenofovir	of
	andomised controlled non-inferiority trial. Lancet	previously	diagnosed	B/F/TAF group (n=314);		alafenami	participants
Number) (Id	london, england). 2017;390(10107):2063-72.	untreated	within the 30	DTG/ABC/3TC group		de	with plasma
		and had	days prior to	(n=315)			HIV-1 RNA
		plasma HIV-	screening	Age (years) 31 (18–71);			< 50 copies
		1 RNA	(refer to study	32 (18–68)			per mL at
		concentratio	protocol)	Female 29 (9%); 33			week 48, as
		ns of 500	Decompensat	(10%)			defined by
		copies per	ed cirrhosis	Male 285 (91%); 282			the US
		mL or more,	(e.g., ascites,	(90%)			Food and
		no hepatitis	encephalopat	Race:			Drug
		B virus	hy, or variceal	White 180 (57%); 179			Administrati
		infection,	bleeding)	(57%)			on (FDA)
		were HLA-	Current	Black 114 (36%); 112			snapshot
		B*5701-	alcohol or	(36%)			algorithm.
		negative, had an	substance	Asian 6 (2%); 10 (3%)			Additional
		eGFR of 50	use judged by the	American Indian or			prespecified
		mL/min or		Alaska Native 2 (1%); 4 (1%)			efficacy
		more	Investigator	Native Hawaiian or			endpoints included the
		(Cockcroft–	to potentially interfere with	Pacific Islander 1			proportion
		Gault	subject study	(<1%); 2 (1%)			of
		equation),	compliance	Other 9 (3%); 8 (3%)			participants
		and had no	Females who	Not permitted 2 (1%); 0			with plasma
		documented	are pregnant	Hispanic or Latino 72			HIV-1 RNA
		resistance	(as confirmed	(23%); 65 (21%)			<50 copies



to	by positive	HIV disease status:		per mL at
	serum	Asymptomatic 286		week 48
	pregnancy	(91%); 286 (91%)		after
	test)	Symptomatic 16 (5%);		imputation
	Females who	14 (4%)		of missing-
	are	AIDS 12 (4%); 15 (5%)		as-failure
	breastfeeding	HIV risk factor:		and
	Chronic	Heterosexual sex 61		missing-as-
	Hepatitis B	(19%); 62 (20%)		excluded
	Virus (HBV)	Homosexual sex 251		values.
	infection	(80%); 250 (79%)		
		Intravenous drug use 5		
		(2%); 4 (1%)		
		HIV-1 RNA (log10		
		copies per mL) 4·42		
		(4.03–4.87); 4.51		
		(4.04–4.87)		
		HIV-1 RNA >100 000		
		copies per mL 53		
		(17%); 50 (16%)		
		CD4 count (cells per		
		μL): 443 (299–590); 450		
		(324–608)		
		<50: 7 (2%); 10 (3%)		
		≥50 to <200: 29 (9%);		
		22 (7%)		
		≥200 to <350: 69 (22%);		
		58 (18%)		
		≥350 to <500: 87 (28%);		
		91 (29%)		
		≥500: 122 (39%); 134		
		(43%)		
		Creatinine clearance		
		(mL/min)* 125-9		
		(107-7–146-3); 123-0		
		(107-0-144-3)		
		Body-mass index		
		(kg/m²) 25·1 (22·4–		
		28.7); 24.9 (22.5–29.1)		
		Data are median (IQR		
		[range for age]) or n		
		(%).		



				B/F/TAF=bictegravir, emtricitabine, and tenofovir alafenamide. DTG/ABC/3TC=dolutegr avir, abacavir, and lamivudine. *Estimated with the Cockcroft— Gault equation.			
Thompso MN; Anti Brainard emtricital dolutegra treatmen randomis inferiority DOI: 10. https://www.	A; Yazdanpanah, Y; Baumgarten, A; Clarke, A; on, MA; Brinson, C; Hagins, D; Ramgopal, nori, A; Wei, X; Acosta, R; Collins, SE; , D; Martin, H. Bictegravir combined with bine and tenofovir alafenamide versus avir, abacavir, and lamivudine for initial at of HIV-1 infection: week 96 results from a sed, double-blind, multicentre, phase 3, non-y trial. The lancet. HIV 2019; 6(6): e355-363. 1016/S2352-3018(19)30077-3. www.cochranelibrary.com/central/doi/10.1002/cN-01963192/full	As above	As above	As above	As above	As above	As above


Table . Comparisons included in this section

Study name/ NCT number	Intervention (ABC/3TC+ any 3rd agent)	Comparator (TAF/FTC + any 3 rd agent)
NCT02607930; GS-US-380-1489; 2015-004024-54 (EudraCT Number)	Dolutegravir, abacavir and lamivudine	Bictegravir, emtricitabine and tenofovir alafenamide

Virological success, failure and missing data

Forest plot of comparison: 9 ABC/3TC vs TAF/FTC + any 3rd agent, outcome: 9.1 Virological success.





Test for subgroup differences: Chi² = 0.06, df = 1 (P = 0.80), I^2 = 0%

Forest plot of comparison: 9 ABC/3TC vs TAF/FTC + any 3rd agent, outcome: 9.2 Virological failure.



	ABC/3TC + any 3rd	d agent	TAF/FTC + any 3rd	agent		Odds Ratio	Odds I	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed	I, 95% CI	
9.2.1 48 weeks									
NCT02607930; Gallant 2017 Subtotal (95% CI)	8	315 315	3	314 314	100.0% 100.0 %	2.70 [0.71, 10.28] 2.70 [0.71, 10.28]	-		
Total events Heterogeneity: Not applicable Test for overall effect: Z = 1.46 (P	8 = 0.14)		3						
9.2.2 96 weeks									
NCT02607930; Wohl 2019 Subtotal (95% CI)	7	315 315	2	314 314	100.0% 100.0%	3.55 [0.73, 17.20] 3.55 [0.73, 17.20]	‡		_
Total events Heterogeneity: Not applicable Test for overall effect: Z = 1.57 (P	7 = 0.12)		2						
							0.05 0.2 1 Favours ABC/3TC	5 Favours TAF/FTC	20

Test for subgroup differences: $Chi^2 = 0.07$, df = 1 (P = 0.80), $I^2 = 0\%$

Figure 17. Success, failure and missing data at 48 weeks







Figure 18. Success, failure and missing data at 96 weeks






Failing with resistance

Forest plot of comparison: 9 ABC/3TC vs TAF/FTC + any 3rd agent, outcome: 9.3 Failure with resistance.






Test for subgroup differences: Not applicable

Adverse event (AE)-driven discontinuation

Forest plot of comparison: 9 ABC/3TC vs TAF/FTC + any 3rd agent, outcome: 9.4 AE-driven discontinuation.






Test for subgroup differences: $Chi^2 = 0.01$, df = 1 (P = 0.92), $I^2 = 0\%$

Serious adverse events

Forest plot of comparison: 9 ABC/3TC vs TAF/FTC + any 3rd agent, outcome: 9.5 Serious AE.






Test for subgroup differences: Chi² = 0.26, df = 1 (P = 0.61), I^2 = 0%

Drug-related SAE

Forest plot of comparison: 9 ABC/3TC vs TAF/FTC + any 3rd agent, outcome: 9.6 Drug-related serious AE.






Test for subgroup differences: $Chi^2 = 0.36$, df = 1 (P = 0.55), $I^2 = 0\%$

Grade 3/4 AE

Forest plot of comparison: 9 ABC/3TC vs TAF/FTC + any 3rd agent, outcome: 9.7 Grade 3/4 AE.






Test for subgroup differences: $Chi^2 = 0.24$, df = 1 (P = 0.62), $I^2 = 0\%$

Drug-related Grade 3/4 AE

Forest plot of comparison: 9 ABC/3TC vs TAF/FTC + any 3rd agent, outcome: 9.8 Drug-related grade 3/4 AE.





GRADE table for critical outcomes

	Anticipated absol				Certainty of the	
Outcomes	Risk with TAF/FTC + any 3rd agent	Risk with ABC/3TC	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological success - 48 weeks	924 per 1,000	930 per 1,000 (879 to 960)	OR 1.10 (0.60 to 2.01)	629 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Virological success - 96 weeks	879 per 1,000	899 per 1,000 (843 to 936)	OR 1.22 (0.74 to 2.00)	629 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Virological failure - 48 weeks	10 per 1,000	25 per 1,000 (7 to 90)	OR 2.70 (0.71 to 10.28)	629 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	



	Anticipated absolu	Anticipated absolute effects* (95% CI)			Certainty of the	
Outcomes	Risk with TAF/FTC + any 3rd agent	Risk with ABC/3TC	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Virological failure - 96 weeks	6 per 1,000	22 per 1,000 (5 to 99)	OR 3.55 (0.73 to 17.20)	629 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Failure with resistance - 48 weeks	0 per 1,000	0 per 1,000 (0 to 0)	not estimable	5 (1 RCT)	-	No events in either group
Failure with resistance - 96 weeks	0 per 1,000	0 per 1,000 (0 to 0)	not estimable	5 (1 RCT)	-	No events in either group
AE-driven discontinuation - 48 weeks	0 per 1,000	0 per 1,000 (0 to 0)	OR 9.09 (0.49 to 169.48)	629 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
AE-driven discontinuation - 96 weeks	0 per 1,000	0 per 1,000 (0 to 0)	OR 11.14 (0.61 to 202.35)	629 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Serious AE - 48 weeks	61 per 1,000	79 per 1,000 (44 to 138)	OR 1.34 (0.72 to 2.48)	629 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Serious AE - 96 weeks	115 per 1,000	124 per 1,000 (80 to 186)	OR 1.09 (0.67 to 1.77)	629 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Drug-related serious AE - 48 weeks	3 per 1,000	3 per 1,000 (0 to 49)	OR 1.00 (0.06 to 16.01)	629 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Drug-related serious AE - 96 weeks	10 per 1,000	3 per 1,000 (0 to 30)	OR 0.33 (0.03 to 3.19)	629 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	
Grade 3/4 AE - 48 weeks	73 per 1,000	76 per 1,000 (44 to 130)	OR 1.04 (0.58 to 1.89)	629 (1 RCT)	⊕⊕⊖⊖ Low ^{a,b}	



BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022

	Anticipated absolu	te effects* (95% CI)			Certainty of the	
Outcomes	Risk with TAF/FTC + any 3rd agent	Risk with ABC/3TC	Relative effect (95% CI)	№ of participants (studies)	evidence (GRADE)	Comments
Grade 3/4 AE - 96 weeks	134 per 1,000	117 per 1,000 (77 to 176)	OR 0.86 (0.54 to 1.38)	629 (1 RCT)	⊕⊕⊜⊖ Low ^{a,b}	
Drug-related grade 3/4 AE - 48 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome
Drug-related grade 3/4 AE - 96 weeks	not pooled	not pooled	not pooled	(0 studies)	-	No studies reporting this outcome

^{*}The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: confidence interval; OR: odds ratio

GRADE Working Group grades of evidence

High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

Explanations

- a. Small proportion of study participants with advanced HIV disease, and a small proportion of female participants.
- b. 95% Confidence interval spans 1



Comparison of all studies for discontinuations for AE

Discontinuations due to AE (48 weeks)

	Regimen																	
Study	ABC, DTG, 3TC	ATV/r, FTC, TDF	BIC, FTC, TAF	COBI, DRV, FTC, TAF	COBI, DRV, FTC, TDF	COBI, EVG, FTC, TAF	COBI, EVG, FTC, TDF	DOR, FTC, TDF (or DOR, ABC, 3TC)	DOR, TDF, 3TC	DRV/r, FTC, TDF (or DRV/r, ABC, 3TC)	DTG, FTC, TAF	DTG, FTC, TDF	DTG, FTC, TDF (or DTG, ABC, 3TC)	DTG, 3TC	DTG, TDF, 3TC	EFV, FTC, TDF	EFV, TDF, 3TC	RAL, FTC, TDF (or RAL, ABC, 3TC)
ADVANCE											1/351 (0.3%)	0/351 (0%)				10/351 (2.8%)		
NAMSAL															0/310 (0%)		0/303 (0%)	
SINGLE	10/414 (2.4%)														,	42/419 (10.0%)	(/	
GS-US- 380-1489	4/315 (1.3%)		0/314 (0%)															
GS-US- 380-1490			5/320 (1.6%)								1/325 (0.3%)							
ARIA	10/248 (4.0%)	17/247 (6.9%)																
FLAMINGO										9/242 (3.7%)			3/242 (1.2%)					
DRIVE- FORWARD								6/383 (1.6%)		12/383 (3.1%)								
DRIVE- AHEAD									11/364 (3.0%)							24/364 (6.6%)		
GEMINI												16/717 (2.2%)		15/716 (2.1%)				
SPRING-2													10/411 (2.4%)					10/411 (2.4%)
Sax 2015						8/866 (0.9%)	13/867 (1.5%)											
AMBER				7/362 (1.9%)	16/363 (4.4%)													
Mills 2015				2/103 (1.9%)	2/50 (4.0%)													
Total	24/977 (2.5%)	17/247 (6.9%)	5/634 (0.8%)	9/465 (1.9%)	18/413 (4.4%)	8/866 (0.9%)	13/867 (1.5%)	6/383 (1.6%)	11/364 (3.0%)	21/625 (3.4%)	2/676 (0.3%)	16/1068 (1.5%)	13/653 (2.0%)	15/716 (2.1%)	0/310 (0%)	76/1134 (6.7%)	0/303 (0%)	10/411 (2.4%)

Green: <1%; Yellow: 1-3%; Orange: 3-5%; Red: >5%



Appendix A. Search strategy

Medline

Limits: Humans, English, MEDLINE, from 2019/8/1 - 2021/6/30

Search strategy:

Search

number Query Search Details Results

(("hiv"[MeSH Terms] OR "acquired immunodeficiency syndrome"[MeSH Terms]) AND ("humans" [MeSH Terms] AND "medline" [Filter] AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language]) AND (((("anti retroviral agents"[MeSH Terms] OR "antiretroviral therapy, highly active"[MeSH Terms] OR "HAART"[Title/Abstract] OR ("therap*"[Title/Abstract] OR "treat*"[Title/Abstract] OR "agent*"[Title/Abstract] OR "drug*"[Title/Abstract] OR "medication*"[Title/Abstract] OR "regime*"[Title/Abstract]) OR ("nrti*"[Title/Abstract] OR "nnrti*"[Title/Abstract]) OR "reverse transcriptase inhibitor*"[Title/Abstract] OR ("protease"[Title/Abstract] OR "integrase"[Title/Abstract])) AND ("humans"[MeSH Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language])) OR (((("didanosine"[Title/Abstract] OR "lamivudine"[Title/Abstract] OR "nevirapine"[Title/Abstract] OR "stavudine"[Title/Abstract] OR "zidovudine"[Title/Abstract] OR "indinavir"[Title/Abstract] OR "nelfinavir"[Title/Abstract] OR "ritonavir"[Title/Abstract] OR "saguinavir"[Title/Abstract] OR "emtricitabine"[Title/Abstract] OR "rilpivirine"[Title/Abstract] OR "lopinavir"[Title/Abstract] OR "amprenavir"[Title/Abstract] OR "fosamprenavir"[Title/Abstract] OR "atazanavir"[Title/Abstract] OR "darunavir"[Title/Abstract] OR "tipranavir"[Title/Abstract] OR "maraviroc"[Title/Abstract] OR "enfuvirtide"[Title/Abstract] OR "raltegravir"[Title/Abstract] OR



```
"etravirine"[Title/Abstract] OR "abacavir"[Title/Abstract] OR
"tenofovir"[Title/Abstract] OR "efavirenz"[Title/Abstract] OR
"Kaletra" [Title/Abstract] OR "Combivir" [Title/Abstract] OR
"Truvada"[Title/Abstract] OR "Atripla"[Title/Abstract] OR "Trizivir"[Title/Abstract]
OR "Sustiva"[Title/Abstract]) AND ("humans"[MeSH Terms] AND "medline"[Filter]
AND 2019/08/01:2021/06/30[Date - Publication] AND "english" [Language])) OR
(("Stribild"[Title/Abstract] OR "eviplera"[Title/Abstract] OR "kivexa"[Title/Abstract]
OR "elvitegravir" [Title/Abstract] OR "ziagen" [Title/Abstract] OR
"emtriva"[Title/Abstract] OR "epivir"[Title/Abstract] OR "complera"[Title/Abstract]
OR "retrovir"[Title/Abstract] OR "viread"[Title/Abstract] OR
"stocrin"[Title/Abstract] OR "intelence"[Title/Abstract] OR
"viramune"[Title/Abstract] OR "edurant"[Title/Abstract] OR
"revataz"[Title/Abstract] OR "prezista"[Title/Abstract] OR "telzir"[Title/Abstract] OR
"norvir"[Title/Abstract] OR "aptivus"[Title/Abstract] OR "celsentri"[Title/Abstract]
OR "dolutegravir" [Title/Abstract] OR "tivicay" [Title/Abstract] OR
"vitekta"[Title/Abstract] OR "isentress"[Title/Abstract]) AND ("humans"[MeSH
Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication]
AND "english" [Language])) OR (("Trii" [Title/Abstract] OR "epzicom" [Title/Abstract]
OR "zerit"[Title/Abstract] OR "amdoxovir"[Title/Abstract] OR
"videx"[Title/Abstract] OR "rescriptor"[Title/Abstract] OR
"delavirdine"[Title/Abstract] OR "lersivirine"[Title/Abstract] OR
"crixivan"[Title/Abstract] OR "invirase"[Title/Abstract] OR "lexiva"[Title/Abstract]
OR "viracept"[Title/Abstract] OR "fuzeon"[Title/Abstract] OR
"selzentry"[Title/Abstract] OR "cenicriviroc"[Title/Abstract] OR
"ibalizumab"[Title/Abstract]) AND ("humans"[MeSH Terms] AND "medline"[Filter]
AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language])) OR
(("Biktarvy"[Title/Abstract] OR "bictegravir"[Title/Abstract] OR "tenofovir
alafenamide"[Title/Abstract] OR "doravirine"[Title/Abstract] OR
"Pifeltro"[Title/Abstract] OR "Delstrigo"[Title/Abstract] OR
"Descovy"[Title/Abstract] OR "cabotegravir"[Title/Abstract]) AND ("humans"[MeSH
```



Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language]))) AND ("humans"[MeSH Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language]))) AND ("humans"[MeSH Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language])) AND (("firstline"[Title/Abstract] OR "firstline"[Title/Abstract] OR "firstline"[Title/Abstract] OR "initial"[Title/Abstract] OR "start*"[Title/Abstract] OR "begin*"[Title/Abstract] OR "initiat*"[Title/Abstract] OR "naive"[Title/Abstract] OR "naive"[Title/Abstract]) AND ("humans"[MeSH Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language]))) AND ((humans[Filter]) AND (medline[Filter]) AND (2019/8/1:2021/6/30[pdat]) AND (english[Filter]))

firstline[Title/Abstract] OR first line[Title/Abstract] OR first-line[Title/Abstract] OR initial[Title/Abstract] OR start*[Title/Abstract] OR begin*[Title/Abstract] OR initiat*[Title/Abstract] OR naïve[Title/Abstract] OR naive[Title/Abstract]

("firstline"[Title/Abstract] OR "first-line"[Title/Abstract] OR "first-line"[Title/Abstract] OR "start*"[Title/Abstract] OR "begin*"[Title/Abstract] OR "initiat*"[Title/Abstract] OR "naive"[Title/Abstract] OR "naive"[Title/Abstract] OR "naive"[Title/Abstract] OR "naive"[Title/Abstract]) AND ((humans[Filter]) AND (medline[Filter]) AND (2019/8/1:2021/6/30[pdat]) AND (english[Filter]))

89,354

((("anti retroviral agents"[MeSH Terms] OR "antiretroviral therapy, highly active"[MeSH Terms] OR "HAART"[Title/Abstract] OR ("therap*"[Title/Abstract] OR "treat*"[Title/Abstract] OR "agent*"[Title/Abstract] OR "drug*"[Title/Abstract] OR "medication*"[Title/Abstract] OR "regime*"[Title/Abstract]) OR ("nrti*"[Title/Abstract] OR "nnrti*"[Title/Abstract]) OR "reverse transcriptase inhibitor*"[Title/Abstract] OR ("protease"[Title/Abstract] OR "integrase"[Title/Abstract]) AND ("humans"[MeSH Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language])) OR (((("didanosine"[Title/Abstract] OR "lamivudine"[Title/Abstract] OR

9



```
"nevirapine"[Title/Abstract] OR "stavudine"[Title/Abstract] OR
"zidovudine"[Title/Abstract] OR "indinavir"[Title/Abstract] OR
"nelfinavir"[Title/Abstract] OR "ritonavir"[Title/Abstract] OR
"saguinavir"[Title/Abstract] OR "emtricitabine"[Title/Abstract] OR
"rilpivirine"[Title/Abstract] OR "lopinavir"[Title/Abstract] OR
"amprenavir"[Title/Abstract] OR "fosamprenavir"[Title/Abstract] OR
"atazanavir"[Title/Abstract] OR "darunavir"[Title/Abstract] OR
"tipranavir"[Title/Abstract] OR "maraviroc"[Title/Abstract] OR
"enfuvirtide"[Title/Abstract] OR "raltegravir"[Title/Abstract] OR
"etravirine"[Title/Abstract] OR "abacavir"[Title/Abstract] OR
"tenofovir"[Title/Abstract] OR "efavirenz"[Title/Abstract] OR
"Kaletra" [Title/Abstract] OR "Combivir" [Title/Abstract] OR
"Truvada" [Title/Abstract] OR "Atripla" [Title/Abstract] OR "Trizivir" [Title/Abstract]
OR "Sustiva" [Title/Abstract]) AND ("humans" [MeSH Terms] AND "medline" [Filter]
AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language])) OR
(("Stribild"[Title/Abstract] OR "eviplera"[Title/Abstract] OR "kivexa"[Title/Abstract]
OR "elvitegravir" [Title/Abstract] OR "ziagen" [Title/Abstract] OR
"emtriva"[Title/Abstract] OR "epivir"[Title/Abstract] OR "complera"[Title/Abstract]
OR "retrovir"[Title/Abstract] OR "viread"[Title/Abstract] OR
"stocrin"[Title/Abstract] OR "intelence"[Title/Abstract] OR
"viramune"[Title/Abstract] OR "edurant"[Title/Abstract] OR
"revataz"[Title/Abstract] OR "prezista"[Title/Abstract] OR "telzir"[Title/Abstract] OR
"norvir"[Title/Abstract] OR "aptivus"[Title/Abstract] OR "celsentri"[Title/Abstract]
OR "dolutegravir" [Title/Abstract] OR "tivicay" [Title/Abstract] OR
"vitekta"[Title/Abstract] OR "isentress"[Title/Abstract]) AND ("humans"[MeSH
Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication]
AND "english" [Language])) OR (("Trii" [Title/Abstract] OR "epzicom" [Title/Abstract]
OR "zerit"[Title/Abstract] OR "amdoxovir"[Title/Abstract] OR
"videx"[Title/Abstract] OR "rescriptor"[Title/Abstract] OR
"delavirdine"[Title/Abstract] OR "lersivirine"[Title/Abstract] OR
```



"crixivan"[Title/Abstract] OR "invirase"[Title/Abstract] OR "lexiva"[Title/Abstract] OR "viracept"[Title/Abstract] OR "fuzeon"[Title/Abstract] OR "selzentry"[Title/Abstract] OR "cenicriviroc"[Title/Abstract] OR "ibalizumab"[Title/Abstract] AND ("humans"[MeSH Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language])) OR (("Biktarvy"[Title/Abstract] OR "bictegravir"[Title/Abstract] OR "tenofovir alafenamide"[Title/Abstract] OR "doravirine"[Title/Abstract] OR "Pifeltro"[Title/Abstract] OR "Delstrigo"[Title/Abstract] OR "Descovy"[Title/Abstract] OR "cabotegravir"[Title/Abstract]) AND ("humans"[MeSH Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language]))) AND ("humans"[MeSH Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language]))) AND ((humans[Filter]) AND (medline[Filter]) AND (2019/8/1:2021/6/30[pdat]) AND (english[Filter]))

((("didanosine"[Title/Abstract] OR "lamivudine"[Title/Abstract] OR
"nevirapine"[Title/Abstract] OR "stavudine"[Title/Abstract] OR
"zidovudine"[Title/Abstract] OR "indinavir"[Title/Abstract] OR
"nelfinavir"[Title/Abstract] OR "ritonavir"[Title/Abstract] OR
"saquinavir"[Title/Abstract] OR "emtricitabine"[Title/Abstract] OR
"rilpivirine"[Title/Abstract] OR "lopinavir"[Title/Abstract] OR
"amprenavir"[Title/Abstract] OR "fosamprenavir"[Title/Abstract] OR
"atazanavir"[Title/Abstract] OR "darunavir"[Title/Abstract] OR
"tipranavir"[Title/Abstract] OR "maraviroc"[Title/Abstract] OR
"enfuvirtide"[Title/Abstract] OR "raltegravir"[Title/Abstract] OR
"etravirine"[Title/Abstract] OR "abacavir"[Title/Abstract] OR
"tenofovir"[Title/Abstract] OR "efavirenz"[Title/Abstract] OR
"Kaletra"[Title/Abstract] OR "Combivir"[Title/Abstract] OR
"Truvada"[Title/Abstract] OR "Atripla"[Title/Abstract] OR "Trizivir"[Title/Abstract]
OR "Sustiva"[Title/Abstract]) AND ("humans"[MeSH Terms] AND "medline"[Filter]



AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language])) OR (("Stribild"[Title/Abstract] OR "eviplera"[Title/Abstract] OR "kivexa"[Title/Abstract] OR "elvitegravir" [Title/Abstract] OR "ziagen" [Title/Abstract] OR "emtriva"[Title/Abstract] OR "epivir"[Title/Abstract] OR "complera"[Title/Abstract] OR "retrovir" [Title/Abstract] OR "viread" [Title/Abstract] OR "stocrin"[Title/Abstract] OR "intelence"[Title/Abstract] OR "viramune"[Title/Abstract] OR "edurant"[Title/Abstract] OR "reyataz"[Title/Abstract] OR "prezista"[Title/Abstract] OR "telzir"[Title/Abstract] OR "norvir"[Title/Abstract] OR "aptivus"[Title/Abstract] OR "celsentri"[Title/Abstract] OR "dolutegravir" [Title/Abstract] OR "tivicay" [Title/Abstract] OR "vitekta"[Title/Abstract] OR "isentress"[Title/Abstract]) AND ("humans"[MeSH Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication] AND "english" [Language])) OR (("Trii" [Title/Abstract] OR "epzicom" [Title/Abstract] OR "zerit" [Title/Abstract] OR "amdoxovir" [Title/Abstract] OR "videx"[Title/Abstract] OR "rescriptor"[Title/Abstract] OR "delavirdine"[Title/Abstract] OR "lersivirine"[Title/Abstract] OR "crixivan"[Title/Abstract] OR "invirase"[Title/Abstract] OR "lexiva"[Title/Abstract] OR "viracept" [Title/Abstract] OR "fuzeon" [Title/Abstract] OR "selzentry"[Title/Abstract] OR "cenicriviroc"[Title/Abstract] OR "ibalizumab"[Title/Abstract]) AND ("humans"[MeSH Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication] AND "english"[Language])) OR (("Biktarvy"[Title/Abstract] OR "bictegravir"[Title/Abstract] OR "tenofovir alafenamide"[Title/Abstract] OR "doravirine"[Title/Abstract] OR "Pifeltro"[Title/Abstract] OR "Delstrigo"[Title/Abstract] OR "Descovy"[Title/Abstract] OR "cabotegravir"[Title/Abstract]) AND ("humans"[MeSH Terms] AND "medline"[Filter] AND 2019/08/01:2021/06/30[Date - Publication] AND "english" [Language]))) AND ((humans[Filter]) AND (medline[Filter]) AND (2019/8/1:2021/6/30[pdat]) AND (english[Filter]))



6	Biktarvy[Title/Abstract] OR bictegravir[Title/Abstract] OR tenofovir alafenamide[Title/Abstract] OR doravirine[Title/Abstract] OR Pifeltro[Title/Abstract] OR Delstrigo[Title/Abstract] OR Descovy[Title/Abstract] OR cabotegravir[Title/Abstract]	("Biktarvy"[Title/Abstract] OR "bictegravir"[Title/Abstract] OR "tenofovir alafenamide"[Title/Abstract] OR "doravirine"[Title/Abstract] OR "Pifeltro"[Title/Abstract] OR "Delstrigo"[Title/Abstract] OR "Descovy"[Title/Abstract] OR "cabotegravir"[Title/Abstract]) AND ((humans[Filter]) AND (medline[Filter]) AND (2019/8/1:2021/6/30[pdat]) AND (english[Filter]))	219
	Trii[Title/Abstract] OR epzicom[Title/Abstract] OR zerit[Title/Abstract] OR amdoxovir[Title/Abstract] OR videx[Title/Abstract] OR rescriptor[Title/Abstract] OR delavirdine[Title/Abstract]		
5	OR lersivirine[Title/Abstract] OR crixivan[Title/Abstract] OR invirase[Title/Abstract] OR lexiva[Title/Abstract] OR viracept[Title/Abstract] OR fuzeon[Title/Abstract] OR selzentry[Title/Abstract] OR cenicriviroc[Title/Abstract] OR ibalizumab[Title/Abstract]	("Trii"[Title/Abstract] OR "epzicom"[Title/Abstract] OR "zerit"[Title/Abstract] OR "amdoxovir"[Title/Abstract] OR "videx"[Title/Abstract] OR "rescriptor"[Title/Abstract] OR "delavirdine"[Title/Abstract] OR "lersivirine"[Title/Abstract] OR "crixivan"[Title/Abstract] OR "invirase"[Title/Abstract] OR "lexiva"[Title/Abstract] OR "viracept"[Title/Abstract] OR "fuzeon"[Title/Abstract] OR "selzentry"[Title/Abstract] OR "cenicriviroc"[Title/Abstract] OR "ibalizumab"[Title/Abstract]) AND ((humans[Filter]) AND (medline[Filter]) AND (2019/8/1:2021/6/30[pdat]) AND (english[Filter]))	25
	Stribild[Title/Abstract] OR	("Stribild"[Title/Abstract] OR "eviplera"[Title/Abstract] OR "kivexa"[Title/Abstract]	
4	eviplera[Title/Abstract] OR kivexa[Title/Abstract] OR elvitegravir[Title/Abstract]	OR "elvitegravir"[Title/Abstract] OR "ziagen"[Title/Abstract] OR "emtriva"[Title/Abstract] OR "epivir"[Title/Abstract] OR "complera"[Title/Abstract] OR "retrovir"[Title/Abstract] OR "viread"[Title/Abstract] OR	299



OR ziagen[Title/Abstract] OR emtriva[Title/Abstract] OR epivir[Title/Abstract] OR complera[Title/Abstract] OR retrovir[Title/Abstract] OR viread[Title/Abstract] OR stocrin[Title/Abstract] OR intelence[Title/Abstract] OR viramune[Title/Abstract] OR edurant[Title/Abstract] OR revataz[Title/Abstract] OR prezista[Title/Abstract] OR telzir[Title/Abstract] OR norvir[Title/Abstract] OR aptivus[Title/Abstract] OR celsentri[Title/Abstract] OR dolutegravir[Title/Abstract] OR tivicay[Title/Abstract] OR vitekta[Title/Abstract] OR isentress[Title/Abstract]

"stocrin"[Title/Abstract] OR "intelence"[Title/Abstract] OR

"viramune"[Title/Abstract] OR "edurant"[Title/Abstract] OR

"reyataz"[Title/Abstract] OR "prezista"[Title/Abstract] OR "telzir"[Title/Abstract] OR

"norvir"[Title/Abstract] OR "aptivus"[Title/Abstract] OR "celsentri"[Title/Abstract]

OR "dolutegravir"[Title/Abstract] OR "tivicay"[Title/Abstract] OR

"vitekta"[Title/Abstract] OR "isentress"[Title/Abstract]) AND ((humans[Filter]) AND

(medline[Filter]) AND (2019/8/1:2021/6/30[pdat]) AND (english[Filter]))

didanosine[Title/Abstract] OR lamivudine[Title/Abstract] OR nevirapine[Title/Abstract] OR stavudine[Title/Abstract] OR zidovudine[Title/Abstract] OR indinavir[Title/Abstract] OR nelfinavir[Title/Abstract] OR ritonavir[Title/Abstract] OR saquinavir[Title/Abstract]

("didanosine"[Title/Abstract] OR "lamivudine"[Title/Abstract] OR "nevirapine"[Title/Abstract] OR "stavudine"[Title/Abstract] OR "zidovudine"[Title/Abstract] OR "indinavir"[Title/Abstract] OR "nelfinavir"[Title/Abstract] OR "ritonavir"[Title/Abstract] OR "saquinavir"[Title/Abstract] OR "emtricitabine"[Title/Abstract] OR "rilpivirine"[Title/Abstract] OR "lopinavir"[Title/Abstract] OR "amprenavir"[Title/Abstract] OR "fosamprenavir"[Title/Abstract] OR "atazanavir"[Title/Abstract] OR "darunavir"[Title/Abstract] OR

"tipranavir"[Title/Abstract] OR "maraviroc"[Title/Abstract] OR



OR

emtricitabine[Title/Abstract]
OR rilpivirine[Title/Abstract]
OR lopinavir[Title/Abstract]
OR

. . .

amprenavir[Title/Abstract]

OR

fosamprenavir[Title/Abstract]
OR atazanavir[Title/Abstract]

OR darunavir[Title/Abstract]

OR tipranavir[Title/Abstract]

OR maraviroc[Title/Abstract]

OR enfuvirtide[Title/Abstract]

OR raltegravir[Title/Abstract]

OR etravirine[Title/Abstract]

OR abacavir[Title/Abstract]

OR tenofovir[Title/Abstract]

OR efavirenz[Title/Abstract]

OR Kaletra[Title/Abstract] OR

Combivir[Title/Abstract] OR

Truvada[Title/Abstract] OR

Atripla[Title/Abstract] OR

Trizivir[Title/Abstract] OR

Sustiva[Title/Abstract]

(((((((antiretroviral
 agents[MeSH Terms]) OR
 (highly active antiretroviral
 therapy[MeSH Terms])) OR
 (HAART[Title/Abstract])) OR

"enfuvirtide"[Title/Abstract] OR "raltegravir"[Title/Abstract] OR

"etravirine"[Title/Abstract] OR "abacavir"[Title/Abstract] OR

"tenofovir"[Title/Abstract] OR "efavirenz"[Title/Abstract] OR

"Kaletra"[Title/Abstract] OR "Combivir"[Title/Abstract] OR

"Truvada"[Title/Abstract] OR "Atripla"[Title/Abstract] OR "Trizivir"[Title/Abstract] OR "Sustiva"[Title/Abstract]) AND ((humans[Filter]) AND (medline[Filter]) AND

(2019/8/1:2021/6/30[pdat]) AND (english[Filter]))

("anti retroviral agents" [MeSH Terms] OR "antiretroviral therapy, highly active" [MeSH Terms] OR "HAART" [Title/Abstract] OR "therap*" [Title/Abstract] OR "treat*" [Title/Abstract] OR "agent*" [Title/Abstract] OR "drug*" [Title/Abstract] OR "medication*" [Title/Abstract] OR "regime*" [Title/Abstract] OR "nrti*" [Title/Abstract] OR "reverse transcriptase"



1

(therap*[Title/Abstract] OR treat*[Title/Abstract] OR agent*[Title/Abstract] OR drug*[Title/Abstract] OR medication*[Title/Abstract] OR regime*[Title/Abstract])) OR (NRTI*[Title/Abstract] OR NNRTI*[Title/Abstract])) OR ("reverse transcriptase inhibitor*"[Title/Abstract]))

OR (protease[Title/Abstract] OR integrase[Title/Abstract])

inhibitor*"[Title/Abstract] OR "protease"[Title/Abstract] OR "integrase"[Title/Abstract]) AND ((humans[Filter]) AND (medline[Filter]) AND (2019/8/1:2021/6/30[pdat]) AND (english[Filter]))

("hiv"[MeSH Terms]) OR (aids[MeSH Terms])

("hiv"[MeSH Terms] OR "acquired immunodeficiency syndrome"[MeSH Terms]) AND ((humans[Filter]) AND (medline[Filter]) AND (2019/8/1:2021/6/30[pdat]) AND (english[Filter]))

4,004



Cochrane

Date Run: 01/06/2021

Search strategy:

- ID Search Hits
- #1 MeSH descriptor: [AIDS Serodiagnosis] explode all trees 102
- #2 MeSH descriptor: [HIV Infections] explode all trees 12861
- #3 MeSH descriptor: [HIV] explode all trees 3134
- #4 MeSH descriptor: [HIV Long-Term Survivors] explode all trees 7
- #5 #1 OR #2 OR #3 OR #4 13004
- #6 (HIV or HIV1 or HIV2 or "human immun* deficien[*3]" or PLWH or AIDS near/3 virus or "acquired immun* deficien[*3]"):ti,ab,kw27426
- #7 ("human immunodeficiency virus" or "human immunedeficiency virus" or "human immuno-deficiency virus" or "acquired immunodeficiency syndrome" or "acquired immuno-deficiency syndrome" or "acquired imm
- #8 #5 OR #6 OR #7 28894
- #9 MeSH descriptor: [Anti-Retroviral Agents] explode all trees 4342
- #10 MeSH descriptor: [Antiretroviral Therapy, Highly Active] this term only 1230
- #11 (HAART or ((antiretroviral or anti-retroviral) near/3 (therap* or treat* or agent* or drug* or medication* or regime*)) or NRTI* or NNRTI*):ti,ab,kw 9426
- #12 (((nucleoside or non-nucleoside) near/2 "reverse transcriptase inhibitor*") or ((protease or integrase) near/1 inhibitor*) or ((anti-HIV or anti-aids) near/1 (drug* or agent* or therap* or treat* or agent* or regime*))):ti,ab,kw 6135



- #13 #9 OR #10 OR #11 OR #12 12386
- ((didanosine or lamivudine or nevirapine or stavudine or zidovudine or indinavir or nelfinavir or ritonavir or saquinavir or emtricitabine or rilpivirine or lopinavir or amprenavir or fosamprenavir or atazanavir or darunavir or tipranavir or maraviroc or enfuvirtide or raltegravir or etravirine or abacavir or tenofovir or efavirenz or Kaletra or Combivir or Truvada or Atripla or Trizivir or Sustiva):ti,ab,kw 10561
- ((Stribild or eviplera or kivexa or elvitegravir or ziagen or emtriva or epivir or complera or retrovir or viread or stocrin or intelence or viramune or edurant or reyataz or prezista or telzir or norvir or aptivus or celsentri or dolutegravir or tivicay or vitekta or isentress):ti,ab,kw 1248
- #16 ((Trii or epzicom or zerit or amdoxovir or videx or rescriptor or delavirdine or lersivirine or crixivan or invirase or lexiva or viracept or fuzeon or selzentry or cenicriviroc or ibalizumab)):ti,ab,kw 280
- #17 ((Biktarvy or cictegravir or tenofovir alafenamide or doravirine or Pifeltro or Delstrigo or Descovy or cabotegravir)):ti,ab,kw 708
- #18 #14 OR #15 OR #16 OR #17 10810
- #19 #13 OR #18 17346
- #20 (((firstline or first-line or initial or start* or begin*) near/2 (therap* or regim* or anti-retroviral* or antiretroviral* or agent* or drug* or HAART or ART or treat* or medication*))):ti,ab,kw 40736
- #21 ((naïve)):ti,ab,kw 17774
- #22 #20 OR #21 56435
- #23 #5 AND #19 6988
- #24 #23 AND #22 1726
- #25 #24 with Cochrane Library publication date Between Aug 2019 and Jun 2021 245



HIV conferences

CROI 2020 (<u>croi2020-boston-abstract-ebook.pdf</u> (<u>croiconference.org</u>)) and 2021 (<u>vCROI-2021-Abstract-eBook.pdf</u> (<u>croiconference.org</u>)) (2020: n=38 and 2021: n=41)

IAS <u>Abstract Archive (abstract-archive.org)</u> for 2020 (2021 not until July <u>Conferences (iasociety.org)</u>); no pdf but archives searched (n=15)

EAC 2019 (EACS 2019 – Abstract Book (wiley.com)) (2021 not until October AIDS Conference London 2021 | 18th European AIDS Conference (eacs-conference2021.com)) (n=60)

HIV drug therapy Glasgow 2020 (<u>HIV Glasgow – Virtual, 5–8 October 2020 (wiley.com)</u> or <u>HIV Glasgow – Virtual, 5–8 October 2020: Journal of the</u> International AIDS Society: Vol 23, No S7 (wiley.com)) (n=34)

BHIVA/BASHH joint conference 2021 (<u>AbstractBook2021.pdf (bhiva.org)</u>) (2020 cancelled due to Covid-19 [<u>Conference Abstracts (bhiva.org)</u>]; virtual programme saved <u>BHIVA Virtual Conference 2020</u>) (n=7)









Appendix B. Risk of bias assessments for each study

3rd agent comparisons

The following tables show the risk of bias assessments for the studies using the Cochrane ROB 2.0 tool.

1 DOL vs EFV + any 2NRTI

		1. Biases arising fro	om the randomisation process		
Study name/ NCT number		1.1 Was the allocation sequence random?	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	1.3 Did baseline differences between intervention groups suggest a problem with the randomisation process?	Risk of bias judgement
NCT03122262; ADVANCE	Judgement	Yes	Yes	No	Low
	Description	Electronically generated	Electronically generated	Baseline characteristics were balanced across the groups	
NCT02777229; New	Judgement	Yes	Yes	No	Low
Antiretroviral and Monitoring Strategies in HIV-Infected Adults in Low-Income Countries (NAMSAL) ANRS 12313	Description	Computer- generated	The randomization lists was produced prior to the start of the trial and will be given as confidential lists specifically to the person designed as responsible for the randomization center. This person was not directly involved in the trial and study team was blinded to randomization sequence.	Demographic and disease characteristics at baseline were well balanced between the two treatment groups	
NCT01263015; SINGLE	Judgement	Yes	Yes	No	Low
	Description	Randomization was performed in block sizes of six	Use of a central procedure	Demographic and disease characteristics at baseline were well balanced between the treatment groups	

	2. Bias due to deviations from the intended intervention (Effect of assignment to intervention)								
Study name/	2.1 Were	2.2 Were	2.3 If yes/	2.4 If yes/	2.5 If	2.6 Was an	2.7 If no/	Risk of	
NCT number	participants	carers and	probably	probably yes	yes/possibly	appropriate	probably	bias	
	aware of their	trial people	yes/no	to 2.3, were	yes/no	analysis used	no/no	judgement	
	assigned	delivering the	information to	these	information	to estimate	information to		
	intervention	interventions	2.1 or 2.2,	deviations	to 2.4 Were	the effect of	2.6. Was there		
	during the	aware of the	were there	likely to have	these	assignment to	potential for a		
	trial?	participants	deviations		deviations	intervention?	substantial		



			assigned intervention during the trial?	from the intended intervention that arose because of the trial context?	affected the outcomes?	from intended intervention balanced between groups?		impact (on the result) of the failure to analyse the participants in the group to which they had been randomised?	
NCT03122262; ADVANCE	Judgement	Yes	Yes	No information	NA	NA	Yes	NA	Some concerns
	Description	Open label	Open label	No details	NA	NA	Intention-to-treat analysis. After the testing for noninferiority, the treatment groups were compared for differences in efficacy. For these tests, an overall 1.7% significance level (P = 0.017) was used, to adjust for the three pairwise treatment comparisons being made.	NA	
NCT02777229; New	Judgement	Yes	Yes	No information	NA	NA	Yes	NA	Some concerns
Antiretroviral and Monitoring Strategies in HIV-Infected Adults in Low- Income Countries	Description	Open label	Open label	No details	NA	NA	Intention to treat	NA	



(NAMSAL) ANRS 12313									
NCT01263015;	Judgement	No	No	NA	NA	NA	Yes	NA	Low
SINGLE	Description	Double-blind	Double-blind	NA	NA	NA	Intention to	NA	
	-						treat		

		2. Risk of bias d	ue to deviations fro	om the intended in	terventions (Effect	of adhering to int	ervention)	
Study name/ NCT number		2.1 Were participants aware of their assigned intervention during the trial?	2.2 Were carers and people delivering the interventions aware of the participants assigned intervention during the trial?	2.3 [If applicable] If yes/probably yes/ no information to 2.1 or 2.2 Were important non-protocol interventions balanced across intervention groups?	2.4 [If applicable] Were there failures in implementing the intervention that could have affected the outcome?	2.5 [If applicable] Was there non-adherence to the assigned intervention regimen that could have affected participant's outcomes?	2.6. If no/probably no/no information to 2.3, or yes probably yes/no information to 2.4 or 2.5 Was an appropriate analysis used to estimate the effect of adhering to the intervention?	Risk of bias judgement
NCT03122262;	Judgement	Yes	Yes	No information	NA	NA	No information	Some concerns
ADVANCE	Description	Open label	Open label	No details	NA	NA	No details	
NCT02777229;	Judgement	Yes	Yes	No information	NA	No	No information	Some concerns
New Antiretroviral and Monitoring Strategies in HIV-Infected Adults in Low- Income Countries (NAMSAL) ANRS 12313	Description	Open label	Open label	No details	NA	Adherence to treatment was high on the basis of scores on a validated questionnaire. Adherence to treatment was similar in the two groups	No details	
NCT01263015;	Judgement	No	No	NA	NA	No	NA	Low
SINGLE	Description	Double-blind	Double-blind	NA	NA	Adherence to treatment was	NA	



	similar in the two study groups; 3 participants (2 participants in	
	the DTG-ABC- 3TC group and 1 in the EFV- TDF-FTC group) were excluded from the per-protocol population owing to an	
	interruption of the study drug for more than 10% of the total time of treatment	

		3. Bias due to missing	g outcome data			
Study name/ NCT number		3.1 Were outcome data available for all, or nearly all participants randomised?	3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing outcome data?	3.3 If N/PN/NI to 3.2: Could missingness in the outcome depend on its true value?	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	Risk of bias judgement
NCT03122262; ADVANCE	Judgement	No	No	Yes	Yes	High risk at week 48 for virological outcomes. Low at week 96 and other outcomes
	Description	By week 48, the number of patients who had discontinued treatment or who had missing data was 41 (12%) in the TAF-based group, 39	Differences in efficacy between the groups at 48 weeks were driven by a higher number of discontinuations in the standard-care	Differences in efficacy between the groups were driven by the number of discontinuations	Differences in efficacy between the groups were driven by the number of discontinuations	



		(440/) in the TDE	and the second second		T	
		(11%) in the TDF-	group than in the			
		based group, and 55	other two groups. In			
		(16%) in the	the per-protocol			
		standard-care group.	analysis, the			
		By week 98 the	percentage of			
		numbers of patients	patients with an HIV-1			
		who had no	RNA level <50			
		virological data,	copies/mL was similar			
		including those who	across the groups at			
		discontinued for any	week 48 (96% in the			
		reason other than	TAF-based group,			
		lack of efficacy and	95% in the TDF-			
		those with missing	based group, and			
		data within the visit	96% in the standard-			
		window were: 64/351	care group).			
		(18.2%) in the TAF-	At week 96, the			
		based group, 62	difference in rate of			
		(17.7%) in the TDF-	missing data was			
		based group, 126/702	similar between			
		(17.9%) in the	groups, and the			
		combined DOL	differences in			
		groups and 78/351	virological outcomes			
		(22.2%) in the	between groups were			
		standard-care group	not significant either			
		(not significantly	when missing data			
		different).	were classified as			
		,	treatment failures or			
			when missing were			
			excluded.			
NCT02777229; New	Judgement	Yes	NA	NA	NA	Low risk
Antiretroviral and	Description	All included in intent	NA	NA	NA	
Monitoring Strategies	2 coonpact	to treat analysis. Of		1.0.1	'*'	
in HIV-Infected Adults		the 616 participants				
in Low-Income		who underwent				
Countries (NAMSAL)		randomisation, 24				
ANRS 12313		participants (4%)				
7		were excluded from				
		the per-protocol				
		analysis owing to				
		deviations from the				
		protocol				
	l	Protocoi		l		



NCT01263015; SINGLE	Judgement	No	No	Yes	Yes	High risk at 48 and 96 weeks for virological outcomes; low for other outcomes
	Description	At weeks 48, virological outcome data were missing for 7.7% in the DOL group and 15.0% in the EFV group.	Overall differences in response (intention-to-treat analysis) were due primarily to discontinuations because of adverse events (10 of 414 participants [2%] in the DTG-ABC-3TC group and 42 of 419 [10%] in the EFV-TDF-FTC group). At week 96, differences in the virological response rate were driven by a lower rate of discontinuations due to AEs or deaths in the dolutegravir + abacavir/ lamivudine arm than in the efavirenz/tenofovir DF/emtricitabine arm: 13/414 (3%) vs. 48/419 (11%)	Differences in efficacy between the groups were driven by the number of discontinuations	Differences in efficacy between the groups were driven by the number of discontinuations	

	4. Bias in the measurement of the outcome							
Study name/ NCT number	4.1 Was the method of measuring the outcome inappropriate?	4.2 Could measurement or ascertainment of the outcome have differed between	4.3 If N/PN to 4.1 and 4.2: Were outcome assessors aware of the intervention received by the	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of	Risk of bias judgement		



			intervention	study	intervention received?	intervention received?	
NCT02422262	ludgomont	No	groups?	participant?	I .		Low riok
NCT03122262; ADVANCE	Judgement Description	No The primary end point was the percentage of patients with an HIV-1 RNA level < 50 copies/mL at week 48. Secondary objectives were to evaluate additional viral-load thresholds, CD4 count changes, and side-effect profile and safety, including findings on physical examination, laboratory analyses, and dual-energy x-ray absorptiometry (DXA) scans.	No Independent objective measurements as well as data from symptom screening, vital- signs measurement, symptom-directed physical examination, laboratory assessments, and multiple questionnaires, including a sleep questionnaire	Yes Open label	Probably no Independent objective measurements as well as data from symptom screening, vital- signs measurement, symptom-directed physical examination, laboratory assessments, and multiple questionnaires, including a sleep questionnaire	NA NA	Low risk
NCT02777229;	Judgement	No	No	Yes	No	NA	Low risk
New Antiretroviral and Monitoring Strategies in HIV- Infected Adults in Low-Income Countries (NAMSAL) ANRS 12313	Description	The primary end point was the proportion of participants with a viral load of less than 50 copies/mL at week 48, on the basis of the Food and Drug Administration (FDA) snapshot algorithm	Objective measures at specified timepoints in protocol	Open label	Objective measures at specified timepoints in protocol	NA	
NCT01263015;	Judgement	No	No	No	NA	NA	Low risk
SINGLE	Description	The primary efficacy end point	The Abbott Real- Time HIV-1 assay	Double blind	NA	NA	



was the of particle a plasma RNA level than 50 at week determine the use a Snapshot algorithm Food an Adminis	ints with the plasma level of HIV-1 RNA (lower limit of detection, does/mL). inth as CD4+ T-cell the assessed by means of flow cytometry in a central laboratory.
---	--

Ī	5. Risk of bias in selection of the reported result	RCT overall risk of
	•	bias



Study name/ NCT number		5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	5.2. Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	5.3 Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible analyses of the data?	Risk of bias judgement	
NCT03122262; ADVANCE	Judgement	Yes	No	No	Low	High risk at 48 weeks for virological outcomes Some concerns at 96 weeks (open label)
	Description	Pre-specified analysis plan	Pre-specified endpoints	Pre-specified analyses		
NCT02777229; New Antiretroviral and	Judgement	Yes	No	No	Low	Some concerns due to open label study
Monitoring Strategies in HIV-Infected Adults in Low-Income Countries (NAMSAL) ANRS 12313	Description	Pre-specified analysis plan	Pre-specified endpoints	Pre-specified analyses		
NCT01263015; SINGLE	Judgement	Yes	No	No	Low	High risk at 48 and 96 weeks for virological outcomes; low for other outcomes
	Description	Pre-specified analysis plan	Pre-specified endpoints	Pre-specified analyses		

SINGLE: Only 16% of the participants were women, and the proportion of participants with a CD4+ T-cell count of less than 200 per cubic millimeter was relatively low.



2 DOL vs BIC + any 2NRTI

		1. Biases arising	1. Biases arising from the randomisation process					
Study name/ NCT number		1.1 Was the allocation sequence random?	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	1.3 Did baseline differences between intervention groups suggest a problem with the randomisation process?	Risk of bias judgement			
NCT02607930; GS-US-	Judgement	Yes	Yes	No	Low			
380-1489; 2015-004024-54 (EudraCT Number)	Description	Computer- generated allocation sequence	Automated treatment assignment	Demographics and baseline characteristics were similar between groups				
NCT02607956; GS-US-	Judgement	Yes	Yes	No	Low			
380-1490; 2015-003988-10 (EudraCT Number)	Description	Computer- generated allocation sequence	Study investigators identified eligibility of the participant, obtained a participant number, and received automated treatment assignment based on a randomisation sequence.	Demographics and baseline characteristics were balanced between the two treatment groups				

		2. Bias due to	deviations from th	ne intended inter	vention (Effect of	assignment to	intervention)		
Study name/ NCT number		2. Bias due to de 2.1 Were participants aware of their assigned intervention during the trial?	2.2 Were carers and trial people delivering the interventions aware of the participants assigned	2.3 If yes/ probably yes/no information to 2.1 or 2.2, were there deviations from the	vention (Effect of 2.4 If yes/ probably yes to 2.3, were these deviations likely to have affected the outcomes?	assignment to 2.5 If yes/ possibly yes/no information to 2.4 Were these deviations from	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	2.7 If no/ probably no/no information to 2.6. Was there potential for a substantial impact (on the	Risk of bias judgement
			intervention during the trial?	intended intervention that arose because of the trial context?		intended intervention balanced between groups?		result) of the failure to analyse the participants in the group to which they had been randomised?	
	Judgement	No	No	NA	NA	NA	Yes	NA	Low



NCT02607930; GS-US-380- 1489; 2015- 004024-54 (EudraCT Number)	Description	Investigators, participants, and study staff giving treatment, assessing outcomes, and collecting data were masked to group assignment.	Investigators, participants, and study staff giving treatment, assessing outcomes, and collecting data were masked to group assignment.	NA	NA	NA	Full analysis set (all participants who were randomly assigned and had received at least one dose of the study drug, regardless of whether they returned for post-baseline assessments)	NA	
NCT02607956; GS-US-380- 1490; 2015- 003988-10 (EudraCT Number)	Judgement Description	No Double-blind	No Double-blind	NA NA	NA NA	NA NA	Yes US FDA snapshot algorithm	NA NA	Low

		2. Risk of bias du	ue to deviations fro	om the intended in	terventions (Effect	of adhering to int	ervention)	
Study name/ NCT number		2.1 Were participants aware of their assigned intervention during the trial?	2.2 Were carers and people delivering the interventions aware of the participants assigned intervention during the trial?	2.3 [If applicable] If yes/probably yes/ no information to 2.1 or 2.2 Were important non-protocol interventions balanced across intervention groups?	2.4 [If applicable] Were there failures in implementing the intervention that could have affected the outcome?	2.5 [If applicable] Was there non-adherence to the assigned intervention regimen that could have affected participant's outcomes?	2.6. If no/probably no/no information to 2.3, or yes probably yes/no information to 2.4 or 2.5 Was an appropriate analysis used to estimate the effect of adhering to the intervention?	Risk of bias judgement
	Judgement	No	No	NA	NA	NA	NA	Low



NCT02607930; GS-US-380- 1489; 2015- 004024-54 (EudraCT Number)	Description	Investigators, participants, and study staff giving treatment, assessing outcomes, and collecting data were masked to group assignment.	Investigators, participants, and study staff giving treatment, assessing outcomes, and collecting data were masked to group assignment.	NA	NA	NA	NA	
NCT02607956;	Judgement	No	No	NA	NA	NA	NA	Low
GS-US-380- 1490; 2015- 003988-10 (EudraCT Number)	Description	Double-blind	Double-blind	NA	NA	NA	NA	

		3. Bias due to missing	outcome data			
Study name/ NCT number		3.1 Were outcome data available for all, or nearly all participants randomised?	3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing outcome data?	3.3 If N/PN/NI to 3.2: Could missingness in the outcome depend on its true value?	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	Risk of bias judgement
NCT02607930; GS-	Judgement	Yes	NA	NA	NA	Low
US-380-1489; 2015- 004024-54 (EudraCT Number)	Description	<6% missing values for virological outcomes at 48 weeks and <10% missing values for virological outcomes at 96 weeks	NA	NA	NA	
NCT02607956; GS- US-380-1490; 2015- 003988-10 (EudraCT	Judgement	Yes	NA	NA	NA	Low at 48 weeks; some concerns at 96 weeks
Number)	Description	6.0% missing data for virological outcomes at 48 weeks and 11.2% missing data for virological	NA	NA	NA	



outcomes at 96		
weeks		

		4. Bias in the mea	surement of the outc	ome			
Study name/ NCT number		4.1 Was the method of measuring the outcome inappropriate?	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	4.3 If N/PN to 4.1 and 4.2: Were outcome assessors aware of the intervention received by the study participant?	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	Risk of bias judgement
NCT02607930;	Judgement	No	No	No	NA	NA	Low
GS-US-380-1489; 2015-004024-54 (EudraCT Number)	Description	Snapshot algorithm	Snapshot algorithm	Investigators, participants, and study staff giving treatment, assessing outcomes, and collecting data were masked to group assignment.	NA	NA	
NCT02607956;	Judgement	No	No	No	NA	NA	Low
GS-US-380-1490; 2015-003988-10 (EudraCT Number)	Description	Snapshot algorithm	Snapshot algorithm	Double-blind	NA	NA	

	5. Risk of bias in select	. Risk of bias in selection of the reported result						
					bias			
Study name/ NCT	5.1 Were the data	5.2. Is the numerical	5.3 Is the numerical	Risk of bias				
number	that produced this	result being	result being	judgement				
	result analysed in	assessed likely to	assessed likely to					
	accordance with a	have been selected,	have been selected,					
	pre-specified	on the basis of the	on the basis of the					
	analysis plan that	results, from	results, from					
	was finalized before	multiple eligible	multiple eligible					
	unblinded outcome	outcome						



		data were available for analysis?	measurements (e.g. scales, definitions, time points) within the outcome domain?	analyses of the data?		
NCT02607930; GS-	Judgement	Yes	No	No	Low	Low
US-380-1489; 2015-	Description	Pre-specified analysis	Pre-specified	Pre-specified		
004024-54 (EudraCT Number)		plan	endpoints	analyses		
NCT02607956; GS- US-380-1490; 2015- 003988-10 (EudraCT	Judgement	Yes	No	No	Low	Low at 48 weeks; some concerns at 96 weeks
Number)	Description	Pre-specified analysis	Pre-specified	Pre-specified		
		plan	endpoints	analyses		

Gallant 2017: small proportion of study participants with advanced HIV disease, and a small proportion of female participants.

Sax 2017: A small number of participants had advanced HIV-related immunosuppression (12%) or high HIV-1 RNA at baseline (19%), or were women.



3 DOL vs b/PI + any 2NRTI

		1. Biases arising from	the randomisation process		
Study name/ NCT number		1.1 Was the allocation sequence random?	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	1.3 Did baseline differences between intervention groups suggest a problem with the randomisation process?	Risk of bias judgement
NCT01910402;	Judgement	Yes	Yes	No	Low
ARIA	Description	Validated computerised system	Randomisation and identifier code assignment were allocated centrally	Demographics and baseline characteristics were similar between groups	
NCT01449929;	Judgement	Yes	Yes	No	Low
FLAMINGO	Description	Computer-generated	Central interface	Baseline demographics and disease characteristics were similar between treatment groups	

		2. Bias due to d	deviations from th	ne intended interv	vention (Effect of	assignment to in	ntervention)		
Study name/ NCT number		2.1 Were participants aware of their assigned intervention during the trial?	2.2 Were carers and trial people delivering the interventions aware of the participants assigned intervention during the trial?	2.3 If yes/ probably yes/no information to 2.1 or 2.2, were there deviations from the intended intervention that arose because of the trial context?	2.4 If yes/ probably yes to 2.3, were these deviations likely to have affected the outcomes?	2.5 If yes/possibly yes/no information to 2.4 Were these deviations from intended intervention balanced between groups?	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	2.7 If no/ probably no/no information to 2.6. Was there potential for a substantial impact (on the result) of the failure to analyse the participants in the group to which they had been randomised?	Risk of bias judgement
NCT01910402;	Judgement	Yes	Yes	Probably no	NA	NA	Yes	NA	Low
ARIA	Description	Open label	Open label	No details	NA	NA	US FDA snapshot algorithm for the intention-to- treat exposed (ITT-E) population,	NA	



							defined as all participants who received at least one dose of study medication.		
NCT01449929;	Judgement	Yes	Yes	Probably no	NA	NA	Yes	NA	Low
FLAMINGO	Description	Open label	Open label	No details	NA	NA	Snapshot algorithm	NA	

		2. Risk of bias do	ue to deviations fro	om the intended in	terventions (Effect	t of adhering to int	ervention)	
Study name/ NCT number		2.1 Were participants aware of their	2.2 Were carers and people delivering the	2.3 [If applicable] If yes/probably	2.4 [If applicable] Were there	2.5 [If applicable] Was there non-	2.6. If no/probably no/no	Risk of bias judgement
		assigned intervention during the trial?	interventions aware of the participants assigned intervention during the trial?	yes/ no information to 2.1 or 2.2 Were important non-protocol interventions balanced across intervention groups?	failures in implementing the intervention that could have affected the outcome?	adherence to the assigned intervention regimen that could have affected participant's outcomes?	information to 2.3, or yes probably yes/no information to 2.4 or 2.5 Was an appropriate analysis used to estimate the effect of adhering to the intervention?	
NCT01910402;	Judgement	Yes	Yes	NA	NA	NA	NA	Some concerns
ARIA	Description	Open label	Open label	NA	NA	NA	NA	
NCT01449929;	Judgement	Yes	Yes	NA	NA	NA	NA	Some concerns
FLAMINGO	Description	Open label	Open label	NA	NA	NA	NA	

3. Bias due to missing outcome data



Study name/ NCT number		3.1 Were outcome data available for all, or nearly all participants randomised?	3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing outcome data?	3.3 If N/PN/NI to 3.2: Could missingness in the outcome depend on its true value?	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	Risk of bias judgement
NCT01910402; ARIA	Judgement Description	No 13.5% missing data for virological outcomes	No The ARIA study reported superiority primarily driven by the lower rates of adverse-event-related discontinuations and virological non- response in the dolutegravir group.	Yes Open label	Yes Open label	High risk
NCT01449929;	Judgement	No	No	Yes	Yes	High risk
FLAMINGO	Description	7% missing data for virological outcomes	The FLAMINGO study reported that discontinuation due to adverse events or stopping criteria at 48 weeks was less frequent for dolutegravir (four [2%] patients) than for darunavir plus ritonavir (ten [4%] patients) and contributed to the difference in response rates. This study also reported that part of the difference in the virological response rates at 96 weeks was driven by a higher percentage of discontinuations for other reasons (e.g., lost to follow-up) in the darunavir plus	Open label	Open label	



	ritonavir group than in the dolutegravir group.		

		4. Bias in the mea	surement of the outc	ome			
Study name/ NCT number		4.1 Was the method of measuring the outcome inappropriate?	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	4.3 If N/PN to 4.1 and 4.2: Were outcome assessors aware of the intervention received by the study participant?	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	Risk of bias judgement
NCT01910402; ARIA	Judgement	No	No	Yes	No	NA	Low
	Description	Snapshot algorithm	Snapshot algorithm	Open label	Objective outcome	NA	
NCT01449929;	Judgement	No	No	Yes	No	NA	Low
FLAMINGO	Description	Snapshot algorithm	Snapshot algorithm	Open label	Objective outcome	NA	

	5. Risk of bias in selec	ction of the reported res	sult		RCT overall risk of bias
Study name/ NCT number	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before	5.2. Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible	5.3 Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible	Risk of bias judgement	



		unblinded outcome data were available for analysis?	outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	analyses of the data?		
NCT01910402; ARIA	Judgement	Yes	No	No	Low	High risk
	Description	Pre-specified analysis	Pre-specified	Pre-specified		
		plan	endpoints	analyses		
NCT01449929;	Judgement	Yes	No	No	Low	High risk
FLAMINGO	Description	Pre-specified analysis	Pre-specified	Pre-specified		
		plan	endpoints	analyses		

ARIA: women only

FLAMINGO: Low number of non-white, female, co-infected (HIV and hepatitis B or HIV and hepatitis C) patients or patients with advanced disease were enrolled

4 DOR vs b/PI + any 2NRTI

		1. Biases arising fro	om the randomisation process		
Study name/ NCT number		1.1 Was the allocation sequence random?	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	1.3 Did baseline differences between intervention groups suggest a problem with the randomisation process?	Risk of bias judgement
NCT02275780; DRIVE-	Judgement	Yes	Yes	No	Low
FORWARD; MK-1439- 018	Description	Interactive voice and web response system	Interactive voice and web response system	Demographics and baseline characteristics were balanced between the two treatment groups	

	2. Bias due to	deviations from the	ne intended inter	vention (Effect of	assignment to i	ntervention)		
Study name/	2.1 Were	2.2 Were	2.3 If yes/	2.4 If yes/	2.5 If yes/	2.6 Was an	2.7 If no/	Risk of bias
NCT number	participants	carers and	probably	probably yes	possibly	appropriate	probably	judgement
	aware of	trial people	yes/no	to 2.3, were	yes/no	analysis used	no/no	
	their	delivering the	information to	these	information	to estimate	information to	



		assigned intervention during the trial?	interventions aware of the participants assigned intervention during the trial?	2.1 or 2.2, were there deviations from the intended intervention that arose because of the trial context?	deviations likely to have affected the outcomes?	to 2.4 Were these deviations from intended intervention balanced between groups?	the effect of assignment to intervention?	2.6. Was there potential for a substantial impact (on the result) of the failure to analyse the participants in the group to which they had been randomised?	
NCT02275780;	Judgement	No	No	NA	NA	NA	Yes	NA	Low
DRIVE- FORWARD; MK-1439-018	Description	Double-blind	Double-blind	NA	NA	NA	US FDA snapshot algorithm	NA	

		2. Risk of bias d	ue to deviations fro	om the intended in	terventions (Effect	t of adhering to int	ervention)	
Study name/ NCT number		2.1 Were participants aware of their assigned intervention during the trial?	2.2 Were carers and people delivering the interventions aware of the participants assigned intervention during the trial?	2.3 [If applicable] If yes/probably yes/ no information to 2.1 or 2.2 Were important non-protocol interventions balanced across intervention groups?	2.4 [If applicable] Were there failures in implementing the intervention that could have affected the outcome?	2.5 [If applicable] Was there non-adherence to the assigned intervention regimen that could have affected participant's outcomes?	2.6. If no/probably no/no information to 2.3, or yes probably yes/no information to 2.4 or 2.5 Was an appropriate analysis used to estimate the effect of adhering to the intervention?	Risk of bias judgement
NCT02275780; DRIVE- FORWARD; MK-1439-018	Judgement Description	No Double-blind	No Double-blind	NA NA	NA NA	NA NA	NA NA	Low

o. Dido due to inicomy cateomic data	3. B	ias due to missing outcome data
--------------------------------------	------	---------------------------------



Study name/ NCT number		3.1 Were outcome data available for all, or nearly all participants randomised?	3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing outcome data?	3.3 If N/PN/NI to 3.2: Could missingness in the outcome depend on its true value?	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	Risk of bias judgement
NCT02275780; DRIVE-FORWARD; MK-1439-018	Judgement	Yes	NA	NA	NA	Low at 48 weeks; some concerns at 96 weeks
	Description	6.0% missing data for virological outcomes at week 48 and 11.8% missing data for virological outcomes at week 96	NA	NA	NA	

		4. Bias in the mea	asurement of the outc	ome			
Study name/ NCT number		4.1 Was the method of measuring the outcome inappropriate?	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	4.3 If N/PN to 4.1 and 4.2: Were outcome assessors aware of the intervention received by the study participant?	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	Risk of bias judgement
NCT02275780;	Judgement	No	No	No	NA	NA	Low
DRIVE- FORWARD; MK- 1439-018	Description	Snapshot algorithm	Snapshot algorithm	Double-blind	NA	NA	

	5. Risk of bias in sele	RCT overall risk of bias			
Study name/ NCT number	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that	5.2. Is the numerical result being assessed likely to have been selected, on the basis of the results. from	5.3 Is the numerical result being assessed likely to have been selected, on the basis of the results, from	Risk of bias judgement	



		was finalized before unblinded outcome data were available for analysis?	multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	multiple eligible analyses of the data?		
NCT02275780; DRIVE-FORWARD; MK-1439-018	Judgement	Yes	No	No	Low	Low at 48 weeks; some concerns at 96 weeks
	Description	Pre-specified analysis plan	Pre-specified endpoints	Pre-specified analyses		

Molina 2018: low number of women (121 [16%]) and participants aged older than 65 years (1%) enrolled in the trial.



5 DOR vs EFV + any 2NRTI

		1. Biases arising fr	rom the randomisation process		
Study name/ NCT number		1.1 Was the allocation sequence random?	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	1.3 Did baseline differences between intervention groups suggest a problem with the randomisation process?	Risk of bias judgement
NCT02403674; DRIVE-	Judgement	Yes	Probably yes	No	Low
AHEAD; MK-1439A Protocol 021	Description	No details	No details	Demographics and baseline characteristics were generally similar between the treatment groups	

		2. Bias due to	deviations from t	he intended inter	vention (Effect of	assignment to	intervention)		
Study name/ NCT number		2.1 Were participants aware of their assigned intervention during the trial?	2.2 Were carers and trial people delivering the interventions aware of the participants assigned intervention during the trial?	2.3 If yes/ probably yes/no information to 2.1 or 2.2, were there deviations from the intended intervention that arose because of the trial context?	2.4 If yes/ probably yes to 2.3, were these deviations likely to have affected the outcomes?	2.5 If yes/ possibly yes/no information to 2.4 Were these deviations from intended intervention balanced between groups?	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	2.7 If no/probably no/no information to 2.6. Was there potential for a substantial impact (on the result) of the failure to analyse the participants in the group to which they had been randomised?	Risk of bias judgement
NCT02403674;	Judgement	No	No	NA	NA	NA	Yes	NA	Low
DRIVE- AHEAD; MK- 1439A Protocol 021	Description	Double-blind	Double-blind	NA	NA	NA	Snapshot algorithm	NA	

	2. Risk of bias du	2. Risk of bias due to deviations from the intended interventions (Effect of adhering to intervention)							
Study name/	2.1 Were	.1 Were 2.2 Were carers 2.3 [If 2.4 [If 2.5 [If 2.6. If Risk of bias							
NCT number	participants	articipants and people applicable] If applicable] applicable] no/probably judgement							



		aware of their assigned intervention during the trial?	delivering the interventions aware of the participants assigned intervention during the trial?	yes/probably yes/ no information to 2.1 or 2.2 Were important non- protocol interventions balanced across intervention groups?	Were there failures in implementing the intervention that could have affected the outcome?	Was there non- adherence to the assigned intervention regimen that could have affected participant's outcomes?	no/no information to 2.3, or yes probably yes/no information to 2.4 or 2.5 Was an appropriate analysis used to estimate the effect of adhering to the intervention?	
NCT02403674;	Judgement	No	No	NA	NA	NA	NA	Low
DRIVE-AHEAD; MK-1439A Protocol 021	Description	Double-blind	Double-blind	NA	NA	NA	NA	

		3. Bias due to missing	g outcome data			
Study name/ NCT number		3.1 Were outcome data available for all, or nearly all participants randomised?	3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing outcome data?	3.3 If N/PN/NI to 3.2: Could missingness in the outcome depend on its true value?	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	Risk of bias judgement
NCT02403674;	Judgement	Yes	No	Yes	Yes	High risk
DRIVE-AHEAD; MK- 1439A Protocol 021	Description	7.0% missing data for virological outcomes at week 48 and 10.9% missing data for virological outcomes at week 96	Rates of discontinuations for AEs differed between groups	Rates of discontinuations for AEs differed between groups	Rates of discontinuations for AEs differed between groups	

	4. Bias in the r	4. Bias in the measurement of the outcome							
Study name/ NCT	4.1 Was the	.1 Was the 4.2 Could 4.3 If N/PN to 4.1 4.4 If Y/PY/NI to 4.5 If Y/PY/NI to Risk of bias							
number	method of	nethod of measurement or and 4.2: Were 4.3: Could 4.4: Is it likely judgement							
	measuring the	ascertainment of	outcome	assessment of	that				
	outcome	the outcome	assessors aware	the outcome	assessment of				
	inappropriate?	have differed	of the	have been	the outcome was				



			between intervention groups?	intervention received by the study participant?	influenced by knowledge of intervention received?	influenced by knowledge of intervention received?	
NCT02403674;	Judgement	No	No	No	No	NA	High risk
DRIVE-AHEAD; MK-1439A Protocol 021	Description	Snapshot algorithm	Snapshot algorithm	Double-blind	Independent objective measurements	NA	

		5. Risk of bias in selec	ction of the reported res	sult		RCT overall risk of bias
Study name/ NCT number		5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	5.2. Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	5.3 Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible analyses of the data?	Risk of bias judgement	
NCT02403674; DRIVE-AHEAD; MK- 1439A Protocol 021	Judgement	Yes	No	No	Low	Low at 48 weeks; some concerns at 96 weeks
	Description	Pre-specified analysis plan	Pre-specified endpoints	Pre-specified analyses		

Orkin 2019: Low numbers of women (15.4%), Blacks/African Americans (18.5%), and those with high baseline viral loads (>100000 copies/mL, 21.3%), low CD4+ T-cell counts (≤200/mm3, 12.4%), or hepatitis B/C co-infections (2.7%).



6 DOL/LAM vs TDF/FTC/DOL

		1. Biases arising from t	he randomisation process		
Study name/ NCT number		1.1 Was the allocation sequence random?	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	1.3 Did baseline differences between intervention groups suggest a problem with the randomisation process?	Risk of bias judgement
NCT02831673 (GEMINI-	Judgement	Yes	Yes	No	Low
1) and NCT02831764 (GEMINI-2)	Description	Central randomisation schedule generated with SAS	Treatment assignment was done in accordance with a central randomisation schedule generated with SAS	Key demographic and baseline clinical characteristics were well balanced between the treatment groups	

		2. Bias due to	deviations from th	ne intended interv	ention (Effect of	assignment to ir	ntervention)		
Study name/ NCT number		2.1 Were participants aware of their assigned intervention during the trial?	2.2 Were carers and	2.3 If yes/ probably yes/no information to 2.1 or 2.2, were there deviations from the intended intervention that arose because of the trial context?	2.4 If yes/ probably yes to 2.3, were these deviations likely to have affected the outcomes?	2.5 If yes/possibly yes/no information to 2.4 Were these deviations from intended intervention balanced between groups?	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	2.7 If no/probably no/no information to 2.6. Was there potential for a substantial impact (on the result) of the failure to analyse the participants in the group to which they had been randomised?	Risk of bias judgement
NCT02831673	Judgement	No	No	NA	NA	NA	Yes	NA	Low
(GEMINI-1) and NCT02831764 (GEMINI-2)	Description	Double blind; the study masked both participants and	Double blind; the study masked both participants and	NA	NA	NA	Snapshot algorithm	NA	



investigat	rs investigators to
to treatme	nt treatment
assignme	t assignment
until weel	96. until week 96.

		2. Risk of bias du	ue to deviations fro	om the intended in	terventions (Effec	of adhering to int	ervention)	
Study name/ NCT number		2.1 Were participants aware of their assigned intervention during the trial?	2.2 Were carers and people delivering the interventions aware of the participants assigned intervention during the trial?	2.3 [If applicable] If yes/probably yes/ no information to 2.1 or 2.2 Were important non-protocol interventions balanced across intervention groups?	2.4 [If applicable] Were there failures in implementing the intervention that could have affected the outcome?	2.5 [If applicable] Was there non-adherence to the assigned intervention regimen that could have affected participant's outcomes?	2.6. If no/probably no/no information to 2.3, or yes probably yes/no information to 2.4 or 2.5 Was an appropriate analysis used to estimate the effect of adhering to the intervention?	Risk of bias judgement
NCT02831673	Judgement	No	No	NA	NA	NA	NA	Low
(GEMINI-1) and NCT02831764 (GEMINI-2)	Description	Double blind; the study masked both participants and investigators to treatment assignment until week 96.	Double blind; the study masked both participants and investigators to treatment assignment until week 96.	NA	NA	NA	NA	

	3. Bias due to missing	. Bias due to missing outcome data					
Study name/ NCT	3.1 Were outcome	3.2 If N/PN/NI to 3.1:	3.3 If N/PN/NI to 3.2:	3.4 If Y/PY/NI to 3.3:	Risk of bias		
number	data available for all,	Is there evidence	Could missingness	Is it likely that	judgement		
	or nearly all	that the result was	in the outcome	missingness in the			



		participants randomised?	not biased by missing outcome data?	depend on its true value?	outcome depended on its true value?	
NCT02831673	Judgement	Yes	NA	NA	NA	Low
(GEMINI-1) and NCT02831764 (GEMINI-2)	Description	5.3% missing data for virological outcomes at week 48 and 9.7% missing data for virological outcomes at week 96; similar between groups	NA	NA	NA	

		4. Bias in the mea	surement of the outc	ome			
Study name/ NCT number		4.1 Was the method of measuring the outcome inappropriate?	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	4.3 If N/PN to 4.1 and 4.2: Were outcome assessors aware of the intervention received by the study participant?	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	Risk of bias judgement
NCT02831673	Judgement	No	No	No	NA	NA	Low
(GEMINI-1) and NCT02831764 (GEMINI-2)	Description	Snapshot algorithm	Snapshot algorithm	Double-blind	NA	NA	

	5. Risk of bias in select	. Risk of bias in selection of the reported result					
Study name/ NCT number	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that	5.2. Is the numerical result being assessed likely to have been selected, on the basis of the results, from	5.3 Is the numerical result being assessed likely to have been selected, on the basis of the results, from	Risk of bias judgement			



BH	IVA 🌣
British F	HIV Association

		was finalized before unblinded outcome data were available for analysis?	multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	multiple eligible analyses of the data?		
NCT02831673	Judgement	Yes	No	No	Low	Low
(GEMINI-1) and	Description	Pre-specified analysis	Pre-specified	Pre-specified		
NCT02831764		plan	endpoints	analyses		
(GEMINI-2)						

Cahn 2019: Enrolled mostly men younger than 50 years; female participants were limited to those using contraceptives and who were not pregnant when initiating treatment. People with HIV-1 RNA of more than 500 000 copies per mL, hepatitis B virus infection or resistance mutations excluded.



7 DOL vs RALT + any 2 NRTIs

		1. Biases arising from the randomisation process						
Study name/ NCT number		1.1 Was the allocation sequence random?	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	1.3 Did baseline differences between intervention groups suggest a problem with the randomisation process?	Risk of bias judgement			
NCT01227824; SPRING-2	Judgement Description	Yes Computer-generated	Yes Central procedure using phone and web interface	No Baseline demographics and disease characteristics were similar between treatment groups	Low			

		2. Bias due to	deviations from th	ne intended interv	ention (Effect of	assignment to in	ntervention)		
Study name/ NCT number		2.1 Were participants aware of their assigned intervention during the trial?	2.2 Were carers and trial people delivering the interventions aware of the participants assigned intervention during the trial?	2.3 If yes/ probably yes/no information to 2.1 or 2.2, were there deviations from the intended intervention that arose because of the trial context?	2.4 If yes/ probably yes to 2.3, were these deviations likely to have affected the outcomes?	2.5 If yes/possibly yes/no information to 2.4 Were these deviations from intended intervention balanced between groups?	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	2.7 If no/ probably no/no information to 2.6. Was there potential for a substantial impact (on the result) of the failure to analyse the participants in the group to which they had been randomised?	Risk of bias judgement
NCT01227824; SPRING-2	Judgement Description	No Double-blind	No Double-blind	NA NA	NA NA	NA NA	Yes Intent-to-treat snapshot analysis	NA NA	Low



		2. Risk of bias d	ue to deviations fro	om the intended in	terventions (Effec	t of adhering to int	ervention)	
Study name/		2.1 Were	2.2 Were carers	2.3 [If	2.4 [If	2.5 [If	2.6. If	Risk of bias
NCT number		participants aware of their assigned intervention during the trial?	and people delivering the interventions aware of the participants assigned intervention during the trial?	applicable] If yes/probably yes/ no information to 2.1 or 2.2 Were important non-protocol interventions balanced across intervention groups?	applicable] Were there failures in implementing the intervention that could have affected the outcome?	applicable] Was there non- adherence to the assigned intervention regimen that could have affected participant's outcomes?	no/probably no/no information to 2.3, or yes probably yes/no information to 2.4 or 2.5 Was an appropriate analysis used to estimate the effect of adhering to the intervention?	judgement
NCT01227824;	Judgement	No	No	NA	NA	NA	NA	Low
SPRING-2	Description	Double-blind	Double-blind	NA	NA	NA	NA	

		3. Bias due to missing	outcome data			
Study name/ NCT number		3.1 Were outcome data available for all, or nearly all participants randomised?	3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing outcome data?	3.3 If N/PN/NI to 3.2: Could missingness in the outcome depend on its true value?	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	Risk of bias judgement
NCT01227824; SPRING-2	Judgement	No	No	Yes	Yes	Low at week 48; high at week 96
	Description	7% missing data for virological outcomes in each group at week 48; 14% vs 13% at week 96.	The difference between week 48 and week 96 responses was driven mainly by discontinuations for reasons other than adverse events; the proportion of virological non- response was	The difference between week 48 and week 96 responses was driven mainly by discontinuations for reasons other than adverse events; the proportion of virological non- response was	The difference between week 48 and week 96 responses was driven mainly by discontinuations for reasons other than adverse events; the proportion of virological non- response was	



unchange	ged for u	unchanged for	unchanged for	
dolutegra	avir from	dolutegravir from	dolutegravir from	
week 48	to week 96,	week 48 to week 96,	week 48 to week 96,	
whereas	s it rose by 2%	whereas it rose by 2%	whereas it rose by 2%	
for ralteg	gravir from f	for raltegravir from	for raltegravir from	
week 48	to week 96	week 48 to week 96	week 48 to week 96	

		4. Bias in the mea	surement of the outc	ome			
Study name/ NCT number		4.1 Was the method of measuring the outcome inappropriate?	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	4.3 If N/PN to 4.1 and 4.2: Were outcome assessors aware of the intervention received by the study participant?	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	Risk of bias judgement
NCT01227824;	Judgement	No	No	No	NA	NA	Low
SPRING-2	Description	Snapshot algorithm	Snapshot algorithm	Double-blind	NA	NA	

	5. Risk of bias in selec	ction of the reported res	sult		RCT overall risk of bias
Study name/ NCT number	5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	5.2. Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible outcome measurements (e.g. scales, definitions, time points) within	5.3 Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible analyses of the data?	Risk of bias judgement	



BHIVA guidelines on antiretroviral treatment for adults living with HIV-1 2022

			the outcome domain?			
NCT01227824; SPRING-2	Judgement	Yes	No	No	Low	Low at week 48; high at week 96 for virological outcomes
	Description	NCT record posted in October 2010 at start of recruitment	Pre-specified endpoints	Pre-specified analysis populations		

SPRING-2: A limitation of this study is the low number of non-white and female patients enrolled, which is not fully representative of the HIV global epidemic.



NRTI backbone comparison

8 TDF/FTC vs TAF/FTC with any 3rd agent

		1. Biases arising from th	e randomisation process		
Study name/ NCT number		1.1 Was the allocation sequence random?	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	1.3 Did baseline differences between intervention groups suggest a problem with the randomisation process?	Risk of bias judgement
NCT03122262; ADVANCE	Judgement	Yes	Yes	No	Low
	Description	Electronically generated	Electronically generated	Baseline characteristics were balanced across the groups	
NCT01780506 (also known as	Judgement	Yes	Yes	No	Low
GS-US-292-0104) and NCT01797445 (also known as GS-US-292-0111)	Description	Computer generated	Automated treatment assignment	Baseline characteristics were balanced across the groups	
NCT02431247; AMBER	Judgement	Yes	Yes	No	Low
	Description	Computer-generated interactive web-response system	Computer-generated interactive web-response system	Baseline characteristics were balanced between the two groups	
NCT01565850 (GS-US-299-	Judgement	Yes	Yes	No	Low
0102)	Description	Randomised centrally by a third party interactive voice/web response	Randomised centrally by a third party interactive voice/web response	Baseline demographic and general disease characteristics were similar between groups	

	2. Bias due to d	ias due to deviations from the intended intervention (Effect of assignment to intervention)									
Study name/ NCT number	2.1 Were participants aware of their assigned intervention during the trial?	2.2 Were carers and trial people delivering the interventions aware of the participants	2.3 If yes/ probably yes/no information to 2.1 or 2.2, were there deviations	2.4 If yes/ probably yes to 2.3, were these deviations likely to have affected the	2.5 If yes/possibly yes/no information to 2.4 Were these deviations	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	2.7 If no/ probably no/no information to 2.6. Was there potential for a substantial	Risk of bias judgement			
		assigned	from the	outcomes?	from		impact (on the				
		intervention	intended		intended		result) of the				



			during the trial?	intervention that arose because of the trial context?		intervention balanced between groups?		failure to analyse the participants in the group to which they had been randomised?	
NCT03122262; ADVANCE	Judgement	Yes	Yes	No information	NA	NA	Yes	NA	Some concerns
	Description	Open label	Open label	No details	NA	NA	Intention-to-treat analysis. After the testing for noninferiority, the treatment groups were compared for differences in efficacy. For these tests, an overall 1.7% significance level (P = 0.017) was used, to adjust for the three pairwise treatment comparisons being made.	NA	
NCT01780506	Judgement	No	No	NA	NA	NA	Yes	NA	Low
(also known as GS-US-292- 0104) and NCT01797445 (also known as GS-US-292- 0111)	Description	Double-blind	Double-blind	NA	NA	NA	Intention to treat	NA	
NCT02431247;	Judgement	No	No	NA	NA	NA	Yes	NA	Low
AMBER	Description	Double-blind	Double-blind	NA	NA	NA	Intention to treat	NA	
	Judgement	No	No	NA	NA	NA	Yes	NA	Low



NCT01565850	Description	Double-blind	Double-blind	NA	NA	NA	Intention to	NA	
(GS-US-299-							treat		
0102)									

		2. Risk of bias de	ue to deviations fro	om the intended in	terventions (Effect	of adhering to int	ervention)	
Study name/ NCT number		2.1 Were participants aware of their assigned intervention during the trial?	2.2 Were carers and people delivering the interventions aware of the participants assigned intervention during the trial?	2.3 [If applicable] If yes/probably yes/ no information to 2.1 or 2.2 Were important non-protocol interventions balanced across intervention groups?	2.4 [If applicable] Were there failures in implementing the intervention that could have affected the outcome?	2.5 [If applicable] Was there non-adherence to the assigned intervention regimen that could have affected participant's outcomes?	2.6. If no/probably no/no information to 2.3, or yes probably yes/no information to 2.4 or 2.5 Was an appropriate analysis used to estimate the effect of adhering to the intervention?	Risk of bias judgement
NCT03122262;	Judgement	Yes	Yes	No information	NA	NA	No information	Some concerns
ADVANCE	Description	Open label	Open label	No details	NA	NA	No details	
NCT01780506	Judgement	No	No	NA	NA	NA	NA	Low
(also known as GS-US-292- 0104) and NCT01797445 (also known as GS-US-292- 0111)	Description	Double-blind	Double-blind	NA	NA	NA	NA	
NCT02431247;	Judgement	No	No	NA	NA	NA	NA	Low
AMBER	Description	Double-blind	Double-blind	NA	NA	NA	NA	
NCT01565850	Judgement	No	No	NA	NA	NA	NA	Low
(GS-US-299- 0102)	Description	Double-blind	Double-blind	NA	NA	NA	NA	



		3. Bias due to missing	outcome data			
Study name/ NCT number		3.1 Were outcome data available for all, or nearly all participants randomised?	3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing outcome data?	3.3 If N/PN/NI to 3.2: Could missingness in the outcome depend on its true value?	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	Risk of bias judgement
NCT03122262; ADVANCE	Judgement	No	No	Yes	Yes	High risk at week 48. Low at week 96
	Description	By week 48, the number of patients who had discontinued treatment or who had missing data was 41 (12%) in the TAF-based group, 39 (11%) in the TDF-based group, and 55 (16%) in the standard-care group. By week 98 the numbers of patients who had no virological data, including those who discontinued for any reason other than lack of efficacy and those with missing data within the visit window were: 64/351 (18.2%) in the TAF-based group, 62 (17.7%) in the TDF-based group, 126/702 (17.9%) in the combined DOL groups and 78/351 (22.2%) in the standard-care group (not significantly different).	Differences in efficacy between the groups at 48 weeks were driven by a higher number of discontinuations in the standard-care group than in the other two groups. In the per-protocol analysis, the percentage of patients with an HIV-1 RNA level <50 copies/mL was similar across the groups at week 48 (96% in the TAF-based group, 95% in the TDF-based group, and 96% in the standard-care group). At week 96, the difference in rate of missing data was similar between groups, and the differences in virological outcomes between groups were not significant either when missing data were classified as	Differences in efficacy between the groups were driven by the number of discontinuations	Differences in efficacy between the groups were driven by the number of discontinuations	



NCT01780506 (also known as GS-US- 292-0104) and NCT01797445 (also known as GS-US- 292-0111)	Judgement Description	Yes Data missing for 0.6% for virological outcomes	treatment failures or when missing were excluded. NA NA	NA NA	NA NA	Low
NCT02431247;	Judgement	Yes	NA	NA	NA	Low
AMBER	Description	Data missing for 6% for virological outcomes	NA	NA	NA	
NCT01565850 (GS-	Judgement	No	No	Yes	Yes	High risk
US-299-0102)	Description	Data missing for 6.5% for virological outcomes overall but not balanced between groups	The difference in virologic response rates at week 48 was primarily driven by the higher rate of participants in the TAF group (6.8%) compared with the TDF group (2%) who discontinued study drug with last available VL <50 copies/mL (e.g. due to reasons other than virologic failure such as loss to follow-up or investigator's discretion).	Differences in efficacy between the groups were driven by the number of discontinuations	Differences in efficacy between the groups were driven by the number of discontinuations	

	4. Bias in the meas	urement of the outco	ome			
Study name/ NCT	4.1 Was the	4.2 Could	4.3 If N/PN to 4.1	4.4 If Y/PY/NI to	4.5 If Y/PY/NI to	Risk of bias
number	method of	measurement or	and 4.2: Were	4.3: Could	4.4: Is it likely	judgement
	measuring the	ascertainment of	outcome	assessment of	that	
	_	the outcome	assessors aware	the outcome	assessment of	



		outcome inappropriate?	have differed between intervention groups?	of the intervention received by the study participant?	have been influenced by knowledge of intervention received?	the outcome was influenced by knowledge of intervention received?	
NCT03122262; ADVANCE	Judgement Description	No The primary end point was the percentage of patients with an HIV-1 RNA level < 50 copies/mL at week 48. Secondary objectives were to evaluate additional viral-load thresholds, CD4 count changes, and side-effect profile and safety, including findings on physical examination, laboratory analyses, and dual-energy x-ray absorptiometry (DXA) scans.	No Independent objective measurements as well as data from symptom screening, vital- signs measurement, symptom-directed physical examination, laboratory assessments, and multiple questionnaires, including a sleep questionnaire	Yes Open label	Probably no Independent objective measurements as well as data from symptom screening, vital- signs measurement, symptom-directed physical examination, laboratory assessments, and multiple questionnaires, including a sleep questionnaire	NA NA	Low risk
NCT01780506 (also known as GS-US-292-0104) and NCT01797445 (also known as GS-US-292-0111)	Judgement Description Judgement	No Proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48 as defined by the US Food and Drug Administration (FDA) snapshot algorithm No	No Objective outcomes; double- blind	No Double-blind	NA NA	NA NA	Low



NCT02431247; AMBER	Description	Percentage viral load <50	Objective outcomes; double-	Double-blind	NA	NA	
		copies/mL (FDA- snapshot analysis)	blind				
NCT01565850	Judgement	No	No	No	NA	NA	Low
(GS-US-299-0102)	Description	Percentage viral load <50 copies/mL (FDA-snapshot analysis)	Objective outcomes; double-blind	Double-blind	NA	NA	

		5. Risk of bias in selec	ction of the reported res	sult		RCT overall risk of bias
Study name/ NCT number		5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	5.2. Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	5.3 Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible analyses of the data?	Risk of bias judgement	
NCT03122262; ADVANCE	Judgement	Yes	No	No	Low	High risk at 48 weeks Some concerns at 96 weeks
	Description	Pre-specified analysis plan	Pre-specified endpoints	Pre-specified analyses		
NCT01780506 (also	Judgement	Yes	No	No	Low	Low
known as GS-US- 292-0104) and NCT01797445 (also known as GS-US- 292-0111)	Description	Pre-specified analysis plan	Pre-specified endpoints	Pre-specified analyses		
NCT02431247;	Judgement	Yes	No	No	Low	Low
AMBER	Description	Pre-specified analysis plan	Pre-specified endpoints	Pre-specified analyses		
·	Judgement	Yes	No	No	Low	High risk



NCT01565850 (GS-	Description	Pre-specified analysis	Pre-specified	Pre-specified	
US-299-0102)		plan	endpoints	analyses	

Advance: Strengths include generalisability, with representation from across the region and within South Africa, relatively few entry and exclusion criteria, the high proportion of women included, and the fact that participants were recruited from routine HIV testing and care programmes.

Amber: study limitations were inclusion of more than 80% white patients and a comparatively small proportion of female or older (>50 years) participants or who had high viral loads.

Mills: Relatively few women enrolled

Sax 2015: a small proportion of study participants with advanced HIV disease, a small proportion of women participants, and the exclusion of patients with chronic hepatitis B virus infection

ADVANCE had good generalisability but AMBER included >80% white patients and a comparatively small proportion of female or older (>50 years) participants or who had high viral loads; Mills 2015 enrolled relatively few women and Sax 2015 enrolled a small proportion of women or participants with advanced HIV disease, and excluded patients with chronic hepatitis B virus infection.

9 ABC/3TC vs TAF/FTC with any 3rd agent

		1. Biases arising fro	om the randomisation process		
Study name/ NCT number		1.1 Was the allocation sequence random?	1.2 Was the allocation sequence concealed until participants were enrolled and assigned to interventions?	1.3 Did baseline differences between intervention groups suggest a problem with the randomisation process?	Risk of bias judgement
NCT02607930; GS-US-380-	Judgement	Yes	Yes	No	Low
1489; 2015-004024-54 (EudraCT Number)	Description	Computer- generated allocation sequence	Automated treatment assignment	Demographics and baseline characteristics were similar between groups	



		2. Bias due to d	leviations from th	e intended interv	ention (Effect of	assignment to i	ntervention)		
Study name/ NCT number		2.1 Were participants aware of their assigned intervention during the trial?	2.2 Were carers and trial people delivering the interventions aware of the participants assigned intervention during the trial?	2.3 If yes/ probably yes/no information to 2.1 or 2.2, were there deviations from the intended intervention that arose because of the trial context?	2.4 If yes/ probably yes to 2.3, were these deviations likely to have affected the outcomes?	2.5 If yes/ possibly yes/no information to 2.4 Were these deviations from intended intervention balanced between groups?	2.6 Was an appropriate analysis used to estimate the effect of assignment to intervention?	2.7 If no/ probably no/no information to 2.6. Was there potential for a substantial impact (on the result) of the failure to analyse the participants in the group to which they had been randomised?	Risk of bias judgement
NCT02607930;	Judgement	No	No	NA	NA	NA	Yes	NA	Low
GS-US-380- 1489; 2015- 004024-54 (EudraCT Number)	Description	Investigators, participants, and study staff giving treatment, assessing outcomes, and collecting data were masked to group assignment.	Investigators, participants, and study staff giving treatment, assessing outcomes, and collecting data were masked to group assignment.	NA	NA	NA	Full analysis set (all participants who were randomly assigned and had received at least one dose of the study drug, regardless of whether they returned for post-baseline assessments)	NA	

		2. Risk of bias du	ue to deviations fro	om the intended in	terventions (Effect	of adhering to int	ervention)	
S	tudy name/	2.1 Were	2.2 Were carers	2.3 [If	2.4 [If	2.5 [If	2.6. If	Risk of bias
N	CT number	participants	and people	applicable] If	applicable]	applicable]	no/probably	judgement
		aware of their	delivering the	yes/probably	Were there	Was there non-	no/no	
		assigned	interventions	yes/ no	failures in	adherence to	information to	
		intervention	aware of the	information to	implementing	the assigned	2.3, or yes	



		during the trial?	participants assigned intervention during the trial?	2.1 or 2.2 Were important non-protocol interventions balanced across intervention groups?	the intervention that could have affected the outcome?	intervention regimen that could have affected participant's outcomes?	probably yes/no information to 2.4 or 2.5 Was an appropriate analysis used to estimate the effect of adhering to the intervention?	
NCT02607930;	Judgement	No	No	NA	NA	NA	NA	Low
GS-US-380- 1489; 2015- 004024-54 (EudraCT Number)	Description	Investigators, participants, and study staff giving treatment, assessing outcomes, and collecting data were masked to group assignment.	Investigators, participants, and study staff giving treatment, assessing outcomes, and collecting data were masked to group assignment.	NA	NA	NA	NA	

		3. Bias due to missing	outcome data			
Study name/ NCT number		3.1 Were outcome data available for all, or nearly all participants randomised?	3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing outcome data?	3.3 If N/PN/NI to 3.2: Could missingness in the outcome depend on its true value?	3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true value?	Risk of bias judgement
NCT02607930; GS-	Judgement	Yes	NA	NA	NA	Low
US-380-1489; 2015- 004024-54 (EudraCT Number)	Description	<6% missing values for virological outcomes at 48 weeks and <10% missing values for virological outcomes at 96 weeks	NA	NA	NA	

4. Bias in the measurement of the outcome



Study name/ NCT number		4.1 Was the method of measuring the outcome inappropriate?	4.2 Could measurement or ascertainment of the outcome have differed between intervention groups?	4.3 If N/PN to 4.1 and 4.2: Were outcome assessors aware of the intervention received by the study participant?	4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by knowledge of intervention received?	4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by knowledge of intervention received?	Risk of bias judgement
NCT02607930;	Judgement	No	No	No	NA	NA	Low
GS-US-380-1489; 2015-004024-54 (EudraCT Number)	Description	Snapshot algorithm	Snapshot algorithm	Investigators, participants, and study staff giving treatment, assessing outcomes, and collecting data were masked to group assignment.	NA	NA	

		5. Risk of bias in selec	RCT overall risk of bias			
Study name/ NCT number		5.1 Were the data that produced this result analysed in accordance with a pre-specified analysis plan that was finalized before unblinded outcome data were available for analysis?	5.2. Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible outcome measurements (e.g. scales, definitions, time points) within the outcome domain?	5.3 Is the numerical result being assessed likely to have been selected, on the basis of the results, from multiple eligible analyses of the data?	Risk of bias judgement	
NCT02607930; GS- US-380-1489; 2015- 004024-54 (EudraCT Number)	Judgement	Yes	No	No	Low	Low
	Description	Pre-specified analysis plan	Pre-specified endpoints	Pre-specified analyses		

